Reports ranked by overall diligence score. Newer reports break ties, so the list stays stable as fresh research lands.
The three highest-scoring diligence reports in the collection.
CoolIT clears a strong-pass quality bar as a rare scaled direct-to-chip cooling franchise aligned with the AI data center buildout, though new investor access now sits primarily through Ecolab rather than an independent private round.
Commure remains the breadth-and-anchor leader in healthcare AI, but the investment case still depends on incomplete public disclosure around retention, concentration, margins, and security controls.
Stripe is a premium-quality private fintech compounder, but the current tender price still needs more audited support than public evidence can provide.
Remaining reports by score.
Candid built one of the most strategically validated autoimmune T-cell engager platforms in biotech, but after UCB's up-to-$2.2B bid the remaining upside depends more on deal close and Phase 2 execution than on hidden asset discovery.
Hinge Health remains the category leader in digital MSK care, pairing 53% Q2 revenue growth and positive free cash flow with multi-condition expansion, but FDA scrutiny and channel concentration keep the risk/reward profile at Buy/Fair rather than aggressive.
Temporal remains a category-leading durable-execution platform with accelerating enterprise adoption, but the $12.55B Series E prices in a stretched multiple against current ARR.
Enter is the dominant AI-powered mass-litigation platform for Brazil's uniquely vast legal market, growing at exceptional speed with blue-chip customers and Tier-1 investors, but carrying key-person and market-concentration risk as it attempts global expansion.
CloudWalk shows strong reported growth and profitable multi-product expansion, but the investment case remains conditional on validating the durability and economics of its credit and FIDC funding engine.
TRM Labs combines rare government and regulated-finance adoption with strong growth and a $2.0B valuation, but private operating metrics and procurement risks still limit underwriting certainty.
Figma remains a high-quality public software compounder with strong growth, retention, and liquidity, but AI unit economics and some governance details are still not fully disclosed.
NVIDIA's $12.93B acquisition gives Hugging Face a premium exit and strategic validation, but the business still depends on open-platform neutrality and opaque private-unit economics.
Canva is a world-scale, profitable design platform with broad adoption and a fair private valuation, but its AI cost structure and limited disclosure cap upside and confidence.
EquipmentShare remains a buy-and-monitor story: a scaled rental platform with a credible software layer, rising guidance, and improving liquidity, but still dependent on cyclically exposed capital-heavy operations.
Tines is a founder-led workflow automation company with real enterprise traction, expanding AI-native products, and strong channel momentum — attractive, but still priced for continued execution.
Moneybox is a scaled and profitable consumer wealth platform, but the £800 million secondary-market mark is fair rather than clearly attractive until primary economics and transaction terms are disclosed.
Tekion remains the leading cloud-native DMS challenger, backed by strategic OEM investors and strong enterprise adoption, but broad displacement of incumbents still depends on proving large-scale migrations, unit economics, and profitability.
Fal combines a differentiated generative-media infrastructure product with strong developer traction and a $4.5B valuation, but public financial and governance disclosure is still too inconsistent for high-conviction underwriting.
Gusto is a buy at roughly a $9.5B secondary valuation: $1B+ in revenue, 500,000+ customers, and cash-flow positivity support an attractive entry multiple despite private-data blind spots.
Insider remains a scaled omnichannel engagement platform with strong enterprise traction and Bluecore-driven retail expansion, but opaque private financial disclosure keeps the case in track territory rather than buy.
NetSPI remains a scaled offensive-security platform with strong enterprise relevance and sponsor backing, but current economics and valuation are still too opaque to underwrite a precise price.
Oura is the clear smart-ring category leader with strong recurring revenue and habit formation, but the public valuation still depends on legal cleanup, disclosure depth, and continued retention strength.
Abnormal Security is the clearest AI-native disruption story in enterprise email security, with 100% ARR growth, 2,800+ enterprise customers, and a Gartner Magic Quadrant Vision leadership position validated by independent analysts. The $5.1 billion Series D valuation at ~25× ARR is steep relative to public cybersecurity peers (11–15× ARR), but is defensible if the company sustains 70%+ ARR growth through its targeted Q4 2025 IPO. The primary risks are Microsoft Defender's zero-marginal-cost bundling threat and multiple compression if growth decelerates. A **Conditional Buy** for sophisticated investors who can obtain NDR and margin disclosures in due diligence.
Databricks is a premier late-stage data-and-AI platform, but the current $190B price still looks stretched versus public comps and available disclosure.
SpaceX is one of the rare private companies whose public evidence supports both a genuine strategic premium and a disciplined refusal to chase the current price; the right call is track, because the business is exceptional but the valuation already assumes too much future Starship and capital-markets success.
Sigma Computing appears to be a credible scale-stage warehouse-native analytics company, but private operating metrics and valuation terms remain too incomplete for a high-conviction underwriting call.
Bluefors is a scaled private cryogenic infrastructure leader with strong product breadth and installed-base advantages, but limited public visibility into margins, pricing, and operating economics keeps diligence needs high.
Cognite pairs strong industrial-AI traction and enterprise adoption with an agreed $3.1 billion Schneider Electric acquisition, but pricing opacity, incomplete financial disclosure, and closing risk keep it in track territory.
Nozomi Networks remains a category-leading OT/CPS security platform, but undisclosed acquisition economics and limited current pricing evidence keep the case at track.
Abridge remains one of the strongest enterprise ambient AI companies, with real product depth, Epic integration, and clear distribution momentum. The business still deserves a premium strategic view, but public economics are too opaque to justify aggressive underwriting at the current valuation.
QI Tech looks like one of Brazil's highest-quality private financial- infrastructure assets, but incomplete financial and operating disclosure keeps the current US$2B+ mark in TRACK territory rather than BUY.
SmartHR remains a strong Japanese HR-platform story, but current private-company economics and governance detail are still not public enough for a premium valuation call.
Nominal has real product-market fit in a structurally underserved hardware test niche, but undisclosed ARR and gross margins keep a $1 billion valuation at track rather than buy.
Supabase remains a standout open-source backend platform with rapid adoption, but opaque economics and financing terms cap conviction at the current valuation.
Nerdio remains a category-leading Microsoft EUC management platform with $100M+ ARR, 23,000+ customers, and profitable growth, but its durability and valuation are constrained by extreme Microsoft dependency and opaque unit economics.
Armis is a Gartner MQ leader in CPS protection with 35%+ Fortune 100 penetration, $340M+ ARR, and 50%+ YoY growth; acquired by ServiceNow at roughly 22.8x ARR, which looks fair for a high-growth platform leader but still leaves integration and OT depth risk.
Cribl is the dominant independent telemetry pipeline vendor with $300M+ ARR, 9,000+ enterprise deployments, and a five-product platform that makes switching costs substantial and churn unlikely—a compelling late-stage buy at current $3.5B valuation.
ElevenLabs is the category-defining AI voice infrastructure company: 175% ARR growth, elite investor syndicate, and a defensible quality moat — but Series D entry at 33× ARR compresses new investor returns and requires the platform thesis to beat BigTech bundling.
Tabby is a premium-priced, profitable MENA consumer-finance platform that has grown from BNPL into a 25M-user money app at a $6.5B valuation, with upside tied to execution and IPO timing.
Ironclad is a market-leading CLM platform with strong enterprise adoption and credible AI upside, but investors should still insist on retention, margin, and term-sheet proof before accepting the old $3.2 billion headline mark at face value.
Gamma is the most capital-efficient path to $100M ARR in AI SaaS and warrants a conditional buy at a 15–20% discount to the Series B price, subject to private diligence confirming net dollar retention, gross margin, and enterprise revenue durability.
Vi Labs is a qualified BUY as a leading enterprise AI platform for healthcare data intelligence, supported by a $1.64B valuation, a 190M-record data moat, and 100+ enterprise customers, tempered by undisclosed financials.
Fleetio is a category-defining fleet maintenance SaaS platform with a durable maintenance-first moat reinforced by the Auto Integrate shop network; the $1.5B+ valuation appears reasonable at 10–15x estimated ARR, but sustained growth execution and competitive resilience against telematics bundling are the key de-risking factors for investment.
Vanta is the leading GRC automation platform with $300M+ ARR, 63% YoY growth, and a defensible integration moat — a Conditional Buy at ~14× ARR contingent on NRR and margin confirmation.
Foodics has credible regional scale and product breadth, but incomplete financial, retention, and control disclosure supports tracking rather than buying.
Starburst appears to be a strong private data-infrastructure asset with credible enterprise traction, but current price, retention, concentration, margins, cash, and transaction structure remain too opaque for an unconditional buy.
Dataiku has credible late-stage enterprise AI scale and a durable governance-oriented product position, but incomplete current economics and historical valuation evidence support tracking rather than buying.
Corgi remains a fast-scaling, AI-native startup insurer with real product-market pull and strong funding support, but its public valuation still runs ahead of disclosed carrier economics and claims evidence.
Legora has real scale and category momentum, but the current valuation still outruns the public proof on pricing, retention, and margin durability.
Kailera is a well-capitalized public obesity biotech with a broad clinical pipeline and active Phase 3 execution, but it remains precommercial and still needs global efficacy, access, and valuation proof before the investment case graduates from track to buy.
Govini combines durable defense-tech scale and secure procurement moats with opaque unit economics and a material founder-governance overhang, supporting a Buy case only with moderate confidence.
ICEYE combines a defensible sovereign SAR franchise with rapid commercial scale, but the >€10 billion valuation still leaves little room for execution slippage.
Applied Intuition pairs exceptional OEM reach and defense traction with an underdocumented $15 billion private valuation, so the current evidence supports a strategically strong but valuation-sensitive platform.
Turing combines profitable, fast-growing frontier AI revenue with meaningful customer-concentration risk.
Monzo is now a profitable, scaled digital bank with stronger product breadth and governance, but valuation and execution risk still justify a disciplined track stance.
Exotec is Europe's most differentiated warehouse robotics vendor with a defensible 3D AMR moat and a $400M Next-Gen backlog — conditional positive at base-case pricing, subject to four pre-investment diligence conditions.
BVNK looks like a real enterprise stablecoin infrastructure winner with a validated strategic exit, but public economics were too incomplete for a full-conviction pre-close buy call.
Earnix appears to be a strong, scaled vertical-AI decisioning platform for insurers and banks, but public evidence still supports a monitored diligence stance rather than a price-taking buy because retention, margin, and current valuation details remain private.
Astrotalk is a rare profitable, category-dominant consumer marketplace whose $1B unicorn mark is defensible in the base case, but reliance on self-reported metrics, India concentration, and a belief-based category argue for entry discipline rather than a blind chase.
Hadrian has real strategic momentum and unusual policy/customer support, but the August 2026 $7.87B mark leaves little valuation margin of safety without current revenue and margin disclosure.
Morpho has credible potential as embedded onchain credit infrastructure, but the investment case remains blocked on monetization, entity-level financials, token rights, and concentration evidence.
Bambu Lab has a differentiated and increasingly scaled 3D-printing ecosystem, but financial opacity, control disputes, and unverified valuation support tracking rather than a buy call.
Altruist remains a strategically scarce RIA custody-and-software platform, but the public record still does not justify a clean standalone underwriting case at the reported Vanguard takeout range.
Kraken remains one of the strongest private utility-software assets, but the $8.65 billion mark still depends on a clean transition to standalone software economics and disclosure.
Intersect Power is now a Google-owned clean-energy infrastructure platform with proven project-finance scale, but the public record is too opaque to support an independent valuation or operating underwriting case.
ClickHouse remains a strong open-source analytics growth story, but the $15 billion Series D valuation already prices in sustained execution while margin, retention, and concentration visibility stay limited.
Tailscale remains a technically differentiated secure-networking platform with strong adoption momentum, but public evidence still cannot cleanly underwrite the April 2025 Series C without disclosed ARR, margins, or retention.
Lyte combines differentiated robotics perception silicon with early production traction, but public disclosure still leaves commercial scale and unit economics opaque.
Waabi is a strong AV 2.0 platform with real partners and real deployment, but its valuation already prices in a lot of future execution.
Outstanding enterprise AI platform with real revenue and traction; $7.2B valuation at 36x ARR provides insufficient margin of safety given hyperscaler bundling risk and undisclosed NRR.
Spinny has built a credible scaled franchise in India's formalizing used-car market, but incomplete disclosure and GoMechanic integration risk make the current valuation hard to underwrite aggressively.
Track Zerodha as a high-quality, profitable brokerage, but do not underwrite a buy without current price evidence, reconciled segment economics, and durable customer cohorts.
DataSnipper has a credible Excel-native audit automation wedge and strong customer validation, but the $1 billion private valuation still requires current financial, retention, margin, and AI-quality diligence before an investable conclusion.
HiBob has credible product breadth and strategic momentum, but the reported premium valuation remains only partially underwritten until audited operating metrics and capitalization terms are disclosed.
Oxylabs appears to be a scaled AI-era web-data infrastructure company, but the disclosed valuation leaves too little public-evidence edge for a buy call.
Yanolja merits tracking for its scaled consumer platform and higher-margin enterprise software engine, but disclosure gaps and unresolved regulatory scrutiny limit conviction at the reported valuation levels.
Ollin has strong disclosed financing and encouraging early clinical differentiation, but opaque economics and an undisclosed valuation keep the recommendation at track rather than conviction underwriting.
Sun King remains a scaled, category-leading PAYG solar platform with strong distribution and financing access, but public financial and credit disclosure is still too thin to support a buy case.
Synchron's minimally invasive BCI now has deeper patient evidence and strong funding, but commercial visibility is still too thin for a conviction buy.
Mews looks like a scaled hospitality operating system with real product breadth and strong funding access, but the refreshed evidence still leaves valuation underwriting constrained by missing ARR, take-rate, burn, runway, and governance disclosure.
webAI is a differentiated sovereign-AI platform with real public-sector and enterprise proof, but a $2.5B headline valuation and missing operating disclosure keep it in track-and-re-underwrite territory.
Nord Quantique remains a technically differentiated but commercially opaque private quantum-hardware company whose public valuation is buoyed by a May 2026 $30 million round and reported $1.4 billion mark.
Greenko remains India's leading private renewable platform with differentiated storage assets and strong funding access, but high capex, project execution slippage, and opaque financial disclosure keep the investment case fair rather than cheap.
Harmonic remains one of the most technically differentiated formal-reasoning AI companies, but public evidence still supports a cautious track posture because monetization, customer proof, and operating disclosure are thin relative to its valuation.
Cast AI combines strong enterprise adoption and differentiated Kubernetes automation with a $1B+ valuation, but undisclosed ARR, margins, and round economics keep the stock-equivalent risk-reward profile at Track.
TerraPower's regulatory and commercial traction is strong, but undisclosed valuation and first-of-a-kind execution risk still prevent a clean underwriting call.
Aven has built a differentiated secured-consumer-credit platform with real growth signals, but public evidence still leaves too much unanswered on economics, partner terms, and losses to justify a buy.
Securiti AI validated its category position with a strategic exit to Veeam, but the diligence case now turns on integration execution and still-opaque economics.
Unitree is a rare profitable public humanoid-robotics platform with visible scale, but research-heavy demand, valuation ambiguity, and security/geopolitical risk keep the case at track rather than buy.
Fictiv is a strategically valuable MISUMI-integrated digital manufacturing platform: the $350 million acquisition looks fair against the disclosed venture base, but independent underwriting remains constrained by limited private-company disclosure.
Horizon3.ai remains a category-leading autonomous pentesting vendor with FedRAMP High credentials, 7,000+ reported organizations, and 120% ARR growth, but undisclosed absolute ARR, customer concentration, and unit economics keep the investment case at research-more.
Dream Games remains a conditional buy — Royal Match and Royal Kingdom show elite puzzle-game monetization, but single-genre concentration, private financial opacity, and sponsor-backed leverage keep the thesis highly diligence-sensitive.
ElevateBio is a differentiated advanced-therapy infrastructure platform with strong capital backing and strategic partner validation, but opaque private economics and execution risk keep the stance at track.
Anyscale remains a strategically important Ray platform, but its standalone value is now best viewed through the announced Nscale acquisition rather than public SaaS multiples.
ReliaQuest remains a well-capitalized, founder-led cybersecurity platform with strong enterprise traction and a differentiated Open XDR/agentic-AI proposition, but opaque unit economics, undisclosed control terms, and elevated operational risk keep the investment case in buy-with-caution territory.
NinjaOne remains the category leader in MSP RMM with 70% revenue growth, 40,000+ customers, and a verified G2 #1 position — but the $12.3B mark is now expensive without audited financials, NRR, and margin disclosure.
Netskope remains a high-growth SSE/SASE platform with sub-30% revenue growth, roughly $899M ARR, and a strong AI-security product cadence, but competitive pressure from Microsoft Entra SSE keeps the case in track territory.
Porter has established dominant market leadership in India's intra-city logistics segment, reached unicorn status in 2025 with strong revenue growth and first-ever profitability, but faces structural gig-economy regulatory risk and an unclear IPO timeline.
Altana still looks like a differentiated trusted-trade platform with real government and enterprise traction, but the refresh remains valuation-positive mainly on moat and growth evidence rather than on disclosed financials.
Saronic remains the leading pure-play autonomous naval-vessel startup, but its stretched valuation and Navy concentration still make execution the central risk.
Vercel is the dominant Frontend Cloud with genuine competitive moats through Next.js stewardship and the AI deployment flywheel. At $9.3B (27x ARR), the valuation is fair on a growth-adjusted basis but thin on margin of safety.
Runway is the best-positioned independent generative video AI company, with strong revenue momentum, a differentiated product roadmap anchored by GWM-1, and deep enterprise partnerships — but faces meaningful legal, competitive, and profitability risks that stretch its $5.3B valuation.
Zipline remains the category leader in autonomous delivery, with a fresh $7.6B valuation and clear partner momentum, but public financial opacity keeps the case in research-more territory.
Spring Health is an AI-native mental health platform with unusually strong clinical proof and broad enterprise distribution. The company’s 2026 refresh reflects a larger access footprint, a completed Alma acquisition path, and continued product expansion through Guide AI, but it still lacks public disclosure on ARR, retention, gross margin, and the liability/compliance details that would let investors underwrite a precise valuation. The result is a track recommendation for investors who want exposure to the category leader but need more diligence before sizing an entry.
Synthesia is the enterprise AI video market leader — a conditional investment at $4.0B. The company's top-decile metrics (142% NRR, 66% ARR growth, 77%+ gross margin, 70%+ Fortune 100 penetration) justify a premium revenue multiple, but the 27x trailing ARR valuation leaves little margin for execution error. Key risks — EU AI Act compliance gap, undisclosed GRR, and Microsoft/Google AI video bundling — require diligence completion before commitment. CONDITIONAL PROCEED for high risk-tolerance investors with AI regulatory expertise. HolonIQ added Synthesia to its EdTech unicorn list in December 2025 at $4.0B, validating enterprise L&D adoption quality.
Resulticks combines real scale, growth, and profitability with a still-conditional public exit process, making the opportunity attractive but not yet fully de-risked.
DDN looks like a real AI-infrastructure winner, but the public-evidence case is not yet strong enough to call the $5B valuation clearly attractive without deeper diligence or better terms.
Neros Technologies is a high-conviction defense-tech drone company that combines an explosive Series C valuation ($2.5B) with credible evidence of active US military deployments, genuine production scale, and strong investor backing from Sequoia and defense-oriented funds. The primary risks are DoD budget concentration, execution risk on the 1M drones/year target, and regulatory/competition exposure from larger primes. Recommend watch with active follow-on interest.
Dental Monitoring looks like a credible orthodontic workflow leader with unusually strong public customer proof, but current public evidence still supports research-more rather than a confident premium-price buy because retention, financing terms, and audited economics remain private.
Muon Space's end-to-end Mission Foundry model and government contract traction position it as a credible space infrastructure platform, but a $1.5B valuation at 11 satellites in orbit demands flawless manufacturing execution.
Neo4j is a real category leader with strong enterprise proof and credible AI-era upside, but the current ~$2B context looks fair rather than obviously cheap until margin, retention, concentration, and AI-conversion metrics are disclosed.
Genius AI has real category traction and an increasingly credible AI product wedge, but private-company opacity on margins, retention, and governance keeps the stock-underwriting posture at track rather than full conviction.
CAIS is a credible category leader in a growing alternatives-infrastructure market, but the current valuation still warrants TRACK rather than BUY until audited economics and cap-table terms are visible.
EF's $1.3B unicorn valuation is well-anchored by $1.44B implied portfolio equity, validated by world-class informed investors, and driven by a genuinely differentiated pre-idea talent investor model — but the Matt Clifford conflict-of-interest risk and absence of public financial metrics represent material diligence gaps that must be resolved before institutional commitment.
Simile has differentiated research lineage and early enterprise traction, but its $2 billion valuation remains difficult to underwrite without private operating and financing disclosures.
Cockroach Labs is a credible late-stage distributed-database platform with real enterprise adoption, but the current private-market price cannot be underwritten confidently without updated financial disclosure.
Corgi shows strong reported growth and a differentiated full-stack insurance model, but limited underwriting, capital, and claims disclosure supports tracking rather than an immediate investment commitment.
Uzum remains Uzbekistan's dominant digital ecosystem with profitable scale and sovereign-backed financing, but structured capital terms and credit opacity keep this a track-not-buy story.
Nourish pairs payer-integrated virtual dietitian care with strong distribution and capital backing, but the reported $1.75B valuation still outpaces disclosed revenue, margin, and reimbursement evidence.
MaintainX remains a strong vertical SaaS asset in industrial maintenance, but the Autodesk acquisition locks in a stretched valuation while leaving public margins, retention, and cash generation opaque.
Alan pairs rapid growth and domestic profitability with opaque underwriting economics and cross-border execution risk, leaving the €5.5B valuation at Track.
Insilico Medicine has crossed into public-market profitability, but Phase III execution, revenue durability, and valuation opacity still justify a track stance.
Mollie remains a strong European SME payments platform, but its valuation is still stretched and its current underwriting case is constrained by incomplete consolidated disclosures.
Coalition remains the most differentiated technology-enabled cyber insurer in the US market, but financial opacity and unresolved tail-risk economics still justify a conditional proceed rather than a buy.
Agility Robotics has the clearest commercial lead in humanoid warehouse automation, but the valuation remains stretched against thin public financials and a still-unproven scale-up.
AfterQuery looks like a category-leading expert-data platform with exceptional growth, but the business is still priced for perfection and remains exposed to customer concentration, opaque margins, and limited public operating disclosure.
Solugen remains a differentiated industrial biomanufacturing platform with real commercial traction, but the refresh still leaves scale-up, disclosure, and financing-execution risk high enough that the case stays at track rather than buy.
Scaled Indian mobility platform with improved FY25 economics and a fresh $3B valuation, but regulatory and disclosure risk keep the stance at buy rather than strong-buy.
Quantum Systems remains a strong defense-tech growth story, but the new $8B valuation still runs ahead of audited transparency.
Plaid remains the structurally dominant US open-banking infrastructure layer with ~$546M estimated ARR, 70%+ market share, and product diversification, but private disclosure opacity, regulatory headwinds, and a still-recovering valuation profile keep the stance at track until an IPO filing confirms the numbers.
Moniepoint remains Nigeria's scaled SME banking and payments infrastructure — 20M+ accounts, 26M daily payments, and $17B monthly TPV — at a $1B valuation, but current headcount and audited financials are still insufficiently disclosed for high-conviction underwriting.
Notion remains the AI workspace category leader with 100M+ users and $500M+ ARR, but the valuation is still stretched and key unit economics remain opaque.
Island has category leadership and a financial services moat, but the $4.85B Series E prices in near-perfect execution — NDA diligence on NRR and burn is required before any investment.
Revolut combines $75B valuation, 80M+ customers, and a broad banking super-app platform, but regulatory execution and consumer-risk controls remain the core diligence constraints.
Carrier Network Moat and 30%+ Growth Earn Conditional Buy at Secondary Discount — NRR and Gross Margin Disclosure Required Before Full Commitment
OpenPayd combines real scale, regulatory progress, and differentiated stablecoin-linked infrastructure, but the announced valuation already assumes meaningful future proof on margins, retention, and concentration that public sources do not yet fully disclose.
Emerald AI has a real product and market wedge in AI-power flexibility, but the August 2026 $1.05B Series A already prices in substantial forward revenue conversion that public evidence does not yet prove.
Megazone Cloud is a real scaled cloud leader, but the current >KRW 4T private mark already prices in a premium that public evidence has not fully closed.
Fivetran looks like a high-quality enterprise data-integration asset, but the current 8.42B qualification mark still appears stretched without private financial disclosure.
Metsera proved it could build a strategically valuable obesity platform quickly, but the standalone investment opportunity ended when Pfizer acquired and delisted the company in 2025.
LaunchDarkly looks like a real late-stage infrastructure winner, but the public evidence still supports a track posture with price discipline rather than an aggressive premium-entry call.
CARS24 has enough scale, market position, and FY26 operating improvement to stay investable, but the public-evidence recommendation remains track because the $3.3B anchor is stale and too many valuation- critical disclosures remain private.
Monte Carlo looks like a real late-stage category leader with credible customer and product proof, but current public evidence still supports a track / research-more stance rather than a clean buy because valuation and operating-economics support remain incomplete.
Emergent Cold LatAm is a likely category leader in Latin American cold-chain logistics, but public evidence still supports only a research-more recommendation because the exact valuation and core economics remain undisclosed.
Cambridge Aerospace has built the most credible low-cost drone-interceptor franchise in Europe in under two years, but at $3.4B it is priced for a future that is still largely unproven at scale.
Dhan looks like a real, profitable challenger in Indian retail broking, but concentration in derivatives and thin private-company disclosure keep the last-round valuation in the fair rather than clearly attractive bucket.
Base Power has real operating momentum and a differentiated residential-battery model, but the August 2026 $13B Series D already prices in national-scale execution and economics that public evidence still does not prove.
Vivriti looks like a scaled Indian mid-market credit franchise, but leverage, concentration and incomplete post-reorganisation transparency keep the recommendation at track rather than buy.
Icertis appears to be a scaled enterprise contract-intelligence asset with durable workflow relevance, but incomplete public metrics and uncertain current price discovery require continued diligence.
Property Finder appears to be a strong regional property-marketplace asset with credible institutional backing and broad product reach, but private-financial opacity and unresolved marketplace-quality risks keep the stance at research-more rather than buy.
QuEra shows strong technical and deployment momentum, but opaque economics and financing terms support Track rather than Buy.
Prime Intellect shows strong financing, product breadth, and customer traction, but public evidence leaves valuation-critical operating and governance gaps.
Beeline appears to be a well-capitalized private lupus-first immunology company with credible mechanisms and multiple programs, but public evidence is insufficient for price conviction.
Keyfactor appears to be a credible, technically differentiated private trust-infrastructure asset, but incomplete current valuation and operating disclosure supports research-more rather than an unconditional buy.
Augment built a differentiated enterprise coding proposition and attracted substantial financing, but limited public economics and uncertain transaction terms support a track posture.
Blackpoint Cyber has a credible MSP-first MDR position, but current public evidence is insufficient to underwrite valuation or financial returns precisely.
Zero Hash merits continued tracking for its integrated regulated platform and institutional distribution, but missing economics and financing terms prevent an investable price conclusion.
Juniper Square remains a credible private-markets category leader, but valuation discipline still depends on private diligence because audited economics and cap-table detail are not public.
UltraGreen.ai still looks like a high-margin fluorescence-guided-surgery franchise with real public-market proof, but the refreshed evidence leaves competition, APAC conversion, and cap-table clarity unresolved, so the stock remains a track rather than buy.
Sonar remains a category-defining code-verification platform with strong 2026 ARR and adoption signals, but stale valuation disclosure and ongoing private-financial opacity still justify a track stance.
Zopa is a profitable, multi-product UK digital bank with real retail scale and partner distribution, but the public case still favors tracking rather than paying up until primary-banking conversion, pricing resilience, and control/economics disclosure improve.
Octane remains a scaled specialty-finance platform with strong 2026 growth, profitability signals, and expanding institutional funding access, but the public record is still too incomplete to justify paying above the last disclosed valuation with high confidence.
Modal now looks like a real scale business with more than $1 billion in annualized revenue, a $15.75 billion Series D, and a differentiated serverless AI infrastructure platform — but the valuation is stretched and public disclosure still leaves margin quality, retention, and concentration unresolved.
Fresha combines large-scale marketplace reach, embedded payments, and subscription monetization into a strong but still opaque private growth story.
Deepgram remains a credible category leader in real-time voice AI, but the $1.3B Series C still merits a track stance until audited financial denominators and retention metrics are disclosed.
Zenobē has real infrastructure scale and sponsor backing, but the public record is still too thin on economics and equity terms to underwrite a precise price.
ACS has strong military validation and a large Series B, but financial opacity and manufacturing risk keep the profile at track.
Pathos AI remains a well-capitalized clinical-stage oncology biotech with major pharma partnerships, but it is still early in human validation and opaque on burn, cap table, and operating metrics.
BioCatch is a scaled behavioral fraud platform with a definitive $2.4 billion Visa exit, but the public case still supports only a track posture until closing risk and private economics are fully verified.
Stoke Space's differentiated full two-stage reusability thesis is still compelling, but a roughly $9B-$10B private valuation leaves little room for error before orbital proof, customer backlog conversion, and revenue disclosure.
Baseten combines elite AI inference growth with meaningful disclosure and capital-intensity gaps, keeping the latest call at track/research more despite a strong operating story.
EliseAI's dominant multifamily footprint and $200M+ ARR support a Buy, but the $4B valuation and private compliance and unit-economics gaps keep the thesis stretched and high risk.
Divergent has credible technical differentiation and defense-prime traction, but opaque unit economics and an expensive private valuation keep it in track mode.
Caris is scaling a differentiated precision-oncology franchise with strong revenue growth, expanding margins, and ample liquidity, but the stock still looks fairly valued given reimbursement, legal, and execution uncertainty.
Tulip is a credible industrial SaaS platform with strong product differentiation and strategic backing, but revenue opacity and a stretched valuation require deeper financial diligence before conviction.
Grafana Labs is a late-stage observability leader with strong open-source distribution and $600M+ ARR, but the latest private marks still look stretched and the financial-quality disclosure remains incomplete.
Sysdig retains a differentiated runtime-security moat, but the 2026 private-mark reset, opaque financials, and competitive CNAPP pressure keep the case at track.
Qonto is the leading European SME finance platform, but the current evidence still falls short of underwriting a fresh valuation or liquidity thesis.
Mercury is a profitable, fast-growing fintech banking platform with strong startup adoption and a larger 2026 valuation, but it still faces regulatory-dependency and competition risks.
CFS is one of the best-capitalized private fusion developers, but it remains a pre-commercial technical bet until SPARC proves Q>1 and ARC economics become financeable.
Stord's $3.0B Series F and $10B+ GMV scale support a track stance, but opaque segment margins and debt covenants keep the valuation case fair-to-stretched.
Checkout.com is a technically differentiated, direct-acquiring enterprise payment platform with first-ever full-year profitability in 2025 and accelerating TPV growth, but the $12B valuation — a 70% discount from its 2022 peak — reflects genuine opacity risks from Jersey holding structure, key-person concentration, and the absence of new institutional capital for 3+ years.
Arctic Wolf remains a credible, scaled security-operations platform, but the public record is still too stale on valuation and private metrics to justify anything stronger than a tracking stance.
Redwood Materials has built a defensible position in US battery recycling with real technology, strong OEM partnerships, and critical IRA tailwinds, but faces substantial execution risk on its manufacturing scale-up and a challenging lithium price environment.
Vinted is a compounding European internet business — profitable, growing at 38%, with an integrated moat — but the April 2026 €8B secondary entry price (7.3x trailing revenue, 53x EBITDA) offers only modest base-case upside and material bear-case downside from regulatory and execution risks.
Huntress is now a scaled SMB security platform with >$250M ARR and strong channel reach, but private-margin opacity and mixed valuation signals keep the investment case in track territory.
Wiz remains a category-defining cloud security platform, but after Google's $32B acquisition the right lens is post-close product continuity rather than fresh standalone valuation upside.
Rippling remains a strong late-stage compound-software company, but the valuation still depends on private metrics the public evidence does not fully reveal.
Vertically integrated autonomous weapons platform with deep DoD relationships; now priced around $61B after the 2026 Series H, but still underpinned by a large defense AI tailwind.
A rare, profitable, bootstrapped FMCG compounder now institutionally validated at a demanding ~₹35,000 crore — strong franchise, but a stretched multiple and private-company opacity warrant close tracking.
Lancium has genuine strategic value at the intersection of Texas power scarcity and AI campus demand, but the reported ~$10B mark still outruns the public disclosure set and requires disciplined, milestone-based underwriting.
Bitwarden is a well-positioned cybersecurity unicorn with strong open-source community trust and expanding enterprise reach, but faces monetization-opacity and trust-shock risk in a crowded credential-security market.
Delinea is a scaled identity-security platform with >$400M ARR, a broad product surface, and credible customer proof, but valuation and capital-structure opacity keep the name in track territory until a real pricing and disclosure event emerges.
Research more: PDG has credible APAC infrastructure scale and institutional financing access, but public evidence remains insufficient to underwrite current economics, leverage, or valuation.
Ionic Digital has a credible contracted AI-infrastructure anchor, but customer concentration, cash-conversion evidence, expansion execution, and dilution keep the opportunity in research-more territory.
Lumin Digital looks like a credible scaled digital-banking platform, but public disclosure is still too thin to underwrite the current private-market mark with high conviction.
Motive has meaningful scale, enterprise momentum, and product breadth, but the current valuation and financing economics are still too opaque for a buy call.
Scaled CPaaS leader with real profitability and distribution momentum, but opaque private terms keep the call at track rather than buy.
Blitzy has credible enterprise traction and a well-corroborated $1.4 billion financing mark, but public evidence still leaves revenue quality, customer durability, and unit economics opaque enough to keep the call at track.
Infra.Market looks like a real scaled building-materials platform with meaningful channel and manufacturing density, but public evidence still leaves pricing, debt, cash-conversion, and valuation precision too opaque for a tighter underwriting call.
Gong remains a scaled revenue-AI leader, but public evidence still supports tracking rather than buying because the price anchor is stale and private economics remain opaque.
Nord Security looks like a real, scaled cybersecurity platform with strong consumer reach and product breadth, but the public record still leaves enough valuation, governance, and revenue-mix uncertainty that the right stance remains research-more.
Invisible Technologies has credible enterprise AI traction and a broad modular platform, but its >$2B valuation still outpaces the public evidence on software-like margins and retention.
Ualá has real regional scale and sponsor support, but opaque consolidated economics and Mexico credit risk keep the case at TRACK with a fair, price-sensitive valuation.
Socure looks like a scaled identity and risk platform with strong growth and distribution, but valuation, disclosure, and control-system gaps still justify a track stance.
Tanium remains a strategically relevant endpoint-management and security platform with durable enterprise traction, but current underwriting is still blocked by opaque ARR, retention, margin, and capital-stack disclosure.
Twelve is still a category-leading CO2-to-fuels platform, but investors should stay in track mode until AirPlant One proves unit economics and customer scale.
Illumio is a category-leading zero-trust segmentation vendor with strong product, customer, and market signals, but its current private valuation remains too uncertain to underwrite aggressively.
Preply looks like a credible late-stage edtech marketplace with real scale and improving efficiency, but the current valuation still outruns the public evidence on revenue, margin, and retention.
CONDITIONAL INVEST — Enterprise Sovereign AI at 29x ARR with Copyright Overhang
Astronomer appears to be a real category leader in enterprise Airflow and DataOps, but the public record supports a track decision rather than a clean buy because valuation, concentration, and margin transparency lag the strength of the product and customer evidence.
Cresta appears to be a real scaled contact-center AI platform, but absent trustworthy pricing and revenue-quality disclosure, the investable stance remains track rather than buy.
Crypto.com is a scaled and strategically broad crypto-financial platform with credible regulatory reach and a fresh $20 billion institutional price anchor, but the company still needs deeper private diligence before that valuation can be underwritten with high conviction.
Bucketplace has stronger fundamentals than many consumer unicorns because Ohouse now pairs category-leading home-living reach with real profitability, but the public record still does not justify paying confidently above the prior unicorn band without deeper diligence.
Quest Global is a credible scaled engineering-services platform with strong customer quality and a legitimate 2026 valuation anchor, but incomplete public disclosure keeps the underwriting case in track rather than buy territory.
SHINE is one of the more credible private nuclear-technology platforms on public evidence, but its undisclosed 2026 valuation terms and still-unproven Chrysalis economics justify a track stance rather than a buy call.
Recover has graduated from circular-fashion narrative to real commercial platform: it has scaled recycled-cotton capacity, named blue-chip customer proof, and a credible policy tailwind. But the company still withholds the financial detail needed to underwrite a premium late-stage price with conviction, so the current public-evidence conclusion is TRACK with a stretched valuation stance.
Moss has reported late-stage scale and an integrated finance workflow, but conflicting financing disclosures and unverified unit economics, retention, and capital terms leave the €1.0bn mark too difficult to underwrite for a buy.
Truenat's installed base and FY26 growth support a credible diagnostics platform, but demand concentration, cash-conversion uncertainty, and public-market pricing risk keep the recommendation at Track.
Quantum Space has credible government-market traction, but its proposed valuation remains ahead of flight proof, funded-backlog visibility, and operating-data disclosure.
Eliyan appears strategically relevant and technically differentiated, but the visible unicorn valuation still runs ahead of the visible operating proof.
Path Robotics has credible product, customer, and market proof, but public evidence remains too opaque on economics and current pricing for price-insensitive underwriting.
Meshy has strong reported scale and product accessibility, but a stretched financing valuation and incomplete independent evidence on monetization make the opportunity a track rather than an immediate buy.
Factorial has credible European workforce-software scale and adoption signals, but private-company disclosure gaps make the current entry price and return case difficult to underwrite.
Candid Health shows strong financing, growth, and adoption signals, but limited independent financial and customer evidence warrants deeper diligence before underwriting.
Arena shows credible category leadership and commercial traction, but public evidence does not yet justify buy-level conviction at the reported valuation.
Emergent shows genuine breakout growth and a credible product wedge, but public evidence still supports tracking rather than a high-conviction buy.
Aira has built a credible integrated residential-electrification platform, but execution risk and missing unit-economic and valuation disclosure warrant tracking rather than an aggressive investment conclusion.
Track: Karrot is a strong local-network consumer platform with improving monetization, but current valuation and international returns remain under-disclosed.
I-TRACING has credible scale and a broad cybersecurity-services platform, but integration, disclosure, and operating-control gaps keep the refresh recommendation at track.
Abound shows credible lending scale, profitability, and differentiated open-banking underwriting, but the investment case remains research-more because valuation, funding structure, loan-book quality, and governance depth are not publicly reconciled.
Tessera has reached clinical-stage execution with a differentiated but unproven Gene Writing platform, warranting a track or research-more stance until first-in-human data and financial runway become clearer.
LiveKit is strategically relevant voice-AI infrastructure, but the $1 billion financing mark remains stretched without verified revenue, margins, retention, and concentration.
Research more at the $7.5 billion reference: AlphaSense has strong scale, enterprise adoption, and product breadth, but private economics and security terms remain too incomplete for a buy recommendation.
Track: Pine Labs is a scaled Indian merchant-commerce platform with improving profitability and credible valuation upside, but tax, breakage, and disclosure risks still block a cleaner buy case.
KreditBee has credible scale, profitability, and a fresh unicorn valuation, but public evidence still does not make the April 2026 price look clearly cheap against credit, disclosure, and regulatory risks.
DevRev remains a structurally differentiated AI-native enterprise platform with founder pedigree and meaningful customer proof, but the public valuation still prices in substantial execution success that is not yet fully demonstrated at scale.
Rohlik remains one of Europe's strongest full-basket online grocers, with clear scale and improving operating proof, but the current public record still falls short of a current valuation case.
Lenskart is a scaled public eyewear platform with verified profitability and operating momentum, but the retained evidence still leaves valuation stretched and governance detail incomplete.
Juspay is a scaled payments infrastructure platform with real enterprise depth, but the current valuation still prices in durable growth despite channel conflict and disclosure gaps.
Ather is now a scaled public EV OEM with clearly better FY26 operating evidence, but the investment case still depends on disciplined capital deployment and better disclosure around retention, payback, and dilution.
HUMAN Security remains strategically relevant in bot and fraud prevention, but the public record is still too thin on financial quality and capital structure to justify anything better than a tracking posture.
Gymshark remains a scaled, founder-led DTC fitness brand with durable community demand, but stale valuation discovery and rising legal/compliance scrutiny keep the investment case in track / research more territory.
Incode looks like a real-scale identity platform with durable enterprise traction, but the public record still does not justify the reported 2025 valuation step-up with conviction.
OnlyFans is still the creator-subscription scale leader, but the public mark leaves room for caution because governance opacity, payment dependence, and creator-trust risk remain material.
Kpler remains a category-defining physical trade intelligence platform with a hard-to-replicate AIS moat and broad enterprise traction, but the June 2026 Sixth Street entry still implies a stretched valuation and disclosure gaps around unit economics, growth quality, and regulatory overhang.
Bending Spoons now looks like a real public software compounder, but leverage, limited segment disclosure, and customer-trust friction still justify a research-more call.
Darwinbox remains a credible enterprise HCM asset, but public evidence still supports a TRACK call because pricing, retention, margins, and cap-structure visibility remain too thin for a confident buy.
Quantexa remains a scaled Decision Intelligence platform with strong enterprise adoption, but the current case still supports TRACK because public evidence does not resolve margin quality, burn, or late-stage cap-table risk.
GlossGenius combines real vertical software traction with a fresh $1.15 billion re-rating, but the evidence still leaves durability, margin quality, and Genius AI defensibility opaque enough to justify only a Track stance.
Semperis is a category-leading identity-resilience platform for Active Directory and Entra ID with $100M+ ARR, 1,200+ enterprise customers, and a durable directory-recovery moat, but its $1B+ valuation and opaque private metrics keep it in research-more territory rather than an outright buy.
Exabeam remains a differentiated SIEM/UEBA challenger with real scale and strong AI positioning, but investors still face opaque post-merger economics and execution risk around cloud migration and legacy customer retention.
Bolttech retains credible global embedded-insurance scale and strategic momentum, but public disclosure is still too thin to underwrite the $2.1 billion valuation with conviction.
Bugcrowd is a credible crowdsourced cybersecurity platform with 1,200+ enterprise customers, FedRAMP authorization, and a $1.0B+ valuation mark, but opaque ARR/NRR/gross margin disclosure, AI-driven triage strain, and unresolved capital-structure questions keep the investment case stretched.
Wireless Logic appears to be a scaled, strategically credible IoT connectivity platform, but the current private-market price still outruns the public evidence base.
Zum has built real late-stage scale in student transportation, but incomplete disclosure on margins, concentration, and EV project economics keeps the stock-story equivalent at research-more rather than buy.
Mech-Mind now has public-market scale, real industrial deployment depth, and strong overseas margins, but high R&D intensity, customer concentration, and a still-stretched valuation keep the stock in research-more territory.
n8n combines strong enterprise traction and SAP-backed distribution with a stretched valuation that still requires disciplined underwriting.
Group14 remains a credible commercial battery-materials platform with real manufacturing assets and strategic backing, but the investment case is still constrained by opaque economics and a delayed Moses Lake ramp.
Flatpay is growing fast and has clear merchant demand, but the €1.5B valuation still depends on opaque margins, heavy field-sales spend, and unresolved regulatory and retention risk.
Underdog is a scaled consumer sports-gaming platform with strong user traction and a validating $1.225B Series C, but regulatory pressure and a pending $1.3B IG Group acquisition cap upside, leaving the view at track/fair.
Writer combines credible enterprise traction and differentiated full-stack AI with a stretched valuation and persistent financial opacity.
Plata's $405 million Series C and March 2026 banking launch confirm exceptional scale, but pre-profitability economics, opaque governance, wholesale-funding dependence, and unresolved fee-transparency allegations keep the recommendation at TRACK.
Kahua has proven scale and a durable regulated-enterprise moat, but its premium valuation and private financial opacity make this a track, not a buy.
Track PathAI through Roche deal close: the strategic price looks reasonable, but standalone economics remain too opaque for a stronger call.
Saviynt combines strong identity-security breadth and fresh growth capital with credible enterprise demand, but opaque economics and inconsistent public data keep the underwriting at research-more.
Kapital looks like a fast-growing integrated SMB finance platform with real operating scale, but the moat, pricing, and risk-adjusted economics remain under-benchmarked.
Celonis remains a category leader in process intelligence, but the investable price signal is still the stale August 2022 mark, so the report stays at track / research more.
Lambda has credible AI cloud scale and strategic validation, but opaque margins, debt, and concentration keep the case at research-more.
Employment Hero looks like a credible scaled SMB employment platform, but public disclosure is still too thin to underwrite the current private-market mark with high conviction.
Agibot pairs exceptional humanoid production scale with a rich IPO target and limited economic disclosure, making it a track-not-buy story.
Ridgeline combines validated customer demand and sponsor-backed capital with opaque private metrics and a stretched valuation.
Pentera remains a category-leading AEV platform with $100M+ ARR and broad enterprise adoption, but private diligence is still needed to verify retention, margins, concentration, and the durability of its $1B mark.
Isomorphic Labs combines elite AI drug-design capabilities and a $2.7B capital base with three marquee pharma partnerships, but the case still hinges on unproven clinical translation and opaque private-market economics.
Pennylane is the category-leading French accounting OS with strong accountant-led distribution and regulatory tailwinds, but the latest Series E valuation leaves little margin for execution missteps.
Lightmatter remains the leading photonic interconnect bet for AI infrastructure, but the $4.4B-$4.63B valuation still outpaces unverified commercial proof.
WHOOP remains a premium late-stage private wearable subscription business with strong bookings growth and positive operating cash flow, but its stretched valuation and unresolved regulatory and disclosure gaps keep the stance at track.
Maven Clinic remains the category leader in employer-sponsored women's and family health, but a $1.7B valuation and opaque audited economics keep underwriting at Track with a stretched valuation stance.
Deel combines global employment scale and a $17.3 billion financing mark with opaque audited economics, so the defensible stance is research more rather than buy.
ThreatLocker combines differentiated default-deny Zero Trust endpoint security and rapid MSP-led expansion with a rich $1.79B valuation, but opaque financial disclosure, channel concentration, and litigation keep the posture at Track.
Harvey remains the category leader in legal AI, but the business still trades at a stretched private valuation with opaque financials and frontier-model dependency.
Antora now looks like a credible industrial-infrastructure scale-up, but public pricing and operating economics remain opaque.
Meesho is a scaled, now-public Indian value-commerce platform with improving profitability and a differentiated low-friction seller model, but it still needs to defend itself every day against competition, regulation, and trust risk.
Dexterity remains one of the most credible physical-AI warehouse robotics companies, but opaque economics and continuing capital intensity keep the right stance at track rather than aggressive buy.
Torq is a credible AI SOC specialist with strong enterprise traction, but its premium valuation still outruns the public evidence on financial quality.
Flo Health remains a category leader with real scale, but the public evidence still supports a cautious track recommendation rather than a confident buy.
Zepto remains a real category leader with strong scale and a less stretched 2026 valuation, but the equity case is still constrained by heavy losses, governance opacity, and a competitive market that can punish execution misses quickly.
Chainguard has built the deepest supply chain security moat in the market — SLSA L3 provenance, nightly zero-CVE rebuild, and Wolfi OS represent 4+ years of engineering investment that is hard for CNAPP incumbents to replicate. Strong regulatory tailwinds (EO 14028, NIS2, DORA) and a growing developer-led pipeline support the long-term thesis. However, the 87.5x trailing ARR entry multiple is priced for perfection and leaves no margin for execution failure. Recommendation: HOLD — upgrade to BUY on confirmed FY2026 ARR ≥ $80M with NRR ≥ 120%.
Wayve remains one of the best-capitalized autonomy platforms, but the business is still too opaque on pricing, revenue, and margins to call it de-risked.
Anthropic's $965B headline mark and $47B run-rate show extraordinary demand, but normalized economics and financing terms remain opaque.
ClearScore is a scaled and profitable UK consumer-fintech platform, but the rumored 2026 IPO range looks stretched versus public comparables; track pending fuller disclosure or lower entry pricing.
Gatik has unusually strong commercial proof for autonomous freight, but the undisclosed round price and opaque economics keep the investment case conditional.
LiblibAI appears commercially real and strategically interesting at late-stage private scale, but the current valuation already prices in strong execution, so the right stance is disciplined tracking unless private diligence proves retention, margins, and moat quality.
OKX is a scaled and strategically important private crypto platform whose operational breadth justifies serious attention, but whose legal history and financial opacity still argue for price discipline and deeper diligence before paying a premium valuation.
Twenty has real strategic relevance and rare public customer proof in offensive cyber, but the current $1B mark warrants a track posture until revenue quality, margins, renewals, and control evidence are opened to diligence.
Kling has become one of the clearest breakout companies in AI video, but the reported July 2026 price already assumes substantial future execution success and leaves the risk-adjusted stance at Track rather than buy.
Track: Multiverse is one of Europe’s more credible sovereign-AI infrastructure stories, but the current $2.3B post-money valuation still looks stretched relative to the public economic proof available today.
Veeam appears to be a scaled, high-quality private data-resilience leader, but the public record still does not fully justify paying above the known $15B secondary mark without targeted confirmatory diligence.
Chime looks like a scaled public consumer-fintech winner, but the current discount mostly reflects real sponsor-bank, regulatory, and disclosure risks rather than market misunderstanding alone.
Zhiyuan is a credible China humanoid frontrunner with meaningful deployment and shipment evidence, but public economics and financing terms do not yet support a buy call.
Reliable Robotics has credible autonomy, certification, and financing progress, but its above-$1 billion private mark remains difficult to underwrite before commercial certification and operating economics are disclosed.
Cover Genius has credible global embedded-insurance scale and partner proof, but public disclosure remains too thin on economics, concentration, financing terms, and security assurance to underwrite the USD 1.9 billion mark with high confidence.
Carousell merits close tracking and serious diligence because FY25 growth, rising recommerce mix, and positive EBITDA improve the operating case, but the lack of a current price, audited unit economics, and complete risk disclosure prevents a high-conviction investment recommendation.
Crusoe has a differentiated power-first AI infrastructure platform, but the reported valuation still assumes successful hyperscale execution that public evidence does not fully underwrite.
Kairos Power is a strategically credible advanced-nuclear platform, but public-only evidence supports a track stance rather than a buy because valuation and economics remain under-disclosed while first-of-a-kind execution risk stays high.
Palmetto is strategically interesting with real financing and platform breadth, but the evidence supports research-more rather than an unconditional investment decision.
Kakao Mobility remains strategically important and competitively resilient in Korea, but unresolved regulatory exposure and thin standalone disclosure justify a cautious track stance.
Expel looks like a credible premium MDR operating asset, but the current price should remain uncommitted until private confirmation of retention, margins, concentration, liquidity, and terms.
Datavant appears to have a strategically important healthcare-data connectivity position, but public evidence remains too thin on current economics to underwrite a premium valuation with high conviction.
Track Digital Asset for its differentiated institutional product architecture and strategic backing, but do not underwrite the reported valuation until audited economics, production-customer evidence, and financing terms are available.
nesto's C$1.47 billion Series E valuation is anchored by genuine operating scale — C$80B+ MUA, C$37B+ 2026 originations, and confirmed profitability — and by high-quality institutional backing from La Caisse and Fidelity, but revenue opacity, balance-sheet funding dependency, and unresolved M3 channel concentration prevent conviction; the evidence supports a track recommendation at a fair valuation.
Eve has clear plaintiff-law workflow fit and strong financing support, but public evidence still leaves revenue quality, retention, and governance too opaque to underwrite the last unicorn mark aggressively.
Pindrop is a category-relevant voice-security platform with real ARR traction and named enterprise proof, but public economics and valuation remain too opaque to underwrite price with confidence.
MoMo remains Vietnam's scale leader in digital wallets and embedded finance, but opaque user definitions, cap-table terms, and valuation-process uncertainty still justify a cautious research-more stance.
Carsome remains the regional used-car category leader, but the latest refresh still lacks enough pricing disclosure to underwrite a fresh entry.
Vuori appears to be a genuinely strong and profitable premium activewear brand, but the last $5.5B mark still looks too expensive to underwrite confidently without audited financial disclosure.
Upgrade combines meaningful scale and partner-bank distribution with charter optionality, but the gap between its $7.3 billion Series G mark and persistent secondary-market discount keeps the name firmly in Track territory.
1KOMMA5° has clear operating scale and a credible Heartbeat AI transition, but the latest financing mark, preference stack, and standalone software economics remain too opaque for a conviction buy.
Rokt remains a Track at a fair $3.5 billion valuation: the company has real commerce-scale momentum and early IPO-readiness signals, but private-company opacity, partner concentration, and a thin retained take rate keep it out of Buy territory.
Lighthouse combines category-leading hospitality scale with fresh AI-product momentum, but opaque unit economics and a disputed valuation keep the verdict at research-more.
Anaconda remains a real, profitable Python platform with enterprise reach, but the public evidence still does not justify high-conviction underwriting at the $1.5 billion mark.
Aragen remains a credible scaled CRDMO with strong customer depth and improving profitability, but the $1.4 billion private benchmark, concentration risk, and incomplete compliance / unit-economics disclosure still justify a research-more stance ahead of IPO pricing.
Halter has built a credible category-leading livestock operating platform with strong public traction, but public evidence still supports only a research-more posture at the $2B mark until private unit economics, governance, and welfare durability are underwritten.
Awardco is a real enterprise rewards platform with strong customer traction and a differentiated Amazon Business moat, but opaque private economics keep the case in track territory.
VAST Data combines real AI infrastructure scale and differentiated architecture with strong commercial traction, but the $30 billion valuation and unresolved private-market disclosure gaps keep the name in track territory.
Shadowfax is now a public, profitable logistics platform, but client concentration, funding reconciliation and valuation clarity still justify a track stance.
OPay looks operationally scaled and profitable on the latest public figures, but thin audited disclosure and IPO-era valuation claims keep the investment case at track rather than buy.
DeepL is a scaled enterprise Language AI platform with credible customer adoption and a premium private-market mark, but the current underwriting case remains constrained by opaque revenue quality, retention, margin, and financing terms.
Cohesity is a scaled private cyber-resilience leader with strong enterprise reach, but the post-Veritas capital structure and retention economics still justify a cautious track stance.
Stegra remains the leading European green-steel megaproject, but the 2026 financing close only partly de-risks completion because commissioning timing, contract economics, and valuation remain opaque.
Klarna is a scaled public consumer-finance and payments network with improving profitability, but litigation, regulation, and softer German retail demand keep the case at track rather than buy.
Claroty is a scaled CPS security leader with strong enterprise adoption and continuing financing access, but the private-market valuation and operating economics remain insufficiently transparent for a firm price call.
KoBold Metals pairs a differentiated AI mineral exploration platform with a world-class copper asset, but the latest private marks still depend on Mingomba execution and feasibility de-risking.
FourKites remains a credible enterprise logistics platform with meaningful AI upside, but the refreshed public record still leaves enough financial and operational uncertainty that the valuation should be treated as a range, not a point estimate.
Snyk remains a category-leading developer-security platform with strong product breadth and real customer traction, but the valuation is still stretched relative to current public signals, competition is intensifying, and the private-company disclosure gap keeps conviction at track rather than buy.
Speak has credible AI-language-learning traction and real unicorn momentum, but public evidence still undersupports the $1B mark.
Innovaccer looks like a scaled healthcare AI platform with real customer traction and strong strategic backing, but the valuation case is still constrained by opaque margins and concentration risk.
Turso is a credible developer database with real differentiation, but public evidence still does not support a precise valuation call.
Wujie pairs unusual early capital with one of the strongest disclosed Chinese humanoid order signals, but opaque economics and concentrated commercialization risk keep the company in track territory.
Zhuji Dynamics has achieved a late-stage humanoid robotics financing and IPO-preparation milestone, but public evidence still leaves customer economics, deployment scale, and governance transparency too thin for a buy recommendation.
Guardio looks like a legitimate late-stage consumer-cyber breakout with a differentiated browser-security wedge, but the public record is still too thin on retention, margin, and partner economics to underwrite the current valuation with high conviction.
Vestwell is a scaled, category-relevant savings-infrastructure company with a defendable $2B public valuation anchor, but the absence of public margin, retention, and concentration detail keeps the investment call conditional.
Material Security has credible cloud-workspace security differentiation and unusually strong customer proof, but the 2022 unicorn mark is now too stale—and the current financial record too opaque—to support a full-price conviction call from public evidence alone.
Digital Edge appears strategically credible and likely valuable, but public evidence still supports RESEARCH-MORE rather than a conviction-priced entry at an unknown valuation.
Kela has credible early deployment and financing momentum, but its private valuation already assumes substantial execution and allied-market expansion that public operating evidence does not fully underwrite.
Lighter has public scale, technical differentiation, and investor validation sufficient for continued diligence, but the reported $1.5 billion valuation is not cleared by public evidence because revenue quality, customer durability, and regulatory and operational resilience remain under-disclosed.
OriCell has credible clinical and financing momentum in a difficult CAR-T segment, but the public record is not sufficient to underwrite valuation or commercial scale.
IM Motors is a credible, strategically backed premium EV contender, but public evidence supports tracking rather than underwriting a premium current valuation.
Track: Fever shows credible global scale, partner proof, and reported operating momentum, but the $5.2B private valuation remains only conditionally supportable without audited economics, retention, and concentration data.
Spectro Cloud appears strategically relevant in AI infrastructure management, but the reported $1 billion-plus private valuation remains a research-more situation because public operating and economic proof is incomplete.
Pulumi shows credible platform and adoption potential, but conflicting financing evidence and missing operating metrics keep the investment case at research-more.
Lead Bank has differentiated sponsor-bank infrastructure and credible fintech traction, but regulatory, concentration, governance, and financial-disclosure gaps make a price-sensitive track stance more appropriate than an unconditional buy.
Dash0 has credible founder-market fit, standards-native product depth, and adoption momentum, but its $1 billion price is not underwritable without primary financial, customer-quality, control, and financing-term evidence.
Moloco shows credible product breadth and operating scale, but missing current financials, ownership, and entry terms keep the investment decision at research-more.
Credible industrial AI platform with strong customer proof and integrated product design, but incomplete financial disclosure keeps the investment case short of full underwriting.
Category-defining premium berry platform with branded distribution scale and strong investor support, but opaque economics and climate-exposed agriculture keep the investment case at a track rather than buy.
Geek+ is a public, founder-led warehouse-automation platform with strong 2025-2026 operating momentum, but the right stance remains track because valuation dispersion, disclosure gaps, and competition still limit margin of safety.
Nscale has assembled one of Europe's most ambitious AI infrastructure platforms, with sovereign AI positioning, elite investors, and Microsoft-anchored demand — but the public record still lacks revenue disclosure, the customer base is hyperconcentrated, leverage is rising, and UK planning friction keeps the current $14.6B valuation in stretched territory.
TymeBank looks like a scaled, fast-growing digital bank with real customer traction and a demonstrated path to profitability, but the current valuation, post-rebrand operating picture, and latest financial quality remain only partially visible.
La Renon is a late-stage private branded-pharma platform with durable therapy breadth and export reach, but incomplete disclosure keeps the investment case at track rather than buy.
Teleport has real product depth and enterprise proof, but its public underwriting remains capped by a stale 2022 valuation anchor and opaque current economics.
Attentive remains a category-leading consumer martech platform with credible scale and product breadth, but the public valuation anchor is stale and current economics are still too opaque for a high-conviction buy.
Boston Metal shows strong capital access and real technical progress, but public disclosure still does not support a priced underwriting call.
ROKAE is a public Chinese robotics issuer with real commercial scale and improved disclosure, but the evidence still supports caution on valuation discipline and governance concentration.
Track: K2 has real mission and financing traction, but the public record still does not justify full confidence in the $6.8B mark.
Higgsfield has real product breadth and revenue momentum, but public evidence still leaves enough gaps around quality of revenue, margins, and capital structure that the latest mark is better treated as research-more than a buy.
Coralogix has real product breadth, customer traction, and funding momentum, but the public record still leaves revenue quality, retention, and Series F terms too opaque for aggressive underwriting.
Starling remains one of the few profitable European neobanks, but opaque current pricing, Engine economics, and post-fine compliance work keep the stance at track.
Sierra combines elite founders, strong enterprise traction, and deep capital access, but the valuation remains expensive and the private unit-economics picture is still too opaque for a higher-conviction call.
Pudu Robotics combines real global deployment scale, category breadth, and fresh capital access with a still-opaque financial profile, so the April 2026 unicorn valuation remains stretched and best treated as a research-more name.
Ayar Labs remains a technically credible, deeply capitalized optical-I/O platform, but the absence of disclosed revenue and durable operating metrics keeps it in track territory rather than buy.
OLIPOP is a category-leading prebiotic soda brand with profitable growth, but litigation and exit risk cap near-term upside.
Aikido Security is a credible developer-first security platform with strong growth and product breadth, but the $1B valuation is ahead of what retained public operating evidence can support.
Shiprocket combines real public-market scale with a broad commerce stack, but margin pressure, customer-acquisition costs, and funding-history opacity keep it in TRACK territory.
Heartflow is a scaled public coronary-AI platform with strong revenue growth and high gross margin, but the current valuation case remains constrained by missing price inputs, opaque customer economics, and unresolved legal exposure.
CDN77 is a scaled, cash-generative infrastructure provider whose CVC minority investment validates the business but leaves valuation, governance, and margin diligence unresolved.
Harness has credible enterprise DevOps scale and product breadth, but the 22x ARR valuation still depends on undisclosed retention, margin, and compliance proof.
CADDi is a technically differentiated industrial AI platform with strong enterprise validation, but its premium valuation still rests on opaque private metrics.
Verda is scaling quickly into a European sovereign AI cloud leader, but capital intensity, supplier dependence, and incomplete margin disclosure keep the investment case at track.
Arcee AI combines credible sovereign open-weight traction and exceptional training efficiency with a premium valuation and opaque recurring revenue, making it a high-risk research-more name.
Tennr looks commercially promising and well funded, but public evidence is still too thin to underwrite margins, retention, or runway with confidence.
RELEX is a high-quality late-stage enterprise software asset with strong growth and broad customer proof, but the public valuation and financial disclosure remain too opaque to call it a buy.
ClassDojo still has a category-leading K-8 distribution moat, but the public revenue base is too opaque to treat the $1.25B mark as cheap.
Airwallex's $1.3B ARR, $11B valuation, and 85+ licenses make it a CONDITIONAL WATCH; US execution, compliance, and financial transparency remain the key thesis-validation milestones before a more assertive commitment.
Arcadia now looks like a scaled enterprise energy-intelligence platform, but the public record still does not support a clean entry-price call.
Linear is a standout workflow product, but the public evidence base is still too thin to justify paying the last unicorn round price with confidence.
Cleo looks like a real scaled AI-first consumer-finance company, but incomplete price and risk disclosure keep the current call at track rather than buy.
Liquidity is a credible AI-driven private credit platform with strong institutional partners, but it remains too opaque for high-conviction underwriting at a premium to its stale 2023 unicorn mark.
Thrive has built a real AI-enabled services platform with public revenue support above $600M, but the current $12B mark remains stretched until consolidated margins, retention, and regulatory scalability are disclosed.
Qianxun passes on strategic importance and market position, but only a price-disciplined entry around the last well-supported public mark offsets the company’s disclosure and geopolitical risk.
CodeRabbit is a high-momentum AI change-management company with credible enterprise proof, but the $1.5B Series C already prices in execution and economics that public data does not yet confirm.
Suki has enough product, customer, and market evidence to remain investable in principle, but current public disclosure still supports research-more rather than a premium-price conviction call.
Lumilens has stronger-than-average early proof for a private AI optics startup, but public evidence still supports a track-and-verify posture rather than paying a full late-stage price with limited visibility into revenue quality, diversification, and cap-table terms.
Zenity looks like a real and potentially category-defining AI-agent security company, but the current late-stage price should be treated as stretch-sensitive until private metrics validate the public narrative.
Interswitch appears to be a durable Nigerian payments infrastructure franchise with real revenue and renewed profitability, but the public record still favors further diligence over paying materially above its stale 2019 unicorn anchor.
Octopus Energy has credible retail scale and a valuable Kraken software option, but the investment case remains execution- and disclosure-constrained.
Fresh Life Cold Chain has credible operating scale and financing access, but opaque financials and financing terms make the current investment case price-uncertain.
Coda has differentiated gaming-native payments and commerce scale, but current price, combined profitability, and post-Recharge economics are not sufficiently disclosed for an investment decision.
Kraken has credible sovereign-customer and strategic-financing signals, but the public record does not disclose the operating denominators needed to underwrite its reported valuation.
Ominimo shows unusually rapid European motor-insurance growth and strong carrier-backed distribution, but the reported unicorn valuation still outruns the quality of public disclosure on retained economics, governance, and licensing scale-up.
PointClickCare has a strong post-acute care platform position, but incomplete private-company disclosures and unresolved information-blocking litigation keep the underwriting case in research-more territory.
Pigment has credible enterprise-planning traction and a major 2026 financing, but insufficient public operating and deal-term disclosure supports only a price-sensitive research-more stance.
Kurly's profitability inflection and partner-channel growth improve the case, but thin margins, opaque liquidity, and competitive pressure make the current stance track rather than buy.
Flex has credible product breadth and financing momentum, but the reported valuation still depends on unverified revenue quality, credit performance, customer durability, and global-control execution.
Dongchedi has credible automotive-platform reach and ByteDance-linked distribution, but opaque economics, governance, and trust risks keep the reported $3 billion private valuation at a research-more, information-discounted stance.
Newsela has a credible differentiated-content and district-workflow position worth tracking, but public evidence does not support a current buy at an unknown private-market price.
MGT is a credible, scaled SLED technology and advisory platform, but the investment case remains dependent on private diligence of audited economics, capital structure, customer durability, and acquisition quality.
Evoken has credible product breadth and reported scale, but public evidence does not yet verify durable high-margin ARR or clean shareholder economics.
Virta shows differentiated metabolic-care capabilities and stronger 2026 operating momentum, but the public record supports tracking rather than underwriting a new entry until private-market pricing, retention, margins, and risk disclosures improve.
Aledade has credible scale and adoption evidence, but current valuation, financial quality, debt utilization, and ownership economics remain too opaque for a buy decision.
Alentis has a coherent CLDN1 platform and meaningful partner validation, but limited human efficacy, valuation, and runway disclosure support a high-risk track posture.
Quwan appears to be a scaled historical gamer-social asset with credible monetization, but stale operating disclosure and unverified transaction terms keep the investment case conditional.
Atom is a credible neutral-atom platform, but sparse public economics and unverified financing terms support research-more rather than a conviction-priced entry.
PixVerse shows strong product and user momentum and a reported valuation above $2 billion, but undisclosed monetization and unit economics keep the company in track territory.
SenseTime Medical has credible hospital-platform breadth and financing momentum, but unresolved operating economics and financing terms keep the recommendation at research-more.
LeapXpert appears to have a credible governed-communications position and meaningful financing and customer signals, but public disclosure is insufficient to support a confident price-based investment call.
Research more: Stori shows meaningful financing access, product breadth, and reported customer scale, but fair valuation is more defensible than a strong buy until portfolio economics, cohorts, partner dependence, and current valuation are verified.
Redaptive has a credible financing-enabled deployment platform, but current public evidence does not support a confident entry price or underwriting of operating cash conversion.
Oasis Security has credible strategic relevance in non-human identity security, but opaque operating metrics and conflicting acquisition-status evidence support continued diligence rather than outright conviction.
Fox ESS has credible residential-storage scale and reported profitability, but Europe concentration, regulatory exposure, and thin valuation and governance disclosure support tracking rather than an executable investment call.
Safe Security has credible category and financing signals and a broad enterprise cyber-risk platform, but limited financial and independent operating evidence supports tracking rather than an unconditional buy.
eSentire has a credible differentiated MDR proposition and broad customer proof, but the public record is insufficient to underwrite valuation or recurring-revenue durability.
Research more: RunPod combines rapid company-reported growth, broad developer adoption, and competitive GPU pricing with unresolved unit-economics, reliability, compliance-scope, retention, and valuation evidence.
CtrlS is a scaled domestic data-center operator with contracted demand and institutional backing, but a full valuation and return case remains blocked by debt-intensive expansion and private-company opacity.
Global Eggs is a strategically credible multinational egg platform, but the announced US$8 billion valuation is stretched until audited earnings, leverage, and transaction terms are disclosed.
OpenRouter has credible multi-model scale and strategic relevance, but unresolved transaction terms and unaudited economics make research-more the only supportable current stance.
Profound has credible enterprise product breadth and exceptional financing momentum, but its $1.8 billion mark is stretched against public evidence that omits audited recurring revenue, retention, margins, and security-level economics.
Highway has credible category leadership and customer adoption in freight fraud prevention, but public disclosure is still too thin for a price-sensitive investment call.
Viam offers a credible robotics control-plane platform with visible partner-led momentum, but undisclosed revenue, valuation, and customer retention keep the call at track.
Huma remains strategically credible as regulated digital-health infrastructure, but the public record is still too thin on current economics to underwrite a buy call.
Highspot by Seismic is a scaled AI revenue-execution platform with real product momentum, but the merger has raised execution risk and public valuation remains opaque.
Formlabs is a scaled private additive-manufacturing leader with real product breadth and a new $699 entry wedge, but stale valuation marks, limited liquidity visibility, and incomplete private-company disclosure keep the right call at Track rather than Buy.
Allica Bank is a profitable UK SME challenger bank at unicorn scale with strong growth momentum, but credit-cycle risk, declining capital ratios, and private-company opacity cap the case.
Veriff now appears to be a scaled, profitable identity-verification vendor, but public evidence still leaves pricing realization and liquidity unresolved.
X-energy remains a strategically important advanced-nuclear platform with real capital access and named deployment partners, but disclosed economics are still too incomplete for a clean cash-flow underwriting case.
Fireworks is a real, fast-scaling AI-infrastructure platform, but the current public mark already prices in much of the growth and leaves margin durability and concentration unproven.
Erebor shows real deposit and fundraising traction, but public evidence still leaves earnings durability, concentration risk, and product controls insufficiently de-risked.
Luma AI combines frontier multimodal product breadth with exceptional capital access, but public evidence still leaves revenue, retention, and unit economics too opaque to underwrite the $4.0 billion mark confidently.
Goodfire combines a category-leading interpretability team and differentiated runtime safety tooling, but the public record still supports research-more rather than a clean buy.
N26 is now profitable, but BaFin overhang, a stale private valuation, and unresolved cap-table opacity still justify caution.
Hightouch is a credible warehouse-native activation leader with real enterprise traction and strong investor validation, but the current $2.75B valuation leaves little margin of safety given opaque ARR, retention, and margin disclosure.
Harmattan AI combines unusually strong sovereign-defense traction and a $1.4B valuation with opaque unit economics and customer concentration, keeping the investment case in research-more territory.
Calm is a scaled and durable mental-wellness brand with real consumer and sponsor reach, but private-company opacity, leadership-transition risk, and a stale 2020 US$2 billion valuation anchor keep the current stance at track rather than buy.
Varda pairs exceptional flight execution with a credible dual-use platform, but the $1.6 billion Series D still depends on undisclosed customer economics and private financial disclosure.
Decagon has strong enterprise traction and product depth, but private ARR, margins, and cap-table opacity leave its $4.5 billion valuation hard to underwrite from public evidence.
Parloa has strong enterprise traction, blue-chip references, and deep SAP/Azure distribution, but its roughly 60x ARR valuation, opaque gross margins, and platform-absorption risk keep the investment stance at Research More.
Liftoff Mobile's IPO validates a scaled mobile adtech platform, but AppLovin pressure and limited disclosure keep the story in monitor mode.
Alumis looks like a high-risk but still attractive late-stage TYK2 story: strong Phase 3 psoriasis efficacy and ample cash runway support a buy case, but the single-asset regulatory path, competition, and payer execution remain the key swing factors.
CompanyCam combines clear contractor adoption with strong venture backing, but public valuation marks and private operating metrics still leave the entry price unresolved.
OneTrust remains the category-defining privacy and AI governance platform, but the $4.5B down-round mark and opaque unit economics keep the stance at track.
IQM is a leading European sovereign quantum hardware vendor with a newly strengthened balance sheet and visible backlog, but its valuation, concentration risk, and capital-intensive delivery model still justify a cautious stance.
Carro remains a scaled, profitable Southeast Asian automotive platform with credible IPO optionality, but opaque capital structure, customer disclosure gaps, and valuation uncertainty keep the recommendation at Track.
Thyme Care now looks like a scaled oncology-navigation platform with real payer/provider traction and a >$2B financing mark, but public financial opacity and cap-table gaps still justify a track call.
Teamworks remains the category leader in elite sports operating software, but opaque ARR, margins, and integration economics keep the $1.5B-$1.8B private valuation in research-more territory.
Mujin has a defensible robotics-software platform and strong capital backing, but its public economics remain too opaque to underwrite beyond a track stance.
Melio has real SMB payments scale and strategic distribution value, but standalone economics remain too opaque to justify a new entry price.
Astranis has built a credible dedicated small-GEO satellite platform with named customer deployments and substantial funding, but unresolved reliability, execution, and disclosure gaps keep the risk profile high and the valuation only fair.
Kalshi's regulatory moat and revenue growth look real, but the current $22B-to-$40B valuation range still assumes sports-market legal outcomes that remain unresolved, so research-more is the right posture.
SendCutSend looks like a high-quality software-enabled manufacturing platform, but the May 2026 unicorn valuation already prices in a large share of the execution story while audited financials, debt terms, and preference-stack details remain private.
Truveta's provider-governed data moat and genomics optionality remain compelling, but opaque economics, governance complexity, and privacy/execution risk justify a cautious track stance.
Suno has converted consumer virality into a large private AI music business, but unresolved copyright exposure and opaque unit economics keep the $5.4B mark in track-only territory.
BuildOps remains a fast-growing vertical SaaS leader in commercial contractor operations, but opaque unit economics and a stretched $1B valuation keep the stock in Track territory.
Trade Republic is a large, profitable European neobroker-bank with 10 million customers and €150 billion in assets, but the June 2026 PFOF transition, private-company opacity, and a stretched secondary valuation keep the stock at track rather than buy.
TravelPerk remains a credible late-stage corporate travel platform, but the public record still does not provide enough audited financial, contractual, and retention evidence to underwrite the $2.7 billion private mark with high conviction.
Platform Science has a real OEM-native distribution moat and named enterprise traction, but the investment case remains constrained by private financial opacity, OEM/channel concentration, and integration risk.
Flutterwave remains a category-leading African payments infrastructure franchise, but the current $3.2 billion valuation still looks stretched against opaque financials and unresolved regulatory and operating-risk gaps.
Thunes combines deep cross-border network reach, a broad regulatory footprint, and disclosed operating profitability signals, but its exact Series D valuation and audited financial performance remain opaque enough to keep the investment case at track rather than buy.
Lyra remains a category-leading employer mental health platform, but the private valuation still looks stretched given undisclosed unit economics and limited post-2022 financial visibility.
Zetwerk is a late-stage contract-manufacturing platform nearing IPO with strong FY26 growth, but working-capital intensity, concentration, and exceptional charges keep the thesis at track rather than buy.
GreyOrange has credible enterprise scale in warehouse and store automation, but opaque economics, conflicting funding totals, and an undisclosed current valuation keep the right call at track rather than buy.
Headway remains a category-leading insurance-native behavioral health network with strong clinician and payer reach, but the lack of public operating economics keeps the valuation case dependent on private financing marks rather than auditable performance.
Devoted Health remains a scaled, founder-led Medicare Advantage payvidor with strong membership growth and leading Star Ratings, but the private mark is stretched and transparency into audited financials, capital structure, and operating metrics is still limited.
High-scale private physical-security platform with strong product breadth and growth, but continuing regulatory, lock-in, and financial-opacity risk keep the $5.8B mark difficult to underwrite.
NEURA Robotics combines a broad Physical AI platform with a large milestone-based Series C, but public evidence still does not support the reported $7B valuation as a firm cash-and- commercialization case.
Shield AI pairs a differentiated autonomy platform with real defense adoption, but the valuation still prices in a lot of execution and disclosure risk.
Sword Health is a scaled AI digital-care platform with strong enterprise and public-sector traction, but independent validation gaps and a stretched private valuation keep the stance at track.
Mistral AI remains Europe's leading sovereign frontier AI lab, but the new €3 billion Series D and ~$400 million ARR run-rate still leave a high-risk, track-worthy underwriting case until audited margins, retention, and cash generation are disclosed.
Groq has company-reported developer reach and a low-latency inference offering, but the licensing transition, capital requirements and unverified unit economics support tracking rather than a demonstrated durable moat or intrinsic-value conclusion.
1X Technologies is a well-backed humanoid robotics company with real product momentum, but the refreshed record still leaves autonomy, economics, and valuation too opaque for an aggressive stance.
Kavak looks healthier than it did a year ago: profitability is showing up, the balance sheet has fresh support, and the company is still scaling a differentiated used-car and financing platform. The valuation reset and continued disclosure gaps keep the case interesting but not cheap, so the right posture remains to track rather than underwrite aggressively.
Nuro remains a credible AV software licensor with stronger public funding and partnership support than the prior refresh, but it is still pre-commercial and dependent on Lucid/Uber execution and California permitting.
Scale AI holds a defensible position in AI infrastructure with strong government exposure, but faces customer concentration risk, a CEO transition, and a pivotal business model shift away from data-labeling.
Halcyon occupies a defensible niche in anti-ransomware with strong technical differentiation and rapid growth, but limited financial transparency and platform consolidation risk warrant a Track recommendation at medium confidence.
Cato Networks is the Gartner-recognized single-vendor SASE leader with 4,800+ customers and $415M+ ARR, but undisclosed NRR/margin data and IPO uncertainty still cap conviction at the $4.8B valuation.
Axonius has durable CAASM leadership and government penetration, but the $2.6B flat valuation, CEO transition, and unresolved financial opacity demand private diligence before institutional commitment.
Gecko Robotics has real strategic traction in defense and energy, but the public record is still too thin to justify paying the last $1.25B price with confidence.
Marvell paid $3.25B upfront for the most technically advanced silicon photonics scale-up interconnect asset available at a critical inflection point. The acquisition thesis — converting Celestial AI's Photonic Fabric into $500M+ ARR by FY2028 via Marvell's hyperscaler relationships — is coherent, but rests on a pre-revenue foundation with 18+ months of execution runway before revenue recognition. The 6.5x 2-year forward ARR multiple is at the conservative end of AI silicon comps, making the upfront price defensible if the earn-out milestones are achieved; the $2.25B contingent consideration appropriately aligns incentives. Risk rating is high given technology, timing, and talent execution variables.
InoBat looks like a real but still high-risk battery platform: stronger on strategic partnerships, product breadth, and storage traction than on disclosed financial proof.
Color Health is strategically interesting and operationally real, but the public evidence set supports a TRACK call rather than a BUY because the stale $4.6B 2021 mark looks stretched against today's revenue proxy and disclosure quality.
Instinct is a $2.5B consumer AI assistant with extraordinary ARR momentum but material privacy, security, and governance risks that make the valuation stretched at current evidence quality.
Grid-edge platform with strong utility footprint acquired by Octopus at ~50% discount to prior peak valuation
PalmPay looks like a real scaled African fintech and likely unicorn, but incomplete disclosure, Nigeria concentration, and control-sensitive risk keep the current case in track territory rather than buy territory.
Keeper has credible multibillion-dollar platform value and real regulated-market strength, but public evidence still supports only a track / research-more call because price proof lags company proof.
River AI enters the enterprise AI training cloud with a record $1.1B raise backed by NVIDIA and General Catalyst, but is four months old with an unproven product, undisclosed revenue, and intense competitive pressure from both open- and closed-model incumbents.
Bright Machines is a well-funded factory-automation innovator riding the AI infrastructure boom, but long sales cycles, capital-intensive deployments, and opaque economics keep the best public call at track rather than buy.
Category-leading, founder-controlled US yogurt brand compounding revenue at a stretched but defensible ~$20 billion private valuation, gated by opacity, leverage and capital intensity.
Kraken has real sovereign customer proof and strategic sector positioning, but the July 2026 unicorn valuation still depends on fundamentals the public record does not disclose.
JSW One Platforms has a credible full-stack industrial-commerce thesis and a strategically useful JSW Group moat, but the ~$1B valuation still depends on unaudited FY25 operating data and a fast- scaling credit/distribution model that carries meaningful execution and governance risk.
Bolt is Europe's most credible Uber challenger with proven cashflow-positive super-app economics, but the IPO thesis faces a material £200M+ UK legal liability and an EU labour-cost restructuring cycle that investors must model before committing.
CMT has a scaled telematics platform and strategic validation, but opaque economics and an unverified cyber allegation support further diligence rather than an entry decision.
Product breadth and named customer examples support continued diligence, but public evidence does not establish recurring economics, control effectiveness, or a defensible current entry valuation.
Collate has a credible regulated-workflow wedge and strong financing momentum, but the reported near-$1 billion valuation remains stretched until recurring economics and financing terms are verified.
A scientifically differentiated but still binary preclinical ADC platform whose announced Novartis transaction validates strategic scarcity more than clinical proof; track pending closing and human translation.
Elroy Air has differentiated autonomous cargo-aircraft technology and meaningful strategic validation, but public disclosure remains too thin on commercial conversion, operating economics, and transaction cash mechanics to support a high-conviction investment.
EigenQ occupies an attractive quantum-safe infrastructure wedge, but the proposed approximately $3 billion SPAC valuation still outruns the public evidence on operating scale and supports research-more rather than conviction buying.
Crimson has real scale and a differentiated education portfolio, but conflicting valuation marks and limited financial disclosure keep the opportunity in research-more territory rather than a conviction-priced entry.
Assured appears to be a credible vertical-AI claims platform, but the public record does not yet support underwriting its reported $1 billion financing valuation.
Crystalys has a credible late-stage gout asset and substantial disclosed financing, but unresolved clinical, regulatory, capitalization, and launch economics support track rather than a priced-in buy.
Cedar shows credible healthcare enterprise adoption and product breadth, but undisclosed current financial quality and retention keep the investment stance at research-more.
Checkmarx has meaningful enterprise scale and platform breadth, but incomplete financial and retention disclosure prevents high-conviction underwriting.
Cabify shows credible mobility scale and a constructive reported profitability trajectory, but current valuation and cash-generation confidence remain too limited for an investment recommendation beyond further research.
Zyphra has unusually strong public technical and partner evidence for a private AI startup, but customer proof and economics disclosure remain too thin to justify price-insensitive underwriting.
Postman has durable API-workflow relevance and broad adoption signals, but insufficient public evidence on current economics, retention, governance, and valuation supports a research-more stance rather than underwriting at the 2021 peak mark.
Mirakl has meaningful enterprise marketplace scale and a credible category position, but the dated private mark and incomplete financial disclosure support tracking rather than buying.
Ledger is strategically compelling and plausibly scalable, but the public record supports a track posture rather than aggressive premium underwriting.
Quicktron is strategically credible in warehouse robotics, but the investment case remains research-more until audited economics, customer durability, governance terms, and entry pricing are verified.
LimX Dynamics has credible product breadth and financing access, but commercialization quality and operating disclosure remain insufficient for a buy recommendation.
Strong utility workflow evidence supports continued diligence, but opaque financials and a stretched recorded valuation argue against underwriting today.
Track Klook: the marketplace shows meaningful scale and regional breadth, but valuation, retention, governance and cash-conversion uncertainty still warrant diligence before underwriting.
Docplanner merits continued diligence for its scale and integrated workflow position, but public evidence does not support a current priced recommendation.
Nearfield has real technical, customer, and financing proof, but public operating disclosure remains too thin to underwrite the reported valuation as a buy.
Square Yards has credible scale and improving operating leverage, but opaque financing terms and unresolved pre-IPO controls make the security unready for an investment decision.
Blip has credible product breadth, institutional backing, and operating scale, but financial opacity and conflicting valuation evidence prevent a defensible investment price.
Kopi Kenangan has demonstrated regional scale and reported profitability, but unaudited economics and an unconfirmed premium valuation keep the investment recommendation at track rather than buy.
Axiom has credible proof-first technology, research execution, and financing, but its $1.6 billion financing mark remains ahead of publicly verifiable commercial evidence.
Inceptio's commercial deployment evidence merits continued tracking, but absent audited economics, current valuation, and independent assurance prevent entry-price underwriting.
Brevo appears to be a scaled, reportedly profitable customer-engagement platform, but public evidence is insufficient for a price-specific investment recommendation.
Assort Health shows credible patient-access product breadth and commercial pull, but its reported $1.2 billion financing mark remains unsupported by the public operating, safety, and security evidence required for an investment decision.
Exiger has credible product breadth, regulated-market positioning, and company-reported customer scale, but financial, retention, and transaction opacity make the reported valuation context too weak for price approval.
GoCardless has a credible bank-payments franchise and improving profitability, but the completed Mollie acquisition, opaque transaction economics, and governance gaps keep the case at Track.
CAIT remains a strategically credible CATL-backed chassis platform with real OEM traction and fresh capital, but the public record still stops short of underwriting its standalone economics or governance independence.
Tuduoduo is a scaled and profitable industrial B2B platform with credible category depth, but unresolved parent-governance, compliance, and disclosure gaps keep the supportable call at research-more rather than buy.
Trackunit remains a category-leading construction telematics and operating-data platform, but limited post-buyout transparency, undisclosed leverage, and persistent execution and privacy risks keep the evidence base from supporting a higher-conviction call.
LMArena looks like the category leader in AI evaluation, but the $1.7B Series A leaves limited margin of safety until neutrality, governance, and customer-concentration questions are resolved.
Kriya looks strategically differentiated and still well funded, but the public record remains too thin on valuation, cash, and human efficacy to justify a more aggressive stance than track.
Onebrief's military-planning wedge and expanding procurement access still support a credible command-software thesis, but the $2.15B headline remains difficult to underwrite without disclosed revenue, margin, or cap-table terms.
Fireflies is a broad AI meeting-workflow company, but its reported $1B+ secondary valuation still lacks public underwriting support.
Ontic looks like a credible connected-intelligence platform with public-sector validation and real funding momentum, but public valuation and unit-economics disclosure remain too thin for a buy call.
Interos remains strategically relevant in supply-chain risk intelligence, but public evidence still leaves financial quality, control terms, and transaction status too opaque to justify a buy.
Resolve AI looks like a technically credible autonomy-first AI SRE with strong founder-market fit and marquee enterprise proof, but the public record is still too thin on financial visibility and independent benchmark proof to justify a confident valuation upgrade.
Moonshot AI has credible frontier-model momentum and real commercialization signals, but the public evidence still leaves valuation, governance, and revenue quality too opaque for a higher-conviction call.
Tripledot looks like a credible scaled mobile-gaming platform with a directionally defensible implied ~$2.0 billion post-close mark, but audited revenue quality, debt, and preference-stack opacity keep the most supportable call at track rather than buy.
Talos is a strategically strong institutional digital asset infrastructure platform with credible product breadth and customer traction, but its current valuation already prices in substantial future execution while public disclosure remains too thin for high-conviction underwriting.
Moneyview is now a public, scaled consumer-fintech platform, but the right stance remains track because the market has already rewarded the IPO while credit quality, partner economics, and post-listing disclosure still need proof.
PFN remains strategically important in Japan's AI stack, but public evidence still underwrites capital intensity and technical breadth better than valuation precision or monetization quality.
Lovable combines rare prompt-to-production velocity with strong enterprise mindshare, but its $13.3B valuation, opaque margins, and incomplete retention evidence still justify a research-more stance.
Pivot Bio has credible agronomic proof and real commercial reach, but private financial opacity, partial nitrogen-replacement ceilings, and a stretched legacy mark keep it in research-more territory.
CHAOS is a well-funded defense sensing startup with real field-validation and procurement-channel signals, but public revenue and customer-economics disclosure remain too thin to justify the current private-market valuation.
Nirvana combines credible telematics-driven underwriting momentum and fresh Series D backing with enough disclosure opacity that the $1.5 billion valuation still merits caution.
Mambu has real global scale in cloud-native core banking and payments, but opaque financials and a stale 2021 valuation keep the investment case in research-more territory.
Avathon combines credible industrial AI product breadth and marquee customer validation with unresolved financial opacity, leaving it a research-more opportunity rather than a clean buy.
Garner combines real commercial scale and a differentiated care-navigation model with still-opaque private economics; the business looks credible, but public disclosure is not yet enough for a priced buy call at a $2.74 billion Series E valuation.
ID.me remains a real reusable-identity asset with national-scale reach, but the current >$2B private mark still runs ahead of the public evidence on revenue quality, margins, concentration, and policy durability.
Clip has real strategic value as a scaled Mexican SMB-payments platform, but limited audited disclosure and a demanding $2 billion price keep the call at RESEARCH-MORE with medium confidence and a stretched valuation stance.
Serval combines a credible AI-native ITSM architecture and strong venture backing with opaque unit economics and a customer base still concentrated in tech-forward accounts, leaving the $1B valuation as a trackable but stretched bet.
Persona remains a strategically important identity platform, but its $2.0B valuation still looks stretched on public evidence until private ARR, retention, margin, concentration, legal-reserve, and cap-table diligence improve.
Track: Wave combines rare mobile-money scale and strong price-led adoption with limited financial disclosure, regulatory complexity, and stale private equity price discovery.
MiniMax is now a public, fast-growing multimodal AI platform, but thin margins, litigation, and limited transparency keep it in Track territory.
True Anomaly is strategically relevant and well capitalized, but the public record still supports a cautious, research-more stance because mission proof outpaces economic disclosure.
Midi Health has built a scaled insurer-integrated menopause clinic, but public evidence still does not underwrite the current unicorn valuation or core unit economics.
Grow Therapy has clear operating scale and real payer distribution, but the lack of GAAP revenue, margin, and contract transparency still makes the business a research-more rather than a buy.
StackAdapt looks like a real scaled adtech platform with meaningful product breadth and customer reach, but the premium 2025 valuation and private financial opacity keep the underwriting case at track.
Gradiant is a differentiated industrial-water infrastructure company with strong demand in semiconductors and AI data centers, but the $2B valuation and limited financial disclosure keep the decision at Track.
Airalo remains a scaled travel eSIM leader, but private economics and carrier dependence keep the right posture at Track.
Moon Active combines exceptional Coin Master scale and cash generation with high title concentration, recent restructuring, and persistent private-market opacity.
MNT-Halan has become a regional lending-led fintech super app with clear scale, but incomplete disclosure on credit quality, capital structure, and segment economics keeps the case in research-more territory.
Oishii remains one of indoor agriculture's more credible premium brands, but the public case still leans on capital backing and price power more than disclosed operating economics.
Creditas is a scaled Brazilian secured-lending platform with improving revenue and margins, but opaque liquidity, capital-stack, and valuation disclosure still justify only a track stance.
Aura combines a broad consumer digital safety bundle with public-scale ARR and multi-channel distribution, but the March 2026 breach, partner concentration, and incomplete private-company underwriting inputs keep the thesis in research-more territory.
XBOW looks like a category-leading autonomous offensive security platform with strong enterprise traction and top-tier backing, but public financial evidence still stops short of revenue quality and liquidity.
WorkOS remains a category-leading enterprise identity platform with impressive AI-native customer proof, but its $2.0B valuation still outruns public operating disclosure and keeps the recommendation at research-more.
Socket has genuine developer-first product traction and a fresh $1B Series C, but public evidence still does not support a more aggressive valuation view because ARR, retention, margins, burn, and cap-table terms remain undisclosed.
PostHog remains a compelling developer-first platform with real adoption and broad product breadth, but the public evidence still does not justify underwriting its $1.4B valuation with confidence.
Blackwall combines proven hosting-channel scale with strong technical fit, but the underwriting case is limited by private financial opacity and a stretched implied valuation.
Go1 appears to be a scaled and strategically relevant enterprise learning platform, but the public evidence supports the business more cleanly than it supports the latest private valuation.
Bitsight remains a category-defining cyber risk intelligence platform with real scale and expansion momentum, but opaque private-market economics and incomplete public disclosure keep the investment case at research-more.
Eight Sleep has credible product differentiation and a fresh $1.5B financing anchor, but opaque financials, trust-sensitive product risks, and a premium valuation keep the underwriting case in track territory.
BillionToOne merits a TRACK rating: the platform, growth, and liquidity are strong, but the shares still look fairly valued versus unresolved reimbursement, litigation, and control risk.
Vention has credible industrial-automation traction and fresh 2026 capital, but unaudited margins, cap-table opacity, and unresolved customer-retention evidence keep it at track rather than buy.
SafetyCulture still looks like a real frontline-ops category leader, but the AU$2.5B mark remains stretched because audited financials, retention, and governance disclosures are incomplete.
Nexamp remains a scaled and financeable community-solar platform, but public disclosure is still too thin to underwrite the equity confidently.
Chai Discovery looks commercially credible and richly financed, but the latest $3.8B mark still cannot be underwritten from public economics.
Aidoc is a credible scaled clinical-AI platform, but public evidence is still too opaque on price and economics to support more than a research-more stance.
Vectra AI looks strategically important and commercially credible, but current financial opacity and stale valuation evidence keep the investment call at track.
Included Health shows visible product breadth, enterprise scale, and 2026 plan-expansion momentum, but opaque financials, governance, and retention data keep the investment case in research-more territory.
Vestiaire Collective remains a leading European luxury resale platform with near-€1B GMV, about €200M of revenue, and improving margins, but the current valuation and cash-conversion picture remain too incomplete for a higher-conviction stance.
Together AI combines strong product traction and capital access with opaque economics, leaving the $8.3B mark more a financing signal than a fully underwritten intrinsic value.
Navan has a strong growth and cash-generation profile, but litigation, GAAP losses, partner dependence, and AI/control execution risk keep the name in track-only territory.
Nuvemshop remains Latin America's leading independent SMB e-commerce platform, but stale valuation, opaque financials, and uncertain fintech economics keep the case in research-more territory.
Glow is a well-capitalized but still unproven AI-native endpoint security startup: the team and funding are strong, but public revenue, pricing, and independent efficacy validation remain missing.
Ramp's category leadership and 70,000+ business footprint justify a TRACK view, but the $44B valuation remains stretched without public margin and retention disclosure.
Open Cosmos is scaling a differentiated European space-infrastructure platform, but underwriting is constrained by launch dependence, opaque unit economics, and valuation uncertainty.
XDOF shows real early demand and a tangible robotics-data proof point, but the company still looks like a capital-intensive services-and-software business whose durability, margins, and security controls are not yet proven.
EnduroSat pairs strong satellite-manufacturing momentum and flight heritage with high capital intensity, limited margin transparency, and a stretched private-market valuation.
Thatch looks like a real late-stage ICHRA platform with strong growth and distribution, but the public record is still too thin to underwrite the $1B mark with high confidence.
Drata remains a category leader in compliance automation and trust management, but opaque current financials and a stale $2B valuation keep the right posture at research-more.
Augury looks real and strategically relevant, but public financial opacity keeps the valuation case at fair rather than attractive.
Back Market is a category-leading refurbished-electronics marketplace with real scale, but the public evidence still leaves enough operational and valuation uncertainty to keep the recommendation at track.
Physics Wallah is a real public-market edtech asset with strong brand and scale, but the current evidence base is still too thin on retention, margins, and cohort quality to justify more than a track stance.
Guild Education built the largest employer-sponsored tuition benefit platform in the United States, anchored by IRS Section 127's structural tax subsidy and a multi-sided network of 500+ employers and 150+ education institutions. The June 2022 Series F at $4.4B represented a peak valuation reflecting COVID-era labor shortage tailwinds and edtech enthusiasm. Since then, the business has navigated two large-scale restructurings, high-profile client cancellations (Disney, Macy's), and an unconfirmed Walmart Workforce Edge threat — while launching Navigator as the growth catalyst required to justify any premium to distressed public comps. At an implied current EV of $1.5-2B (secondary market), the investment case is a conditional buy at or below $2.0B: the structural market is intact, the platform has demonstrated utility at scale, but financial opacity, decelerated growth (~6% YoY), and execution uncertainty during the CEO transition prevent high-conviction commitment without data room access.
Exein looks like a real, fast-growing Physical AI security vendor, but the public record is still thin on retention, concentration, and margins at the $1.7B mark.
OpenAI’s scale is real and the business is still growing fast, but the $852B entry mark remains stretched because revenue durability and free cash flow are not yet fully proven.
Mainspring has real strategic momentum and credible project proof, but public evidence still supports research-more rather than a price-sensitive buy call.
Cyera remains one of the strongest data-security growth stories, but the current public valuation looks stretched and leaves little margin of safety.
Cyberhaven shows credible category leadership and enterprise traction, but the $1B Series D still requires private diligence on financial quality, litigation exposure, and architecture hardening.
MotherDuck looks like a differentiated DuckDB analytics asset with real funding and adoption signals, but the public record is still too thin on operating metrics to underwrite a buy.
Tarana has credible deep-tech broadband infrastructure and real operator adoption, but the public disclosure package still lags the valuation levels implied by late-stage private-market screens.
Epos Now looks like a real late-stage SMB merchant platform with credible embedded-finance upside, but public evidence remains too incomplete to justify paying a unicorn headline without strong price discipline and direct diligence.
Papaya Global looks strategically relevant in global payroll and EOR, but the investment case remains constrained by execution risk, competitive pressure, and limited financial disclosure.
Zhisquare is strategically important and plausibly a future national-champion-style robotics winner, but the current private mark appears rich relative to publicly disclosed fundamentals.
Kunlunxing is a founder-exceptional humanoid robotics entrant with strong capital-market validation, but the valuation narrative currently runs well ahead of public product and customer proof.
Visby Medical is a category-defining molecular diagnostics company with real first-mover FDA regulatory advantages in OTC PCR testing, but a $1B valuation against only ~$35M estimated revenue demands strong consumer adoption evidence before it can be underwritten with high conviction.
Track Viz.ai: the company looks like a real scaled clinical-AI platform, but the public record does not support paying its stale 2022 unicorn valuation without materially stronger private proof.
Starship looks like the strongest scaled sidewalk-robotics company in public view, but incomplete revenue and term disclosure keep the current case in research-more territory rather than buy territory at or above the last explicit $1.2 billion mark.
Traveloka looks like a strategically relevant regional travel platform with improving financial posture and plausible fair value near recent private marks, but disclosure gaps and persistent trust or regulatory concerns keep the call at track rather than buy.
QuintoAndar appears to be a scaled late-stage proptech winner, but public evidence is still too thin on audited margins, reserve exposure, and current pricing to justify more than a track / research-more stance at premium valuation.
Stark Bank looks like a real, scalable, profitable corporate-finance platform, but the current valuation cannot be underwritten tightly from public evidence alone.
Shengshu is one of the more credible Chinese AI-video startups, with strong product momentum and strategic backing, but missing ARR, margin, and cap-table disclosure keep the name in Track rather than buy territory at opaque unicorn pricing.
Mahindra Last Mile Mobility has enough scale, category leadership, and strategic backing to merit serious diligence, but the July 2026 unicorn price still looks stretched until standalone economics and governance disclosure improve.
Rillet looks like a real category contender in AI-native finance infrastructure, but the $1B Series C price already demands fundamentals that public evidence does not yet verify.
Research-more: ArsenalBio is a high-quality solid-tumor CAR-T platform, but the reported ~$1.9B valuation already assumes more public proof than is currently disclosed.
Gravis Robotics has credible product and partner proof in a painful market, but its new unicorn valuation already prices in execution that public revenue and margin evidence do not yet verify.
Culture Amp looks like a credible scaled employee-experience platform, but public disclosure is still too thin to underwrite the current private-market mark with high conviction.
CarDekho is a credible, scaled auto-commerce platform with a real 2026 IPO path, but incomplete segment disclosure and perimeter ambiguity keep the risk-reward in TRACK territory around the proposed Rs 13,000-15,000 crore range.
BharatPe now looks operationally healthier than its governance-era reputation, but the current private valuation already prices in much of that recovery before the hardest diligence questions are publicly answered.
CygnuSemi has enough strategic and technical proof to merit continued diligence, but the reported ~$1.5B valuation should be treated cautiously until customer breadth, revenue, gross margin, and runway are disclosed.
Playlist's $7.5B valuation is stretched relative to services-heavy comparable companies, but its three-sided fitness platform with 100M+ end-user touchpoints and post-EGYM scale creates a defensible category position that warrants deeper private diligence.
Yotta is a strategically valuable sovereign-AI infrastructure platform, but the current reported valuation still looks stretched versus public comps and available disclosure.
Yimu appears to be one of China’s more strategically interesting tactile-infrastructure companies, but the current unicorn valuation still outruns the public evidence on revenue quality and downside structure, supporting a TRACK stance rather than a buy.
Cult.fit is a scaled and strategically interesting Indian fitness platform, but the visible valuation already prices in more proof than the public record currently delivers.
Shippo looks like a real shipping-infrastructure asset with broad platform reach, but the public record supports research-more and a stretched valuation stance rather than underwriting the stale 2021 unicorn mark at face value.
Kodiak has crossed into real commercial and public-market evidence, but its valuation still depends on scaling a concentrated customer base without repeating the financing and safety stumbles that damaged prior AV trucking peers.
Kahoot is a credible, scaled learning software asset, but the public evidence supports the business more cleanly than it supports paying at or above the 2024 sponsor-entry valuation.
Kajabi appears to be a durable, scaled creator-business platform, but the business is better supported by public evidence than the stale 2021 unicorn valuation.
EcoCeres has enough plant, customer, and policy proof to merit close tracking, but the public evidence is still too thin on economics to justify high-conviction underwriting at rumored IPO-level valuations.
Snorkel has credible product depth and customer proof in one of AI's most important workflow layers, but the current valuation still requires diligence on retention, concentration, and software-like economics.
Polarium has real scale, a credible telecom-to-distributed-energy expansion story, and visible turnaround progress, but current public evidence still supports only a track stance because the stale unicorn mark sits ahead of disclosure quality.
Track AdvanCell rather than underwriting aggressively today: the company looks strategically valuable, but the public record is still too opaque for precise valuation confidence.
Kredivo combines established digital-credit scale and banking optionality, but missing parent economics, credit cohorts, and a current entry price support further diligence rather than an investment commitment.
Obsidian pairs substantial enterprise-spend signals with a credible AI-agent-governance position, but opaque recurring economics make its $1.1 billion mark difficult to underwrite and favor tracking over conviction pricing.
Kry has credible hybrid-care scale and improving operating indicators, but unresolved financing, liquidity and retention disclosure keeps the opportunity in track territory.
Vast has credible generative-3D product traction and category momentum, but opaque economics and conflicting financing disclosures make it a tracking opportunity rather than an underwritable buy.
Track: AI21 has credible enterprise-AI technology and customer evidence, but the historical valuation and limited operating disclosure leave too little public margin of safety for a higher-conviction recommendation.
Augustus has a differentiated regulatory and infrastructure opportunity, but the conditional bank, limited operating disclosure, and unresolved control evidence support tracking rather than buying at the reported valuation.
Aerospace Yuxing has real product and customer proof, but the public record still supports tracking the company more than paying peak-narrative pricing.
Satispay has built meaningful Italian payment-network scale and product breadth, but the public evidence does not yet support a confident view on unit economics, controls, or valuation.
YMTC is a strategically important and commercially credible NAND manufacturer, but export controls, capital intensity, and opaque financial and customer disclosures keep conviction at track rather than buy.
Track Envision Energy: commercial scale and strategic breadth are credible, but disclosure, capital intensity, geopolitics, and valuation uncertainty prevent a fully underwritable investment case.
Earendil has credible strategic and financing validation, but the public record does not yet support underwriting its clinical conversion or economics at a precise price.
Super.com has a credible consumer savings and fintech growth narrative, but opaque segment economics, customer durability, compliance exposure, and capital-stack terms keep the investment posture at track.
Omni has a coherent governed-semantic platform and credible founder-market fit, but limited public durability disclosure and bundle pressure support a track stance at the reported $1.5B valuation.
Tandem/Forus shows meaningful prescription-access traction and strategic value, but the reported $1 billion valuation remains difficult to underwrite without reconciled financing, margin, concentration, and governance disclosure.
KnowBe4 has meaningful scale and recurring-revenue visibility, but leverage, active risk clustering, and limited private-company disclosure support research-more rather than a buy conclusion.
Blacksmith shows strong reported demand and infrastructure differentiation, but insufficient disclosure for a confident investment or valuation decision.
Tripo AI has credible product breadth and financing momentum, but opaque operating economics and valuation terms make it a tracking opportunity rather than a fully underwritable investment.
X Square Robot has credible full-stack technology, strong financing access, and early deployment signals, but opaque economics, limited independent validation, and a stretched valuation make research-more the appropriate stance.
Venice AI combines unusually strong reported early traction with a clear privacy-led wedge, but missing assurance, revenue-quality, retention, and financing evidence make it a track rather than an invest decision.
Nimble has credible robotic-3PL and strategic proof, but public evidence does not yet support underwriting its valuation, utilization, or unit economics.
AppsFlyer is scaled and strategically relevant, but opaque economics and unresolved post-incident evidence support tracking the company rather than underwriting a buy today.
Granola's differentiated bot-free workflow and enterprise-context ambition merit continued diligence, but the $1.5 billion financing mark is not supported by disclosed revenue, retention, margin, or cash data.
BlueVoyant looks like a real late-stage cyber-defense platform with material customer scale and broad service breadth, but the market still lacks a reconciled valuation, cap table, and audited economics, so track remains the right posture.
Tianji looks like a real, scaling robotics hardware supplier, but the public financial evidence still lags the May 2026 valuation.
SHEIN is large enough and operationally capable enough to matter, but the 2026 IPO reset, slower growth, and persistent legal and regulatory overhang keep the risk/reward balanced rather than compelling.
Defense Unicorns has real attributable traction in air-gapped defense software delivery, but the $1B+ Series B valuation still depends on economics the public record does not disclose.
Ent is a well-funded, technically credible workspace security startup with early enterprise adoption signals, but pricing, customer depth, and operating metrics remain too opaque to underwrite aggressively.
Flexe remains a category-defining flexible warehousing platform with credible enterprise traction, but stale financing, opaque unit economics, and post-2023 restructuring keep valuation risk elevated.
Scribe has credible enterprise workflow adoption and a differentiated AI-context wedge, but public evidence still supports only a cautious underwriting view at the 2025 $1.3B valuation.
Forterra has real deployment momentum and partner validation, but the public record still does not support a clean financial underwrite.
Cloaked is a broader privacy bundle with real usage and financing momentum, but undisclosed valuation and financials keep the case at research-more.
Drools is a real-scale pet-food brand with strategic validation, but the public file still does not justify a premium valuation without disclosed Nestlé terms and stronger economics.
Fab2 has attracted extraordinary capital and attention for a semiconductor startup, but public evidence still leaves its operating scale, commercial traction, and Texas footprint only partially verified.
Black Lake looks like a real, scaled manufacturing software business with industrial-AI momentum, but disclosure gaps still keep the valuation case in research-more territory.
Amca has a credible industrial thesis and meaningful early scale, but the $1B-plus mark is hard to underwrite without audited financials or customer-concentration disclosure.
Clay remains a category-leading GTM orchestration platform with real product pull, but its public valuation still outruns disclosed retention, margin, and cap-table evidence.
Vantaca looks like a real category leader with strong operating proof and a credible 2025 financing anchor, but sparse public economics and governance disclosure keep the valuation call at track.
Genspark's agentic workspace adoption is real, but the latest $2.6B valuation still outruns public proof on retention, margins, and cap-table detail.
Forus shows real prescription-access traction and strategic value, but the reported $1 billion valuation remains hard to underwrite because margin, concentration, and governance disclosure are still thin.
Infinium now has credible public proof of commercial electrofuels deployment and sponsor backing, but the retained record still does not disclose enough pricing, valuation, or unit-economics detail to underwrite a priced entry.
Performance Drone Works has credible battlefield traction and real domestic manufacturing scale, but opaque economics, customer concentration, and labor/regulatory friction keep the case in research-more territory.
Aalyria has credible government and commercial validation, but the disclosed $1.3 billion valuation still runs ahead of verified recurring revenue and margin disclosure.
Feedzai combines strong enterprise traction in AI-native financial crime prevention with opaque financial disclosure, keeping the investment case at research-more.
SKIMS combines real brand scale and fresh capital with a still-stretched valuation, so the investable question remains whether retail expansion can outrun opaque margins, cash conversion, and founder concentration.
Zelos remains a real, unusually scaled autonomous-logistics operator with deep ecosystem backing, but the lack of audited unit economics and continued valuation/governance opacity still justify a research-more stance.
Fireblocks remains a category-defining institutional digital asset infrastructure provider, but opaque unit economics and a peak-cycle valuation still justify a research-more call.
Faire remains a category-leading wholesale marketplace with strong scale and monetization breadth, but opaque credit losses, legal friction, and a still-elevated private valuation keep the posture at track.
onXmaps remains a category-leading outdoor mapping franchise with clear product traction and institutional backing, but private financial opacity still prevents a high-conviction underwriting call.
Retool still looks like a category leader in governed internal software, but the unchanged $3.2B valuation, private financial opacity, and pricing friction keep the diligence stance at research-more.
At-Bay built a credible cyber InsurSec platform with meaningful SMB distribution, but the August 2026 Munich Re sale at $575 million confirms a sharp valuation reset and leaves final economics dependent on close and liquidation details.
Razorpay remains India's leading merchant-fintech platform, but zero-MDR economics, regulatory dependence, and an IPO-era valuation reset keep it in research-more territory.
Poolside has outstanding sovereign AI software-engineering assets and a transformative Nvidia-backed liquidity event, but public evidence still does not justify an aggressive valuation stance.
Cohere Health has proven real utilization-management scale, but undisclosed revenue, margins, and cap-table economics keep it in research-more territory.
HawkEye 360 is a differentiated public RF-intelligence franchise with strong revenue growth, backlog visibility, and post-IPO liquidity, but heavy federal-customer concentration, opaque unit economics, and a still-stretched valuation keep it in track territory.
EnerVenue looks better capitalized and more commercially real in 2026, but the combination of opaque financials, unresolved execution history, and still-limited public pricing keeps it in research-more territory.
Redpanda pairs strong Kafka-compatible infrastructure and blue-chip enterprise adoption with opaque unit economics, so the right stance remains track until retention and margin data are disclosed.
Marshmallow has built a real and differentiated UK newcomer-insurance franchise with proven scale and a Series C valuation above $2B, but opaque unit economics and capital-structure details keep the verdict at track.
Handshake still looks like a category leader in early-career recruiting, but stale valuation marks, opaque segment economics, and contractor litigation keep it firmly in research-more territory.
Strava is a scaled social-fitness platform with clear monetization and public-market readiness signals, but the latest private mark still looks rich relative to what public evidence proves.
Radiant Nuclear remains one of the strongest private microreactor contenders on public evidence, but the valuation still runs ahead of verified revenue, licensing completion, and repeatable factory execution.
Clio is a scaled legal-workflow leader with broad product breadth and customer reach, but the current US$5 billion valuation and persistent private-company disclosure gaps still justify only a track stance.
Kraken is a scaled, late-stage private crypto platform with meaningful diversification, but underwriting remains constrained by opaque financial disclosure, cyclical margin compression, and regulatory overhang.
Skydio has built a durable U.S. defense and public-safety drone position, but the April 2026 $4.4B price still assumes software-grade economics that public evidence does not yet prove.
o9 combines credible enterprise planning depth and strong deployment momentum with insufficient public financial disclosure to justify an upgrade beyond research-more.
Fanatics remains a scaled sports platform with credible diversification, but opaque segment economics, capital structure, and valuation marks keep the investment case at research-more.
ByteDance is a remarkably scaled private platform, but the recommendation stays at track because regulatory overhang, AI capex intensity, and disclosure gaps still dominate the risk-adjusted picture.
Silverfort remains a differentiated, well-funded identity-security platform with broad enterprise adoption, but the lack of audited ARR, NRR, and burn disclosure still supports a track stance rather than a buy.
Form Energy is a differentiated long-duration storage company with real customer demand, but the business is still execution-heavy and not yet fully underwritten by public financials.
Opentrons has real product, customer, and investor relevance, but the public record is still too thin to justify paying the 2021 unicorn price with confidence.
Real consumer-AI scale story with strong operating signals, but not enough public denominators to justify a buy recommendation at the disclosed unicorn price.
Regent has crossed from concept to credible industrial program, but public evidence still does not support underwriting its 2026 valuation without private diligence.
Shenji is a real and strategically valuable automotive-chip platform, but at the current private mark the upside is capped by opaque economics, heavy NIO dependence, and unresolved merchant-commercialization risk.
Blue Energy has rare financing and partner quality for a 2023-founded nuclear startup, but the current unicorn mark is only directionally credible rather than fully underwritten because project economics, financing terms, and repeatability beyond one flagship remain private.
Clipboard Health has built a large and operationally credible healthcare staffing marketplace, but public evidence still leaves too much uncertainty on revenue quality, retention and contractor-model resilience to recommend underwriting the old unicorn mark aggressively.
Hostaway looks like a real late-stage category leader in STR software, but the current unicorn valuation floor is better supported than any premium above it; recommendation: research more.
Strategically strong fleet-charging platform, but public economics and price support remain too thin for a high-conviction entry call.
Research-more: BioRay has real revenue, high-margin commercial infrastructure, and credible innovation optionality, but public evidence does not yet justify paying aggressively at its last unicorn-scale private anchor.
Avaada has real scale, financing credibility, and strategic optionality, but current entry underwriting is limited by opaque group valuation, capital structure, and entity-level decomposition.
EasyPost appears to be a real and strategically relevant shipping infrastructure company, but the reported 2026 unicorn valuation is not well enough supported by public evidence to justify a clean investment recommendation.
A fast-executing European humanoid robotics leader with elite partnerships and a large pre-order book, but a $1.35B pre-revenue valuation that rests on still-unproven commercial conversion.
GigaAI is a technically ambitious Beijing physical-AGI company with strong 2026 capital access and credible early deployment signals, but public evidence still does not support underwriting its unicorn valuation with the same confidence one would apply to a more disclosed robotics peer.
HappyRobot has meaningful reported enterprise adoption and a $1.2 billion Series C mark, but opaque financials and unverified operating outcomes support a track recommendation at a stretched valuation.
PatSnap looks like a real scaled innovation-intelligence platform with credible recurring-revenue signals and IPO optionality, but public-only evidence still supports research-more until financial, retention, governance, and offering terms are verified.
Antares has cleared an important hardware milestone and has identifiable government demand, but commercial reliability, licensing, economics, and valuation remain unproven.
Pasqal has credible neutral-atom technology, installed systems, and commercialization pathways, but the gap between public-market expectations and disclosed revenue, renewal, and production economics warrants further research.
Track: Locus has substantial enterprise traction and a credible path from collaborative AMRs to broader warehouse automation, but private-company opacity and unverified current economics do not support an aggressive valuation conclusion.
Lila is a well-capitalized AI-for-science platform with credible system-level ambition, but the public record has not yet shown repeatable commercial or scientific proof sufficient to underwrite a premium valuation.
DriveNets has credible production-network and financing signals, but the reported valuation remains stretched until private operating and capitalization data are disclosed.
Ai.tech has strategically relevant ad-tech assets and a reported bootstrapped-unicorn valuation, but weak operating disclosure leaves the investment case in research-more territory.
Talkdesk shows credible enterprise scale and an active AI transition, but incomplete current economics and capital-structure evidence keep the historical valuation from being underwritten.
Celero has credible technical and financing momentum, but its reported valuation remains difficult to underwrite without current operating, customer, unit-economic, and capitalization evidence.
ZeroAvia has a credible, strategically backed hydrogen-electric platform, but certification timing, financing transparency, and commercial conversion do not yet support a buy decision.
NotCo has credible AI-enabled food-formulation differentiation and partner traction, but current valuation support and operating resilience remain too opaque for more than a track recommendation.
WeDoctor appears to be a strategically important China digital-health platform with meaningful operating scale, but incomplete current disclosure makes a confident investment decision premature.
SPIC Hydrogen Energy looks strategically relevant in China's hydrogen equipment chain, but the public record remains too thin to underwrite a current price.
Proxima Fusion has strong funding, institutional backing, and differentiated stellarator IP potential, but its pre-revenue valuation still depends on unproven technical and commercialization milestones.
Xona has a differentiated LEO navigation infrastructure thesis and meaningful financing and regulatory milestones, but private operating metrics and valuation evidence remain too incomplete for a buy recommendation.
Nowports has a credible regional logistics platform and historical customer and funding traction, but current economics and risk controls remain too opaque for a buy recommendation.
M-KOPA has credible pan-African scale and a compelling asset-finance-to-credit model, but public disclosure is not sufficient to underwrite a premium valuation.
XAG combines real agricultural-robotics depth, international deployment signals, and a reported profit turn, but competition, cash conversion, governance, customer durability, and valuation opacity keep the opportunity at track.
inDrive has differentiated global scale and expanding service optionality, but conflicting financing marks and missing audited economics make a price-sensitive investment case premature.
Research more: ABLY has credible fashion-commerce scale and improving reported 2025 performance, but opaque private-company economics, unresolved financing terms, and execution and regulatory risks limit underwriting confidence at the reported valuation.
Research more: LINE MAN Wongnai has credible Thai scale, ecosystem breadth, and 2025 revenue growth, but current public evidence remains too thin on audited cash economics, capital-structure terms, and subsidy-normalised cohorts to support a premium entry valuation.
Nordic Knots shows credible premium-brand momentum and rapid reported growth, but a third-party $2.2 billion valuation estimate is not underwritable without audited economics, retention, store payback, and capital-structure terms.
Keyrock has credible strategic breadth and a corroborated $1.1 billion financing marker, but absent audited economics, customer-quality data, round terms, and primary acquisition records make the valuation stretched and the investment case research-more.
Research more: Slash shows substantial reported scale and a broad financial operating platform, but a stretched $1.4 billion valuation precedes the audited economics, retention, control assurance, and ownership terms needed for an investment decision.
Rogo shows meaningful institutional adoption, rapid product expansion, and strong financing access, but undisclosed Series D pricing and unverified recurring economics make research-more the supportable decision.
Bose Quantum has credible financing, product, factory, and deployment signals, but missing commercial economics, production proof, and transaction terms make further diligence necessary before pricing an investment.
Andromeda shows meaningful reported GPU-marketplace scale, but its $1.5 billion valuation remains ahead of public evidence on margin quality, concentration, controls, and ownership terms.
Ro remains a scaled D2C healthcare platform with real GLP-1-driven growth and vertical integration, but the stale $7B mark, opaque margins, and manufacturer dependence keep it in track territory rather than buy territory.
Merama remains a scaled Latin American brand holdco, but opaque leverage, inconsistent public metrics, and a concentrated six-brand portfolio keep the case at TRACK.
9fin has built a credible AI-native platform with proven penetration across all top-10 global investment banks and 350+ institutions, warranting a Track stance while financial opacity prevents a clean underwrite of the $1.3 billion valuation.
Musinsa combines category leadership, real profitability, and strong Korean fashion consumer mindshare, but the current private/IPO valuation ambition runs materially ahead of disclosed fundamentals and the company still carries regulatory, trust, and international-execution risk.
SPAN's product differentiation and partner momentum remain credible, but limited operating disclosure still supports a track recommendation rather than a buy.
Liquid Death remains a scaled premium beverage brand with broad distribution and a durable marketing moat, but opaque unit economics, concentration risk, and a premium valuation still justify track / research-more at medium confidence.
JumpCloud remains a credible consolidation-oriented identity and device-management platform, but the public record still lacks current financial proof and a fresh valuation anchor.
Deep Robotics is commercially real and now publicly underwritten by revenue, profit, and a live IPO path, but private disclosure still leaves the right call at track rather than buy.
Andela remains a scaled AI-native talent platform with real enterprise reach, but stale valuation data, limited financial disclosure, and persistent operating-opacity risks keep the investment case in track territory.
Pristyn Care is a real scaled surgery-coordination business, but inconsistent disclosure, patient-safety/governance risk, and bridge-like financing keep the call at research-more.
Owkin has strong strategic validation and visible 2026 product momentum, but opaque economics and conflicting scale signals keep it at track.
EngineAI looks increasingly real as a manufacturer, but it still under-discloses the customer and financial proof needed to justify a step-up from track.
vVARDIS has real clinical traction and strong gross margins, but the missing cash, pricing, and deal terms still prevent a full underwriting.
Avoca looks like a real vertical AI leader with strong home-services workflow fit and top-tier investor validation, but the public economics are still too thin to underwrite the $1B valuation with conviction.
LogicMonitor looks like a scaled observability platform with real ARR and customer proof, but opaque debt, unit economics, and post-Catchpoint integration risk keep the call at track.
Yinwang is strategically important and increasingly validated by OEM partnerships, but the public record still does not support a clean underwrite of standalone economics, governance, or exit path.
Rain combines real product traction and a $1.95B valuation with unusually opaque unit economics and rising regulatory complexity.
Ninja now has enough public scale signals to look like a credible pre-IPO GCC quick-commerce platform, but the case still rests on media-reported growth rather than audited economics.
Decart has built rare momentum in real-time world models and AI infrastructure, but the current ~$4 billion valuation is ahead of what the public revenue record can yet support.
ShopMy is a credible creator-commerce platform with real scale and profitability signals, but public evidence still supports only a track stance because the latest $1.5B valuation sits ahead of disclosed fundamentals and cap-table detail.
HistoSonics has unusual clinical and financing proof for a first-of-kind non-invasive tumor platform, but public evidence still leaves revenue, margins, cash, and runway opaque enough that it remains a research-more name rather than a clean buy.
Tipalti remains a scaled finance-automation platform with real customer traction, but opaque unit economics, debt funding, and a stale 2021 valuation anchor keep the equity in research-more territory.
Sonatype remains a credible software-supply-chain control-plane asset with strong enterprise proof, but private-equity opacity, competitive bundling pressure, and incomplete debt and retention disclosure keep the case in research-more territory.
Periodic Labs still pairs an unusually strong founder roster and major seed financing with a differentiated autonomous-lab thesis, but the public record remains too thin on customers, revenue, and pricing to justify the reported $7.5 billion mark.
Render has strong developer adoption and broad product depth, but limited public financial disclosure still makes its $1.5B valuation difficult to underwrite.
Salt Security remains a credible API security category leader with enterprise traction, but the gap between public operating disclosure and the 2022 unicorn valuation still supports only a research-more stance.
Axiom Space has real execution proof and a stronger 2026 financing base, but the public file still lacks enough unit economics and contract detail to underwrite the valuation cleanly.
Voodoo combines rare private-scale reach and profitability with leverage, opaque unit economics, and BeReal execution risk, so the right stance remains track rather than buy.
Lunar is a real integrated battery and Gridshare VPP platform with meaningful traction and capital access, but opaque economics, California- and partner-heavy exposure, and conflicting valuation signals keep the right call at research-more.
Owner.com looks like a real scaled restaurant software platform, but the evidence still supports only a research-more view because public disclosure stops short of proving durable retention, margin quality, or financing risk at the current valuation.
Liquid AI's differentiated edge-inference stack is backed by substantial capital and real partner logos, but the $2.28B valuation still outruns public proof of ARR, retention, and unit economics.
LangChain combines world-class open-source distribution with meaningful enterprise traction, but the lack of audited 2026 ARR, margin, and retention disclosure still makes the $1.25B valuation expensive on public evidence.
Framer remains a differentiated design-to-publish platform with strong startup and enterprise brand pull, but the $2B valuation still outruns the disclosed operating evidence.
Skyryse has built a differentiated software-defined flight-control platform with meaningful certification progress and credible dual-use partner pull, but its $1.15 billion valuation still prices in substantial execution success before public revenue proof exists.
Pomelo Care combines strong clinical outcome evidence and a large payer distribution footprint with persistent opacity around revenue, retention, burn, and capital structure, supporting a research-more stance at a $1.7 billion valuation.
Iterative Health pairs real clinical-network traction and fresh Series C capital with persistent financial opacity, leaving the valuation case stretched and the underwriting posture cautious.
Whop has real creator-commerce scale and a growing payments / treasury stack, but the February 2026 $1.6B mark still prices in strong execution despite limited audited disclosure and ongoing dispute and payout risk.
Polymarket remains the category leader in prediction markets, with institutional scale and a regulated U.S. path, but valuation, governance opacity, and active legal pressure keep underwriting risk elevated.
Flock Safety is a scaled public-safety platform with a nationwide network and strong venture backing, but opaque unit economics and growing legal and municipal backlash keep the right call at TRACK.
Zip remains a category-leading enterprise procurement platform with strong customer traction, but opaque ARR and margin disclosure still justify a cautious track stance at a stretched valuation.
Zama is the leading public FHE infrastructure company for confidential blockchain workloads, but the current valuation still runs ahead of verified recurring cash revenue and composability risk keeps the underwriting case at research-more.
Cera remains a scaled AI-enabled home-care provider with credible public-sector demand, but debt-heavy financing and opaque margins still justify a track stance.
Isar Aerospace has achieved orbital validation and deep funding access, but it remains a research-more underwriting until recurring commercial cadence and audited economics are visible.
OpenEvidence has extraordinary clinician adoption and revenue momentum, but the valuation still looks stretched against an ad-led model with limited audited disclosure.
Bedrock Robotics has credible field proof and strong autonomy pedigree, but public evidence still does not verify revenue, retention, or unit economics enough to support the $1.75 billion mark.
Helsing has clear access to capital and visible product expansion, but the public record still does not establish current revenue quality, margin structure, or customer concentration.
Research-more: Xaira's science and capital base are compelling, but pricing, valuation, customers, and clinical outputs remain undisclosed.
Upwind is a real and fast-scaling runtime-first cloud security vendor, but the public record still cannot justify the $3.8 billion private mark without private ARR, retention, margin, and financing-terms disclosure.
The Bot Company has strong founder pedigree and capital, but it remains a pre-revenue household robotics bet with no public commercial proof and meaningful legal and execution risk.
RobCo appears to have real industrial traction and strong capital backing, but the asset-heavy RaaS model still lacks enough disclosed economics to underwrite a high-conviction value case.
Rapyd has credible global payments scale and a stronger post-PayU footprint, but opaque standalone economics and integration risk still justify a TRACK stance.
Aqua Security remains a credible runtime-first CNAPP with strong enterprise reach and Trivy-led distribution, but private-company disclosure gaps and renewed supply-chain trust scrutiny keep it in TRACK territory at a stretched valuation stance.
Multiverse looks stronger on customer scale and liquidity after its 2026 refresh, but the combination of opaque unit economics, policy-linked funding exposure, and a $2.1 billion valuation still supports a research-more stance.
ConcertAI remains a research-more case: broad oncology AI reach and a profitable FY2024 exit are encouraging, but audited financials, a current valuation, and capital-structure transparency are still missing.
Koloma is the best-capitalized natural-hydrogen explorer, but it remains pre-revenue and unproven at commercial flow, so the investment case still hinges on frontier geology.
PhonePe combines massive distribution, improving profitability, and a clear IPO path, but the public record still does not support a precise entry valuation.
Sakana AI combines credible Japan-native frontier AI and enterprise deployment signals with opaque economics, leaving the name in TRACK / RESEARCH MORE territory until pricing, retention, margins, burn, and governance are verified.
Skild AI looks like a category-leading robotics foundation-model platform with real technical differentiation and fast commercial scale, but its reported $100M ARR and $14B valuation still outpace independently verifiable operating evidence.
Generate combines a real Phase 3 anti-TSLP asset and a strong post-IPO balance sheet with unresolved commercialization and binary trial risk, leaving the shares near fair value.
Hubble Network has real product traction and a powerful Bluetooth-to-orbit differentiation, but the case still depends on undisclosed revenue quality, high constellation execution risk, and a stretched $1.6 billion valuation.
Netradyne is a credible AI fleet-safety platform worth researching further, but public evidence is not enough to underwrite a premium valuation without private financial and legal diligence.
Semgrep remains a differentiated developer-native AppSec platform with strong customer and product signals, but opaque financials and renewed license/competitive pressure keep the case in research-more territory.
Apptronik is a well-capitalized industrial humanoid robotics company with credible partner validation, but public proof is still too thin to justify a buy at a $5B-plus mark.
Neko Health is a high-growth preventive-health clinic network with strong consumer demand and a premium brand, but the reported $7B valuation still outruns public evidence on revenue, reimbursement, and clinic economics.
Transcarent has assembled a compelling post-Accolade platform (20M+ members, 1,700+ clients, >$550M guided combined revenue) led by a proven CEO, but the investment case still hinges on unverified standalone financials, unresolved integration execution risk, and a $2.2B valuation that looks stretched against the sector's 2022-2024 de-rating. Recent 2026 product and channel additions, including SmithRx pharmacy integration, extend the platform, but FY2025 audited financials and post-merger churn data remain the key diligence blockers.
Einride is a commercially-validated autonomous freight TaaS company with blue-chip CPG references and 500K+ AV km — rich at 39-42x 2024 revenue; monitor with conviction entry on SPAC close with >$100M trust net proceeds.
WeLion has real commercialization proof, rare Chinese semi-solid battery credibility, and a plausible IPO path, but the current RMB 18.5-20.0bn valuation narrative still runs ahead of public evidence on revenue, margins, customer concentration, and manufacturing quality, making Track the most defensible call at low confidence.
MediTrust Health is a real scaled China healthcare-payments infrastructure asset with strong insurer and pharma reach, but current public evidence still points to high execution and pricing risk, making the last private valuation look stretched unless investors get better disclosure, a discounted entry, or explicit downside protection.
Tebra is a meaningful independent-practice software platform, but the public record still lacks the revenue, retention, margin, and cap-table proof needed to underwrite a ~$1B mark with conviction.
Fluidstack has a credible strategic position in the AI infrastructure buildout, but the current $7.5B valuation still outruns the quality of public financial and concentration disclosure.
Baichuan combines real healthcare differentiation, credible funding, and visible commercialization progress, but the current public evidence still supports TRACK rather than an aggressive underwriting call at the last visible private mark.
Neon is a credible scaled Brazilian fintech with improving economics and real institutional validation, but the investment case still hinges on proving customer depth, credit quality, and valuation terms behind the unicorn label.
Clara looks like a credible LATAM corporate-finance platform winner in formation, but the absence of clean public unit economics and a fresh priced valuation makes this a research-more / price-discipline story, not a blind chase.
Prove looks like a serious identity infrastructure company with credible customer and product proof, but the price and evidence gap still argue for research-more rather than a clean buy call.
Upstage has earned its unicorn mark through real model benchmarks, product breadth, and sovereign backing, but a Track recommendation follows because the current valuation is running ahead of publicly verifiable economics.
Aerofugia has enough milestone, partner, and customer proof to merit continued diligence, but not enough economic transparency to justify a price-insensitive endorsement.
NextSilicon has real technical differentiation and flagship HPC proof, but the public record is still too thin on commercialization economics and valuation structure to underwrite a premium private mark with high confidence.
Portside is a credible aviation-operations consolidator with real product breadth and customer proof, but the right call remains track: public economics, retention, and current financing terms are too opaque for a conviction-priced investment.
Valar is now one of the fastest-moving U.S. advanced-nuclear startups, but public evidence still supports research-more rather than paying through its reported $6 billion August 2026 mark.
TRACK — Real Strategic Option Value in Embodied AI, but Public Proof Still Trails the Unicorn Narrative
OneCard looks like a real scaled Indian consumer-fintech asset, but the correct current stance is track rather than commit, because regulatory remediation and private risk metrics matter more than brand strength alone.
Flexiv is a credible Stanford-pedigreed adaptive-robotics franchise with a differentiated force-control stack and unicorn financing, but private disclosure and US-China geopolitics keep the valuation hard to defend.
Moglix is a scaled, improving B2B industrial-procurement platform at an inflection point, but the $2.5–2.6B last-round valuation remains stretched relative to public comparables; track pending profitability confirmation and IPO-readiness disclosure.
osapiens has enough growth, product breadth, and customer proof to justify continued diligence, but the public record still does not defend paying above a $1B valuation with conviction.
Ajaib combines credible retail scale, broadening product coverage, and a fresh strategic financing signal, but disclosure gaps keep risk-adjusted valuation underwriting incomplete.
Track Castelion: strategic demand and financing are credible, but public evidence does not yet support aggressive pricing without verified procurement conversion, factory execution, and unit economics.
Yubi is a strategically credible debt-infrastructure unicorn, but the current private mark should be approached with discipline because public proof on monetization, concentration, cash economics, and regulatory cleanliness still lags the platform story.
Destinus has credible defense-product and partnership momentum, but public evidence does not yet justify underwriting the reported valuation target.
Walden has credible technical and strategic validation, but public proof is too limited to underwrite its reported seed valuation confidently.
D360 Bank has credible licensing, strategic backing, and fast reported growth, but undisclosed economics and risk metrics keep the case at track rather than buy.
Nextop AI addresses a real AI-networking bottleneck with credible technical and investor signals, but the public record is too thin to justify aggressive entry at the reported $4.2B valuation.
Field AI has credible technical differentiation, substantial financing, and concrete deployment signals, but limited public operating disclosure makes the reported 2026 valuation difficult to underwrite.
DeepRoute.ai has credible OEM deployment momentum, but opaque economics, customer concentration, regulatory exposure, and absent valuation disclosure support tracking rather than buying.
Harbinger has credible capital, customer, and product signals, but the public record still supports a track stance because revenue, margins, liquidity, reliability, and scaled delivery remain insufficiently disclosed.
Terralayr has credible capital, utility counterparties, and German BESS scale, but its undisclosed valuation and thin financial disclosure prevent a price-sensitive investment call.
Research more: Jetti has credible strategic and commercial deployment proof, but the stale valuation mark and missing company-level financial and contract disclosure prevent a confident investment decision.
Meril is a scaled, export-oriented Indian medtech platform with strong reported growth and profitability, but litigation, capital intensity, and incomplete private-company disclosures keep the opportunity at Track.
COOWA shows unusually strong reported deployment and operating scale for an urban-robotics company, but the evidence is not yet sufficient to underwrite its reported valuation without audited economics and independent technical proof.
Mesh has credible product and distribution proof in a growing crypto-payments category, but opaque economics, control evidence, and rollout status make the $1 billion financing mark stretched rather than independently validated.
Black Forest Labs is a technically credible visual-AI contender with strong financing and distribution signals, but the latest private valuation remains unvalidated without audited economics, concentration data, and control evidence.
SecurityScorecard remains a category-defining cyber risk ratings platform with real enterprise adoption and credible expansion into managed services and AI workflows, but its current economics are still too opaque to upgrade beyond a track recommendation.
Outrider remains one of the more credible autonomous yard-operations specialists in the market, but public opacity around valuation, revenue, pricing, and customer concentration still keeps the investment case below underwriting grade.
RapidSOS remains a credible category leader in emergency-response interoperability, but thin public economics and a messy financing record still justify a research-more stance.
TARS remains a highly funded humanoid robotics startup with real technical momentum, but public evidence still does not establish revenue, named customers, headcount, or a disclosed post-money valuation.
MatX remains a technically credible but still pre-production bet on LLM- specific silicon: the funding and 2027 roadmap are real, but customer proof, independent benchmarks, and unit economics are still not public.
Agile Robots remains a credible scaled robotics platform, but the public case is still gated by opaque economics, incomplete customer disclosure, and a valuation posture that is not yet clearly cheap.
Transmit Security remains a credible enterprise CIAM and fraud-prevention platform, but public evidence still leaves valuation, current scale, and capital structure too opaque to underwrite confidently.
Quince's M2C model and >$1B revenue milestone are genuinely impressive, but the $10.1B Series E implies a premium the public record cannot fully underwrite and ongoing legal risk keeps the name in track territory.
Metropolis has real operating scale and fresh financing, but the current $5 billion valuation still looks stretched until revenue quality, leverage, and covenant terms are materially better disclosed.
Loggi is a scaled Brazilian last-mile logistics platform with clear network reach and contractor-driven operating leverage, but the stale 2021 valuation anchor and thin disclosure keep the case in research-more territory.
HIF Global has real operating proof and unusually strong strategic backers, but public evidence still supports a research-more stance because commercial-scale execution, power pricing, and valuation transparency remain too opaque.
Rhoda AI combines standout physical-AI ambition and elite backing with too little commercial disclosure to justify the current $1.7B valuation confidently.
OfBusiness is a scaled, profitable industrial commerce platform, but disclosure opacity, financing-cost pressure, and a secondary-heavy IPO structure justify a disciplined track stance near the private valuation anchor.
Dexory has credible product differentiation, named production customer proof, and strong investor backing, but the public evidence still supports a research-more stance because retention, margin structure, and current valuation remain under-disclosed.
Research more: Ascend Money has genuine consumer scale and strategic backing, but opaque financial disclosure, an undisclosed 2024 Series D price, and virtual-bank execution risk keep the equity case stretched.
Tempo pairs elite Stripe-Paradigm sponsorship and a differentiated stablecoin-payments rail with thin public monetization evidence, so research-more remains the right stance.
Degreed remains a leading enterprise learning-and-skills platform with meaningful large-account penetration, but opaque retention, burn, and cap-table data keep the 2026 diligence posture in research-more territory.
Distyl has credible deployment proof and a visible $1.8 billion financing mark, but the public record is still too thin on revenue quality and capital structure to justify an affirmative valuation call.
Chapter looks like a credible, scaled Medicare-navigation business with partner-led distribution and strong public growth signals, but the private valuation and operating-quality details remain too opaque to upgrade beyond a track view.
Meter has a credible full-stack networking product and real customer proof, but the current ~$1B mark is hard to underwrite without revenue, margin, and concentration data.
Game Science proved unmatched commercial velocity and production efficiency with Black Myth: Wukong, but single-franchise revenue concentration and Tencent private shareholding warrant a disciplined research-more posture.
Fourier has a real rehabilitation robotics franchise and a technically credible humanoid roadmap, but conflicting public scale data and missing operating economics keep the valuation hard to underwrite.
Dataminr looks like a scaled real-time intelligence business with meaningful defense validation, but the current investment case is still limited by opaque private-company economics and inconsistent valuation signals.
d-Matrix has a differentiated inference platform and credible financing momentum, but public evidence still falls short of underwriting current revenue quality, customer depth, or capital adequacy.
Enveda has real clinical momentum and ample private capital, but the public record still cannot establish revenue, runway, or unit economics.
Creatio remains a credible late-stage no-code CRM and workflow platform, but the public record still lacks enough denominator data to move beyond a research-more stance on the 2024 $1.2B mark.
Apex's manufacturing thesis and defense demand are credible, but public economics remain opaque; research-more remains the right call at a stretched valuation.
Articulate remains a category-leading workplace-learning platform, but the stale 2021 $3.75B mark and limited disclosure keep the equity case in research-more territory.
Heven AeroTech has credible strategic momentum in hydrogen UAS and defense procurement, but the public record still lacks revenue, backlog, and reliability proof needed to underwrite the $1B valuation anchor.
Loft Orbital has credible platform and backlog evidence, but opaque unit economics and conflicting valuation signals keep the price case at research-more rather than buy.
Chainalysis appears to be a scaled, institutionally adopted blockchain-intelligence vendor, but the evidence base is too inconsistent on funding, valuation, and current economics to underwrite it as anything other than a research-more case.
Cursor remains the category-leading AI coding environment, but unresolved transaction status, inconsistent public metrics, and security and margin risks keep the investment case in research-more territory.
The Exploration Company has strong technical and demand signals, but public valuation and financing terms remain too opaque for a precise entry price.
Corelight remains a credible open NDR leader with strong ecosystem validation, but opaque private-company economics and an undisclosed valuation keep the posture at TRACK.
Watershed looks like a premium climate-native enterprise platform with strong product and customer signal, but opaque economics and weak liquidity evidence keep the stance at research-more.
Veza built a differentiated authorization-centric identity-security asset and won credible enterprise adoption, but the public record tops out at an $808M April 2025 standalone valuation and an acquired status with undisclosed transaction terms. Treat Veza as a closed strategic-exit case rather than a current standalone unicorn, and require private ARR and deal-term disclosure before assigning any premium beyond the last public mark.
Electra combines a differentiated clean-iron process with strong strategic backing, but the investment case still hinges on proving commercial-scale throughput, customer adoption, and capital execution.
sennder's network scale and blue-chip customer anchors support a track thesis, but under-disclosed profitability and integration execution keep the valuation case at fair and the risk rating high.
Research-more: insitro has real partner proof and a plausible route to premium techbio value, but public evidence does not support underwriting an aggressive private valuation without clean terms and stronger clinic-ready proof.
Research-more: Cellares has unusually strong public customer proof for a private cell-therapy manufacturer, but undisclosed pricing and missing economics keep the investment case high-risk and price-sensitive.
Perplexity AI keeps compounding usage and product breadth, but valuation and legal risk still dominate the diligence picture.
VNLIFE is a real scaled Vietnamese payments platform with durable strategic relevance, but thin public economics and only an indicative >US$1B secondary valuation anchor support a RESEARCH MORE recommendation rather than an aggressive buy.
Yuanxin has real scale and category leadership, but the RMB 19.5B pre-IPO mark looks stretched relative to its low margins, slower growth, and unresolved IPO/dilution risk.
Happy Health has enough regulatory and workflow proof to stay on the diligence list, but not enough valuation or financial disclosure to justify a high-confidence premium entry price.
Xingyuanzhi has a credible embodied-brain thesis and real momentum, but public disclosure is still too thin to justify a price-insensitive investment call at unicorn-band levels.
Modern Health looks like a credible, scaled employer mental-health platform, but the visible unicorn valuation anchor is ahead of the proof public investors or crossover buyers would want.
Fasset looks like a credible new fintech unicorn, but the current mark is only fairly supported and still too underdisclosed for a decisive buy recommendation.
Glow Security has real category potential and real launch proof, but the public file is still too thin and too structurally inconsistent for a confident buy call at the current price.
Ant International's network scale, product breadth, and strategic relevance support a RESEARCH-MORE posture, but the US$11.2B price and incomplete standalone disclosure make entry discipline and hard diligence gates essential.
SiFive is the leading late-stage commercializer of RISC-V CPU IP, but the $3.65B Series G still prices in revenue quality and royalty conversion that public sources cannot yet verify.
Automation Anywhere looks strategically relevant and commercially real, but public evidence still supports a disciplined research-more stance rather than a clean late-stage buy.
HiDream.ai has enough technical and strategic substance to justify deeper diligence, but its current unicorn-plus valuation is supported more clearly by financing momentum and product proof than by publicly disclosed economics, leaving the stock of evidence in research-more territory.
Create Music Group is a genuine independent-music monetization leader with aggressive catalog M&A, but the $2.2B valuation is better supported by scale narrative and capital access than by any audited economics; recommendation: research more.
Verdiva is one of the best-capitalized private oral-obesity startups, but public-only evidence still supports a track posture because the valuation already assumes meaningful clinical success while key efficacy, CMC, IP, and financing details remain opaque.
Ivalua has a credible, broad enterprise source-to-pay platform, but undisclosed current economics, transaction terms, and governance prevent a high-conviction valuation call; further diligence is warranted.
Research more before pricing: Xiaohongshu has differentiated search-led discovery and reported scale, but the available evidence does not support an investable entry price.
Genki Forest has meaningful beverage scale and recent reported operating progress, but opaque current financials and entry terms prevent a defensible price-sensitive investment decision.
Purplle has credible reported scale and a differentiated multi-brand model, but conflicting financial evidence and unverified transaction economics warrant further diligence before an investment decision.
XREAL has credible category and platform traction, but negative cash generation and incomplete financing disclosure justify tracking rather than buying.
Tyme Group has credible emerging-market digital-banking traction and a South African profitability proof point, but incomplete consolidated financial, ownership, and current-price disclosure supports tracking rather than a high-confidence buy recommendation.
Main Func shows a meaningful AI-workspace growth story, but its reported $2.6 billion valuation requires verified retention, margins, customer quality, and financing terms before investment.
SiliconFlow appears to be a real and strategically relevant inference platform, but financing momentum is not yet matched by public evidence of durable margins, retention, reliability, or an investable price.
Track DeepSeek for technical leadership and demand momentum, but do not underwrite headline valuations until financial, financing, governance, and access risks are independently verified.
Unisoc has meaningful communications-chip scale and market presence, but incomplete audited disclosure, governance history, and geopolitical exposure support a track recommendation rather than a buy call.
A technically credible and capital-backed advanced-packaging scale-up whose production progress is offset by substantial financial, customer, and financing-term opacity.
Track: Genesis has meaningful pharmaceutical validation and differentiated platform evidence, but public economics, customer durability, and clinical conversion remain too opaque for a stronger recommendation.
Sygnum appears strategically credible as regulated digital-asset infrastructure with institutional proof, but the public record still leaves material revenue, retention, concentration, margin, and capital-structure gaps.
Inertia has unusually strong scientific and strategic starting assets, but public evidence does not yet support a price-sensitive investment decision.
Flying Tulip has a differentiated integrated DeFi design and meaningful financing history, but should remain tracked until independent assurance, commercial traction, and current valuation evidence improve.
High-upside Telegram and TON distribution leverage is offset by opaque economics, structure, and regulatory execution risk.
Research more: Yassir shows credible regional platform breadth and distribution signals, but current economics, financing terms, liquidity, and regulatory execution remain too opaque for a price-supported investment.
Norm Ai has a differentiated full-stack legal-AI model and strong financing validation, but undisclosed operating metrics and unresolved legal-structure, governance, and customer-concentration questions keep the opportunity at track rather than buy.
FINN has built meaningful car-subscription scale and financing access, but its reported unicorn valuation already assumes strong execution while fleet economics, liquidity, and public disclosure remain unresolved.
Huihe appears to be a technically credible cardiovascular-device platform, but the public record is too incomplete to underwrite a confident valuation or commercial-scale investment decision.
Redo has credible post-purchase breadth, 4,500+ company-reported brands, and $81 million of new capital, but opaque economics and unresolved fee-regulation exposure make the reported $1.25 billion valuation difficult to underwrite.
Galaxy Bot has a credible industrial robotics foothold and strong capital backing, but missing operating, contract, safety, and security-rights data prevent underwriting its reported valuation.
Beacon's capital access and AI-enabled acquisition thesis are credible, but opaque consolidated economics, integration outcomes, and current pricing keep the company in research-more territory.
Cadence has scaled an embedded clinical-AI care model, but reimbursement exposure and missing decision-grade financial, retention, security, and regulatory evidence support further research rather than investment at the reported private-market valuation.
Kapital has credible regulated-bank scale and a broad SME platform, but the reported $2.0 billion valuation is not underwritten by public consolidated economics, credit quality, cap-table terms, or completed Intercam integration evidence.
Track Joulent as a strategically validated but high-risk infrastructure platform whose roughly $5 billion implied value remains unproven until Kilby is fully funded and de-risked.
TensorWave has credible infrastructure and strategic AMD backing, but the $1.55 billion reference remains stretched without audited economics, utilization, customer quality, and financing terms.
Oxide shows differentiated technology, substantial announced financing, and reported demand, but private operating economics and undisclosed round terms make the investment unpriceable without further diligence.
Mosyle merits continued diligence for its focused Apple platform and adoption signals, but financial opacity and conflicting scale and financing records prevent a priced investment decision.
Cart.com has credible product breadth, operating scale, named customers, and institutional backing, but opaque financials and financing terms prevent a defensible entry-price decision.
AIsphere's product reach and financing momentum justify continued diligence, but absent audited economics, governance evidence, and entry terms preclude a buy call.
Track Upscale AI rather than buy at the reported $2 billion mark until production adoption, operating economics, technical performance, and financing terms are verified.
ModelBest has credible edge-model and automotive deployment signals, but the reported unicorn-threshold price is not underwritable without audited commercial metrics and financing terms.
Track Unico for its substantial identity-verification scale and international expansion, but defer investment pricing until current financials, ownership terms, and the sealed Serasa-related dispute can be underwritten.
Tide has achieved meaningful SME distribution and product breadth, but the USD 1.5 billion financing mark is not yet supported by decision-grade evidence on consolidated economics, retention, partner concentration, or investor terms.
Parallel has credible agent-web infrastructure, adoption, and production proof, but opaque economics and a rapid valuation step-up keep the company at research-more.
Firestorm pairs a differentiated expeditionary-manufacturing thesis with real defense traction and fresh capital, but public underwriting is still blocked by opaque valuation, financial disclosure, and customer-concentration data.
AscenPower has a credible SiC manufacturing buildout and real funding momentum, but the public record still leaves revenue quality, customer conversion, and margin durability unresolved.
Cosm has real strategic validation and a clearer multi-venue platform story, but it still belongs on the track list because valuation, unit economics, and financing terms remain opaque.
Valon has strong operating proof and fresh capital, but the public package still falls short of underwritten economics.
Mytra combines a differentiated full-pallet warehouse-automation platform with credible deployment proof and strong investor support, but the lack of public financial disclosure and the still-unproven scale economics keep the name in research-more territory.
Just Salad looks like a real scaled concept with differentiated sustainability branding and credible growth momentum, but the current $1 billion mark already prices in strong execution while audited economics, capital-structure details, and retention data remain private.
Aviatrix has credible multicloud security technology and real enterprise proof points, but opaque financials, a difficult competitive landscape, and a sharp gap between its 2021 primary valuation and 2026 secondary signal keep the stock in track-not-buy territory.
Personio remains a strong European HR platform, but the public evidence still supports track rather than a fresh premium valuation call.
SheMed has a credible women-focused GLP-1 and diagnostics narrative, but the reported $1 billion mark still outpaces the public evidence on economics, retention, and terms.
I-care is a real industrial predictive-maintenance platform with meaningful scale, but the insider-led unicorn mark still lacks external price discovery and audited FY2025 economics, so the right posture remains track.
Farther has real advisor-recruiting momentum and fresh Series D capital, but opaque economics and unresolved regulatory and governance gaps still make the entry look stretched rather than compelling.
Xpeng AeroHT has real product, factory, and demand momentum, but the investment case is still gated by certification sequencing, valuation opacity, and limited proof of customer-quality conversion.
Webflow remains a category-leading visual web development platform, but the public record still leaves enough financial opacity to keep the call at research-more.
SemiDrive remains strategically important and commercially credible, but undisclosed 2026 pricing and operating economics keep the right call at Track rather than Buy.
Scandit looks operationally strong but still underwritten with stale public financials, so the report remains at track pending fresher ARR and capital-structure evidence.
EcoVadis remains strategically relevant as a scaled supply-chain sustainability workflow platform, but public disclosure is still too thin on financials and ownership to support a bullish underwriting call.
Clari remains strategically relevant after the Salesloft merger, but the public record still does not support a buy call because pricing, cap-table economics, and merged-company financial quality remain opaque.
World Labs now has real product and strategic-exit momentum, but the public record still lacks enough commercial and governance disclosure to underwrite the business with conviction at current prices.
Sarvam AI remains strategically important, but the public record still supports a research-more stance because valuation momentum is ahead of disclosed software economics.
PaXini looks like a credible tactile-robotics platform with strong financing momentum, but its valuation still runs ahead of public operating disclosure.
Eavor has crossed into first-commercial-power territory, but opaque economics, project execution risk, and limited disclosure on valuation and governance still justify a research-more stance.
ApplyBoard remains a scaled international-student recruitment platform, but stale valuation evidence, opaque private economics, and acute Canada policy exposure keep the right call at track.
Photonic is still one of the more credible private quantum infrastructure stories, but the public record supports continued diligence more than price-insensitive conviction at a $2B valuation.
Judi Health looks like a scaled, strategically differentiated transparent PBM and unified-claims platform, but the public record still does not disclose enough economics to underwrite it beyond a Track stance.
team.blue remains a scaled, PE-backed SMB digital-enablement platform with broad product breadth and distribution reach, but valuation and capital-structure opacity keep the stance at track.
Hithium remains a scaled global ESS contender, but public evidence still supports a track stance rather than a buy because valuation clarity, litigation exposure, receivables quality, and IPO-readiness disclosure remain too thin.
Research-more: Standard Bots has a credible AI-native cobot product narrative and real financing support, but the June 2026 $1B valuation is still too price-sensitive to underwrite from public evidence because revenue, margins, shipment depth, and cap-table terms remain undisclosed.
Modular has real technical differentiation and some named customer proof, but public economics remain too thin to underwrite a stronger call after Qualcomm's acquisition.
EGYM is a real scaled connected-fitness and corporate-wellness platform with strong product breadth and clear merger-era funding support, but the public entry price looks stretched and the post-merger economics remain only partly disclosed.
Pleo still shows clear European spend-management traction and product breadth, but the public evidence leaves the underwriting stance at research-more because valuation, burn, and retention remain only partially observable.
BetterUp still looks like a credible enterprise coaching platform with real customer traction, but private financial opacity and a marked secondary valuation reset keep the decision at research-more.
Versa Networks is a credible late-stage unified-SASE platform with meaningful channel and customer traction, but opaque financial disclosure, execution complexity, and a still-debatable 2024 valuation keep the current stance at research-more rather than buy.
Positron has real deployment proof and fresh capital, but the $5B valuation still outruns disclosed revenue and silicon verification.
Highview Power has a credible strategic position in UK long-duration energy storage, but valuation and operating economics remain under-determined until Carrington proves commercial execution.
Carbon has real production-scale DLS proof and insider-backed runway, but opaque financials and a stale $2.4B valuation anchor keep research-more as the right posture.
NewLimit pairs elite private capital and real preclinical momentum with no human data, leaving the stock-equivalent thesis in research-more territory at an expensive valuation.
Epirus has validated solid-state HPM counter-drone performance and broadened prototype traction, but valuation opacity and prototype-only fielding still justify a track stance.
Vultr is a credible independent cloud and GPU infrastructure operator, but the public record still lacks enough financial detail to underwrite it cleanly at the last $3.5B mark.
Mynt pairs dominant Philippine fintech reach and profitability with an imminent IPO, but the implied $7.7B valuation still looks stretched against take-rate compression, an on-balance-sheet unsecured loan book, and a heavily secondary offering.
Trendyol is Turkey's dominant e-commerce superapp with durable domestic scale and proven operating leverage, but its stale $16.5 billion valuation mark, opaque financial disclosure, and regulatory overhang still justify a Track stance.
Brahma AI combines differentiated enterprise audiovisual AI capabilities with strong commercial validation, but a rich valuation, concentrated revenue base, and governance asymmetry justify a Track stance.
Capitolis is strategically relevant infrastructure for large banks, but the $1.9 billion mark is not fully underwritten because core economics and acquisition terms remain private.
Hai Robotics remains a category-leading warehouse robotics vendor, but IPO execution, redemption overhang, and still-opaque recurring economics keep the stock in track-only territory.
Enpal remains the category-leading German residential electrification platform, but revenue volatility, opaque profitability, legal and labor exposure, and valuation uncertainty keep the right call at Track.
Ambience Healthcare leads the enterprise ambient AI category, but its premium valuation and unresolved retention proof keep the recommendation at research-more.
Toss combines 30M+ users, 2025 profitability, and a powerful super-app distribution engine, but regulatory scrutiny and opaque segment economics keep the valuation case stretched.
Sila has real factory and customer proof, but private economics and valuation dispersion still justify a price-sensitive research-more stance.
Function Health looks like a fast-growing preventive-health platform with strong brand and capital access, but its economics, retention, and regulatory position remain hard to verify.
Verkor looks materially more real than a year ago because the Dunkirk asset is commissioning and demand is contracted, but the economics remain too opaque for a buy call.
Stack AV remains a pre-commercial autonomous trucking venture with strong founder pedigree and capital support, but no disclosed valuation, named customer base, or commercial timeline.
J&T Express is a scaled public logistics operator with real cash-generation and regional density, but platform concentration, China pricing pressure, and regulatory risk keep the call at research-more rather than a price-insensitive buy.
Miro still has real scale and cash generation, but the September 2026 Bending Spoons deal resets the valuation to a fair 2.3x ARR and makes the public-acquirer or secondary path the cleanest way to play it.
Mura Technology has a credible Hydro-PRT commercialization platform and meaningful strategic backing, but public evidence still leaves its economics, throughput, and valuation too opaque for an investable conclusion.
EvenUp appears to be the category leader in plaintiff-side legal AI, but the >$2B valuation is hard to underwrite without audited ARR, gross margin, and retention data.
ShipBob has credible operating scale and customer proof, but stale valuation marks and opaque financials keep the call at research-more rather than a buy.
Tamara combines a licensed Saudi BNPL franchise, large public-reported user and merchant reach, and H1 2026 profitability, but retained opacity around customer durability, credit losses, and leverage keeps the investment case at track.
Helion is the most commercially advanced private fusion developer, but the investment case still hinges on proving repeatable net electricity and hitting the 2028 Microsoft delivery schedule.
Clear Street shows real operating scale and product breadth, but conflicting valuation marks and opaque financials keep the investment case in track-only territory.
Dragos remains a category-leading OT/ICS cybersecurity platform, but current standalone economics and transaction terms are still too opaque to underwrite a price.
BETA combines a real backlog, public-market liquidity, and an expanding charging footprint, but the valuation still depends on FAA certification timing and backlog conversion that the public record does not yet underwrite.
Cerebras combines a differentiated wafer-scale AI platform with huge contracted demand, but customer concentration, capital intensity, and valuation keep the case high risk.
1Password has a credible 200k-business-customer XAM platform and a defensible security architecture, but the $6.8B 2022 valuation has not been refreshed and unit economics remain non-public.
upGrad's FY26 turnaround is real, but the company still looks stretched on valuation and underdisclosed on cash quality.
Nium remains a credible late-stage B2B payments infrastructure candidate, but opaque current economics, partner and regulatory dependencies, and conflicting financing signals keep the name unpriceable without private diligence.
Heidi Health combines exceptional clinical-AI adoption with a stretched private-market valuation and unresolved retention, margin, and financing-risk questions.
Research further at the current Series C benchmark: Wrtn has strong consumer scale and monetization momentum, but audited margins, retention, concentration, legal controls, and valuation terms remain unresolved.
Kiteworks looks strategically relevant and well-funded, but it remains too opaque on financial quality to underwrite with high conviction.
Grammarly has real scale and product pull, but the public evidence still supports a cautious track/research-more posture rather than a clear buy.
Fervo is a real public EGS platform with clear customer demand and a proven project-finance step-up, but it is still too execution-sensitive to justify a buy at this stage.
Bilt has proven scale and a large installed base, but the refreshed evidence still does not support a confident buy-style call because the economics and payment-stack reliability remain opaque.
Figure AI has done what no humanoid robotics company has achieved before: a proven, multi-month deployment at automotive production scale, with BMW manufacturing metrics that are independently corroborated. The $39B valuation prices in a future that requires displacing Tesla Optimus, Agility/Amazon, and every industrial automation incumbent — at 250–650x estimated revenue. The deployment proof is extraordinary; the valuation is extraordinary risk. Specialists with 7–10 year horizons and deep robotics domain expertise may find a speculative entry defensible; generalist growth investors should avoid at this multiple.
Cognition AI is a category-defining autonomous software engineering platform with exceptional ARR growth ($1M → $73M in 9 months), but the $10.2B valuation at ~140× ARR prices in near-flawless execution in a market facing rapid benchmark commoditization and critical undisclosed financial metrics.
Whatnot has scaled into a $20B live-commerce platform with strong user growth, 1B+ lifetime orders, and meaningful seller-community depth, but the valuation now assumes continued category leadership and expansion without transparent public financials. TRACK: the business is clearly working, yet the risk/reward remains valuation-sensitive.
A technically credible open-weight AI lab with real revenue and real products, but the valuation still prices in substantial execution that public data does not yet prove.
Sunrise has credible product and financing momentum in domestic inference infrastructure, but the current RMB 20B valuation still gets ahead of public proof on revenue quality, customer depth, and unit economics.
Krutrim may become one of India’s most important sovereign-AI platforms, but the current public evidence still supports a research-more stance because strategic ambition and reported pricing are ahead of disclosed economics and durable customer proof.
Cityblock demonstrates scaled Medicaid-first value-based care with strong revenue growth but faces valuation reset, margin uncertainty, and regulatory exposure
DJI is the profitable, category-defining global drone leader, but a private, opaque Chinese company whose largest premium market and exit optionality are capped by US regulatory exclusion.
Luminance appears to be a real legal-AI scale asset with meaningful customer breadth and a plausible mid-hundreds-of-millions value, but the current public record is still too opaque to underwrite a premium unicorn-style price with confidence.
Strong regional relevance is real, but current valuation still looks expensive relative to Noon’s public disclosure depth and available comparables.
Xynova sits in a strategically attractive part of the humanoid stack: dexterous hands and actuators. The company has raised enough capital and attracted enough strategic interest to matter, but the public record still lacks the named-customer, reliability, economics, and financing-term evidence needed to underwrite the current unicorn valuation with high conviction.
Scientifically distinctive breeding platform with a large opportunity, but an unproven-at-scale core claim and a rich pre-revenue valuation warrant more diligence before investing.
VulcanForms looks strategically important and technically differentiated, but the current public record still supports a research-more posture rather than a buy call because price support trails business quality.
Track: credentialed founding team and named enterprise traction support a watch position, but undisclosed unit economics and a concentrated customer base require more diligence before a buy call.
MoEngage looks like a real, scaled engagement platform, but public disclosure is too thin and the late-2025 pricing too rich to support a buy call from public evidence alone.
Erebor may become a valuable frontier-sector banking franchise, but current public evidence does not justify underwriting reported valuation talk without deeper diligence and price discipline.
Neo Security has a credible agentic-security thesis and strong reported funding, but insufficient public customer, financial, and technical proof for more than a track/research-more stance.
Keyuan appears to be a substantial operating industrial group, but the public record supports deeper diligence more than conviction pricing.
Track: CuspAI has credible technical and strategic validation, but the reported $2.6 billion mark still assumes commercial economics that public evidence does not establish.
8090 has a credible governed-software thesis and meaningful financing, but public evidence does not yet prove repeatable software economics or justify a valuation-insensitive investment.
StockX is a scaled authenticated-resale platform with clear marketplace relevance, but current financial quality, trust-cost metrics, and cap-table detail remain too thin for a high-confidence valuation.
Konfío appears to be a scaled, institutionally financed SME-finance platform with credible product breadth, but missing current credit, profitability, ownership, and valuation evidence warrants research-more rather than a price-insensitive buy.
Tengden has credible large-UAV engineering and strategic-market relevance, but persistent losses, concentrated and opaque demand, and policy exposure prevent a fully underwritten investment case.
BrainCo has credible neurotechnology breadth and financing scale, but public evidence does not support a company-specific valuation or buy decision.
Track Navi: lending scale and UPI distribution are meaningful, but consolidated losses, regulatory history, and unverified financing and unit economics prevent a buy recommendation.
DexForce merits further diligence because its integrated simulation-to-robot stack, financing, and deployment signals are promising, but the reported unicorn valuation is not yet supported by audited economics, independently verified production reliability, or durable customer evidence.
ModRetro's credible enthusiast products and widening physical-media platform merit continued tracking, but the reported $1 billion valuation is not underwritable without primary financing terms and audited operating economics.
Solace has credible national scale and widening reimbursed distribution, but absent audited economics, payer durability, security assurance, and financing terms keep the opportunity at track rather than invest.
SVOLT combines real manufacturing scale and an active semi-solid roadmap with Europe retrenchment and thin public financial disclosure, so the current view remains research-more rather than buy.
Scaled, sponsor-backed flight-commerce infrastructure with real partner validation and EBITDA evidence, but the current price, leverage, and rights package remain opaque enough that research-more is still the right call.
GalaxySpace is one of China's more credible private LEO broadband and satellite-manufacturing platforms, but public disclosure still falls short of what is needed to underwrite a roughly $4.4 billion valuation with confidence.
Avatr remains a strategically backed premium EV platform with real commercial scale, but 2026 momentum, partner dependence, and opaque valuation terms still support a research-more call.
Impulse Space has unusually strong public proof for a private orbital-mobility company, but Helios execution and opaque economics still justify a research-more / track stance.
Skeleton has real AI-power commercialization and strategic validation, but public economics and cap-table detail are still too thin to underwrite past the latest private mark.
Hermeus has real proof of life—Mach 1.21 flight, a $219 million DIU-backed defense pathway, and a blue-chip investor set—but it is still pre-production, economically opaque, and dependent on difficult Mach 3 / payload-release and procurement-transition milestones, so the prudent stance is research-more rather than buy.
CMBlu combines credible long-duration storage differentiation and strategic capital with a valuation that currently runs ahead of commercial proof, supporting a research-more call rather than a buy.
Code Metal has a differentiated verification-first product and credible defense and industrial demand signals, but the public KPI record is still too thin to underwrite without more diligence.
Wonder has credible platform breadth and fresh capital, but public evidence still supports a research-more stance rather than a clean buy at the reported $9 billion pre-money mark.
Startorus Fusion looks like one of China's more credible private fusion platforms, but the current unicorn valuation still depends more on milestone delivery, policy support, and future disclosure than on proven commercial traction.
Rebel Foods remains a scaled, strategically relevant cloud-kitchen platform, but the public evidence still supports a price-sensitive research-more posture rather than a buy.
MiRus combines a differentiated MoRe-alloy implant franchise with a strategically validated but still investigational TAVR program, leaving the valuation thesis dependent on clinical execution and opaque private economics.
Kitopi is a scaled GCC hospitality platform with real operating breadth, but opaque unit economics and capital intensity keep the equity case expensive and hard to underwrite.
Advanced Navigation looks strategically important in GPS-denied navigation, but the public record still does not support a confident valuation or downside recovery thesis.
Mind Robotics combines a rare Rivian data wedge and $1.015B in capital with elite industrial leadership, but it remains unproven as an arm's-length automation vendor and looks stretched at a $3.4B valuation.
GrubMarket remains a scaled hybrid food-supply-chain operator with real software assets, but acquisition-led growth, missing audited segment economics, and a prior SEC settlement keep the $4.5 billion mark ununderwritable.
Xcimer has reached Phoenix operations and a $100 million Series A, but valuation opacity, no public revenue or customer proof, and severe scale-up risk still justify a research-more call.
Avride is commercially live across Uber and campus channels, but the unresolved safety probe and opaque financing terms still support only a cautious track view.
Revel combines strong technical traction and elite venture backing with near-total financial opacity, leaving the investment case at research-more rather than buy.
Track: Udaan's turnaround is credible, but the $1.8B mark still leaves limited margin of safety until audited cash flow, debt maturity, and embedded-credit disclosures improve.
Filevine is a credible legal-workflow platform with strong product breadth and customer traction, but its ~$3B mark still prices in better margin visibility, AI monetization, and disclosure than public evidence supports.
Darktrace remains a differentiated AI-native security platform with substantial customer scale, but private-company opacity around ARR, debt, and operating performance keeps it in track territory.
Electric Hydrogen combines a credible 100 MW electrolyzer platform with real commercial traction, but project-finance delays and still-limited operating proof keep the stock at track.
SumUp is a scaled and strategically relevant SMB-payments platform, but the public record still supports only a track call because economics, capital structure, and governance disclosure lag the valuation narrative.
Sierra Space remains a well-capitalized but still opaque space-and-defense platform: defense awards and a $8.0 billion March 2026 valuation are real, but Dream Chaser schedule risk, private financial opacity, and unanswered commercialization questions keep the thesis at research-more.
Peregrine combines strong public-sector adoption and Tier-1 investor backing with opaque economics and meaningful surveillance backlash, leaving the $6.8B valuation hard to underwrite.
SambaNova has credible technical differentiation and marquee customer validation, but opaque financials and customer concentration keep the equity story in research-more territory.
BigID looks like a real, strategically relevant late-stage data-security platform, but public evidence is still too opaque to underwrite aggressively above a disciplined secondary-entry price.
Flex has real consumer scale and recurring fee monetization, but opaque credit losses, sponsor-bank dependence, and brand confusion keep the right call at research-more.
Substack has genuine creator-platform scale and differentiated network effects, but the 2025 unicorn valuation looks expensive against estimated ARR, visible creator churn pressure, and elevated legal-platform risk.
Sunfire is a strategically relevant European electrolyzer scale-up with real industrial proof, but public-only evidence still supports a research-more stance because economics, disclosure, and project conversion remain opaque.
MUBI's premium arthouse brand and rebound to 1.7 million subscribers remain real strengths, but backlash sensitivity, hit-driven film economics, opaque margins, and a $1 billion mark still justify a research-more stance.
Novig has real trading traction and federal regulatory approval, but the current investment case still depends on unsettled state preemption fights and unproven monetization.
Armada has a credible sovereign-edge infrastructure wedge and meaningful deployment proof, but opaque economics, factory-scale execution risk, and a stretched private valuation keep it in research-more territory.
Mercor remains a real frontier-AI workflow franchise with credible benchmark and software upside, but the $10B mark already prices in cleaner economics, better diversification, and stronger trust than the public evidence currently proves, so the right call is TRACK.
Hunters appears to be a credible next-gen SOC platform with enterprise traction and a differentiated open-data-lake architecture, but the lack of current financial disclosure and price discovery keeps it in research-more territory rather than an investable buy.
Vast Space has real hardware and customer traction, but it remains pre-revenue, launch-dependent, and richly valued relative to still-opaque unit economics and financing terms.
Imprint is commercially real and well funded, but opaque unit economics, partner concentration, and wholesale debt dependence keep the investment case in research-more territory.
Element has real commercial traction and fresh capital, but valuation opacity and missing audited unit economics still support a research-more stance.
OPSWAT looks like a real, scaled critical-infrastructure cybersecurity platform with strong product breadth and customer traction, but private financial opacity still blocks a high-confidence underwriting view.
Precision is a well-capitalized clinical-stage BCI company with real surgical traction, but it has not yet shown commercial revenue or durable reimbursement proof.
Hello looks strategically important and plausibly valuable, but the current ~$6 billion mark still appears fair-to-full until private financials, cap-table terms, and remediation quality become materially clearer.
SpinQ is a credible late-stage quantum platform and likely low-unicorn asset, but thin public economics and cap-table disclosure keep the case in track territory rather than buy territory.
Animoca Brands has real strategic substance, disclosed 2024 scale, and meaningful ecosystem optionality, but conflicting current valuation signals and thin price-critical disclosure keep the disciplined call at research-more.
Tridge appears commercially real and strategically relevant in agri-trade, but current public evidence does not justify underwriting the old unicorn price without a major private-data refresh.
GTA Semiconductor appears to be one of the more strategically relevant specialty-foundry assets in China’s automotive and power semiconductor stack, but the current private mark is only defensible with better private proof than the public record supplies. The correct public- information stance is research-more: category value and strategic scarcity are real, yet underwritten equity returns still depend on loading, margin conversion, customer concentration, dilution discipline, and incident-free execution.
DispatchHealth has credible strategic relevance and enterprise proof in a hard-to-replicate care-at-home niche, but open evidence does not support paying a peak private-market mark without audited operating data and explicit reconciliation of the 2026 financing signal.
Quaise Energy has credible superhot-geothermal upside and strong strategic backers, but public evidence still supports a research-more / track stance because valuation, financeability, and operating proof remain incomplete.
Amarenco is a strategically interesting solar IPP platform, but the public record still supports only a discounted valuation range and a research-more recommendation.
Omio is a strategically credible multimodal travel platform, but the current roughly $1 billion mark looks stretched on public evidence because it implies a revenue multiple far above public travel-tech comparables without matching disclosure depth on revenue quality, retention, concentration, or debt terms.
Tradeshift looks like a real global B2B network asset, but the public valuation anchor remains stale and expensive relative to 2026 AP and e-invoicing software comps.
Mariana Minerals has a credible strategic-market position and unusually concrete software-plus-asset story, but the current $1.5 billion valuation appears full on public evidence because customer, economic, and financing proof remain under-disclosed.
Well-timed defense-industrial roll-up with real assets and top-tier backing, but financially opaque — research more rather than underwrite the ~$1.1B price on public evidence.
Astromech may be building a differentiated biological-AI platform with strong Colossal adjacency, but the public record still lacks the customer, revenue, and validation proof needed to underwrite the reported $2 billion valuation confidently.
Moove has reported substantial operating scale and a $2.1 billion Series C valuation, but unverified earnings, capital needs, and partner exposure make investment approval premature.
LifeMine's 2026 financing and ongoing Phase 1 program merit tracking, but undisclosed transaction terms, liquidity, and independent clinical outcomes leave valuation and entry price unassessable.
Xsight has credible product and design-in signals, but its $2.8 billion financing mark remains difficult to underwrite without revenue, margin, customer-conversion, and capital-structure denominators.
TruKKer has a documented regional freight platform and financing access, but opaque economics, receivables performance, customer quality, and equity terms support a research-more stance rather than a priced investment.
boAt has category scale and a reported earnings recovery, but audit-control concerns, customer concentration, and unpriced IPO terms warrant a price-disciplined track stance.
Track: Micro Connect has differentiated financing infrastructure and visible deployment, but public disclosure remains too thin to underwrite current economics or valuation.
Aether may be a serious regional enterprise-AI company, but unresolved identity and weak primary disclosure make the reported valuation and operating scale uninvestable without further verification.
VerSe Innovation is a scaled Bharat media asset with improving reported FY25 economics, but stale price discovery, governance overhang, and thin product-level disclosure keep the investable call at track rather than buy.
Pump has a differentiated, low-friction cloud-cost proposition and credible reported scale, but the public evidence is not sufficient for a confident investment decision without verified economics, controls, and financing terms.
Flow has real operating substance and unusual financing access, but public evidence does not justify high-conviction comfort on governance, unit economics, or its reported $2.5 billion private valuation.
Atoms is a well-capitalized but opaque physical-automation platform whose public operating proof is not yet sufficient for a buy recommendation.
Bulage may become an important China embodied-AI platform, but public evidence still does not justify underwriting the reported $2 billion valuation as a buy today.
Zilch has a differentiated, scaled consumer-payments platform and improving reported economics, but the current investment case remains price-sensitive because valuation, retention, liquidity, and post-regulation unit economics are not fully verifiable.
Origin Quantum is a credible full-stack quantum platform, but opaque financials, unverified customer economics, reliability gaps, and unreconciled financing terms support research-more rather than a buy.
Kin shows credible scale and improving underwriting in catastrophe-focused homeowners insurance, but the $2 billion mark remains a research-more case until carrier-level economics and security terms are disclosed.
Stardust Intelligence has credible product and financing momentum, but its aggressive reported valuation remains unsupported by independently verified revenue quality, manufacturing economics, delivery scale, and reliability evidence.
Track: Gokin Solar shows real manufacturing scale, product transition, and global channel proof, but limited audited disclosure and stressed public-peer economics keep the investment case unverified.
BioMap has credible platform and partner validation, but insufficient financial and ownership disclosure for a buy decision.
Spiber remains a strategically differentiated climate-materials platform, but the 2026 management reset and limited disclosure make scale economics and financing durability the central diligence risks.
GI Water as a Service appears strategically credible and commercially worth following, but public evidence remains too thin on economics, governance, and financing terms to underwrite the reported unicorn valuation with comfort.
Acko has a credible digital-insurance and embedded-distribution platform with meaningful scale, but unresolved entity scope, regulatory remediation, profitability, and IPO-economics questions keep it on a research-more watchlist.
Research more: RedotPay has credible product breadth and company-reported payment scale, but audited economics, customer quality, partner resilience, and the outcome of a material contested lawsuit are not yet underwritable.
Track Noetix as an affordability-led humanoid contender, but require primary proof of deliveries, safety, unit economics, and capitalization before investing.
Salla has credible localized product-market scale and institutional backing, but absent valuation terms, audited economics, retention, and control evidence prevent a price-sensitive investment decision.
Egnyte is a scaled, strategically relevant content platform, but conflicting valuation marks and unresolved financial and security evidence make further research necessary before underwriting an investment.
VoltaGrid has credible hyperscale demand, sponsor backing, and emerging operating proof, but investment underwriting remains blocked by concentration, leverage, permitting risk, and absent audited economics.
Rox shows credible enterprise product and financing momentum, but the reported $1.2 billion valuation is not underwritable without verified current revenue, retention, margins, deployment economics, and financing terms.
AlphaChip founder pedigree and $335 million of reported funding justify continued diligence, but a $4 billion valuation remains ahead of public customer, revenue, and Ricursive-specific production proof.
JSW One has meaningful industrial-procurement scale and strategic backing, but the reported private valuation remains stretched without audited economics, current security terms, credit cohorts, and customer durability.
Tibber has credible smart-energy adoption and residential-flexibility scale, but opaque current economics, financing rights, and security remediation keep the case at research-more.
Firmus has credible strategic backing and demand signals, but the reported valuation outruns the public evidence for operating economics, financed delivery, and durable utilization.
Wonderful has credible product breadth, financing strength, and enterprise deployment momentum, but a roughly 71x valuation-to-annualized-revenue signal and missing retention, margin, concentration, control, and financing-term data make further research necessary before underwriting an entry.
Track: ShareChat's vernacular portfolio and operating repair merit continued diligence, but liquidity, financing terms, audited cash generation, and current valuation remain too opaque for an investment commitment.
GSR has credible institutional and product momentum, but absent audited economics, financing terms, and control evidence keep the opportunity in research-more territory.
DeepWay has reached meaningful electric-truck scale, but thin margins, continuing losses, concentrated dependencies, and undisclosed transaction terms make it a diligence-gated tracking opportunity rather than an invest-now case.
Chando remains a real, scaled beauty business, but the refreshed evidence still supports only a track stance because brand concentration, family control, and missing operating detail keep the valuation fair rather than clearly attractive.
Signifyd is a real guarantee-backed commerce protection platform, but stale valuation references and opaque unit economics still justify tracking rather than buying.
Neysa has credible sovereign-AI positioning and sponsor-backed scale capital, but public evidence still does not justify underwriting a buy at the visible ~$1.4B valuation.
Tensordyne looks like a real late-stage AI-inference infrastructure company, but the public record still stops short of proving durable customer adoption or a clean financial picture.
United Imaging Intelligence has genuine deployment scale and a credible platform, but public evidence still leaves the reported $1.4 billion valuation hard to underwrite without standalone economics.
PowerSchool remains a category-leading K-12 platform, but private-company opacity, breach overhang, and undisclosed leverage keep it in research-more territory.
Olix's latest Series B and leadership additions strengthen the story, but the company still lacks public customer, revenue, and benchmark proof to underwrite the valuation with confidence.
Bringg is a credible enterprise last-mile orchestration business with real customer scale and ecosystem depth, but the 2021 unicorn mark still rests on stale public valuation evidence and limited current private disclosure.
Zhuoyu Technology is a strategically important, production-proven ADAS supplier with credible OEM scale and FAW-backed capital, but opaque standalone economics and governance terms keep the case at research-more.
Veritas is a scaled MSME NBFC with real operating momentum, but the absent IPO price band keeps the investment case in track mode.
Hopper remains strategically differentiated in travel fintech, but public evidence still supports only a track call because audited current economics and valuation support remain too thin.
Frore Systems has credible product and capital momentum, but the current $1.64B valuation still runs ahead of publicly verified revenue and customer proof.
Forter appears to be a real category leader in enterprise commerce fraud prevention, but the combination of stale valuation, private-company opacity, and unresolved unit-economics questions supports only a research-more stance.
UForce remains a strategically compelling defense-tech consolidator, but its public economics and control structure are still too thin to support a high-conviction valuation call.
Spirit AI has credible industrial deployment and financing signals, but the reported 20 billion yuan valuation is still not supported by public audited operating metrics or disclosed security terms.
Divert has built a defensible end-to-end food-waste platform with real operating traction, but public financial opacity and unresolved financing terms still justify a track posture rather than an underwritten buy.
Alloy remains strategically relevant and well capitalized, but the public record still does not justify paying the $1 billion mark without clearer operating economics and ownership terms.
RADAR has credible store-scale proof and strong commercial momentum, but the public record is still too thin to underwrite the valuation with confidence.
You.com has credible product breadth, customer proof, and capital access, but public evidence still underwrites relevance more convincingly than durable economics, leaving the $1.5B Series C mark looking stretched.
Xpansiv combines broad environmental-market infrastructure with fresh capital support and real operating scale, but private financial opacity and carbon-market fragility still justify a research-more posture.
Sunday pairs a differentiated real-home data loop and elite robotics pedigree with blue-chip financing, but the public record still lacks the price, customer proof, and unit economics needed to underwrite the $1.15 billion valuation.
SpreeAI has credible product and partnership momentum, but public economics remain too thin to justify the reported $1.5B valuation with confidence.
Zepz remains a scaled remittance incumbent with strong corridor reach and product optionality, but public underwriting is still limited by opaque post-2024 economics, leadership turnover, and a lingering compliance overhang.
Biossil is a well-funded AI-native biopharma startup with a credible asset-rescue model, but the current valuation prices in trial success well ahead of public proof.
Aurora Solar is the category-leading US solar design and sales platform, but its stretched valuation and opaque private metrics keep the investment case at research-more until audited financials confirm durability.
Trulioo remains a strong global identity platform with broad enterprise adoption and positive KYB momentum, but stale valuation, opaque financials, and retention uncertainty keep the stance at Track.
Windsurf built a real AI coding business, but its 2025 split into Google talent-and-license ownership and Cognition asset ownership leaves no clean standalone equity story.
Thought Machine has durable tier-1 bank adoption and differentiated core-banking technology, but opaque economics and a stale 2022 valuation keep the investment case in research-more territory.
Blink Health has national prescription-access reach and fresh Series D backing, but opaque economics, conflicting private-market marks, and regulatory and operational risk keep the case at research-more with a stretched valuation stance.
ZaiNar has a differentiated network-side positioning wedge and notable deeptech credibility, but the public record still supports tracking rather than underwriting the $1B-plus mark.
Jumbotail remains strategically relevant and well-backed, but public evidence still points to thin wholesale economics, opaque post-merger integration, and material execution risk, so the unicorn still belongs on a watchlist.
Nyobolt's technology and commercial validation are real, but the $1 billion Series C still looks stretched until audited margins, customer diversification, and liquidation terms are disclosed.
Proof combines large-scale notarization volume, a broader identity authorization product suite, and notable enterprise partnerships, but the case remains constrained by undisclosed ARR, margins, and retention.
Talkiatry is the category-leading in-network telepsychiatry provider group with 800+ employed psychiatrists and 3M+ visits, but opaque unit economics, fixed W-2 labor costs, and DEA/regulatory exposure keep it a research-more name.
SandboxAQ remains a technically credible quantitative-AI platform with marquee government traction and elite backing, but its $5.75 billion valuation still outpaces disclosed fundamentals.
Curative's preventive-care-first employer plan and 2025 Series B give it a real commercial wedge, but the public record still leaves underwriting economics, reserves, and renewal durability opaque, so the $1.275 billion valuation remains stretched.
Job&Talent shows real operating scale and improving profitability, but the 2025 down-round and opaque capital structure still make the entry point demanding for a higher-conviction call.
Bitdefender remains a scaled, profitable private cybersecurity vendor, but disclosure gaps around ARR, margins, cash flow, customer economics, and capital structure keep the case at research-more.
Druva is a scaled cloud data-protection platform with durable product breadth, but stale private valuation anchors and opaque 2024-2026 financial disclosure keep the thesis at track.
Blue Origin has durable strategic launch assets and deep founder backing, but its capital intensity and still-proven execution profile leave the stock-equivalent case at track rather than buy.
Tekever combines combat-proven autonomous UAS demand with sovereign programme anchors, but the $6.4 billion entry price is still stretched against undisclosed audited financials and contract conversion timing.
Nous Research combines broad open-source developer reach with real monetization options, but the public record still leaves customer durability, economics, and governance under-specified.
Gopuff remains a credible instant-commerce leader, but the refreshed public record still leaves enough opacity around profitability, capital structure, and current operating economics to justify a track stance.
CMR Surgical is a compelling strategic asset — the leading non-ISRG soft-tissue surgical robotics challenger with global clinical traction and U.S. authorization — but a legacy $3B valuation anchor, opaque unit economics, and unproven U.S. commercial execution justify a Track recommendation at medium confidence with high risk.
Relativity still has differentiated manufacturing ambition and meaningful pre-flight demand, but Terran R remains unproven, capital terms remain opaque, and the business is still a Track rather than a Buy.
Eruditus combines category-leading university partnerships and reported FY24 profitability with global scale, but the dated private valuation, conflicting capital-history figures, and opaque security terms still make research-more the only defensible call.
AG1's brand, subscription scale, and retail expansion remain real, but the lack of audited financials, cap-table transparency, and retention disclosure still prevents conviction underwriting.
CRED has built real premium consumer-fintech scale and improved operating leverage, but under-disclosed economics, partner complexity, and a still-stretched $4.5 billion mark make fresh underwriting premature.
GOAT Group remains a scaled resale platform with durable brand reach, but private financial opacity, falling headcount, and persistent authentication and regulatory risks keep the investment case unattractive.
Zocdoc remains a scaled, profitable healthcare marketplace, but the underwriting case is still constrained by opaque financial disclosure, provider-friction risk, and a valuation reset versus legacy peak marks.
Age of Learning still has a durable ABCmouse brand and broad learning product stack, but public evidence leaves current economics, governance, and active user scale opaque, so the 2021 $3B financing mark remains stretched.
Discord still has rare consumer-scale engagement and a durable community moat, but its public entry price remains stretched against opaque margins and unresolved safety and regulatory risk.
Tenstorrent is a technically credible AI-chip and IP-licensing challenger with expanding deployment evidence, but valuation dispersion, private financial opacity, and capital intensity keep it in research-more territory.
Strong Dhan execution and user growth support the platform thesis, but a $1.2 billion valuation, SEBI tightening, and financial disclosure gaps justify a Track stance.
Sharpa is a well-funded tactile robotics company reported as pre-revenue by an undated sector profile; reliability, safety, and unit economics remain unresolved.
Hippocratic AI has real product traction and a strong strategic capital base, but its $3.5B valuation still runs ahead of publicly verified revenue, retention, and margin evidence.
Wispr shows genuine usage-scale traction and a credible lead-investor thesis behind its $2B Series B, but the valuation cannot be confirmed as fairly priced without disclosed absolute revenue, and an unresolved SOC 2 Type II compliance lapse plus active industry-wide voice-biometric regulatory risk keep this a track/research-more call.
Fabric remains a live but opaque robotic fulfillment platform: current customer proof and software repositioning justify continued diligence, but repeated layoffs and missing financial disclosure leave the 2021 unicorn mark looking stretched.
Strategically credible video-AI unicorn, but financially opaque — track / research more rather than buy at a presumed ~$1B entry.
Betterfly merits continued diligence for its strategic platform and distribution assets, but current economics and capitalization are too opaque for a confident valuation call.
SmartNews remains a credible consumer media asset with real product and publisher infrastructure, but current audience, financial, capital-structure, and IPO evidence is too incomplete to support a buy recommendation.
Volant is a serious, well-funded passenger-eVTOL contender with meaningful technical and commercial progress, but certification, cash visibility, contract quality, and unit economics remain insufficiently verified for an investment-grade underwriting decision.
Slate has unusually strong sponsor backing for an affordable-EV startup, but public evidence still supports only a track stance because launch execution, conversion, and valuation remain unresolved.
Noah Medical has real robotic-bronchoscopy traction and workflow differentiation, but public financial opacity and unresolved quality risk keep it in research-more territory.
Zap Energy has credible technical progress and a broadened 2026 platform story, but public evidence still stops well short of current revenue, customer contracts, or fresh valuation discovery, keeping the case in research-more territory.
Powerful backers and a credible payer pain point are real positives, but Tala's public evidence is too thin to justify its $1.2B entry price today.
Mach Industries combines real defense hardware momentum and vertical integration with a $3.7 billion valuation that still outruns public revenue disclosure.
Loadsmart’s integrated freight brokerage, TMS, and dock-scheduling platform remains strategically differentiated, but stale valuation, opaque financials, and freight-cycle sensitivity keep the call at research-more.
Also has moved from Rivian spinout to shipping TM-B consumer bikes and a fresh Series D, but it remains a pre-revenue hardware scale-up priced above $1 billion before unit economics and delivery cadence are proven.
DeployCo pairs a powerful enterprise distribution footprint with embedded FDE delivery, but the $14B launch valuation sits behind a heavy 17.5% yield hurdle and opaque operating economics.
Strive Health has real kidney-care scale and access to capital, but the public record still does not bridge that footprint to disclosed revenue, margin, retention, debt terms, or a current valuation, so public-only diligence remains research-more.
micro1 shows strong demand and rapid scale, but the evidence is still too uneven on economics, data rights, and valuation to underwrite confidently.
Eikon is a post-IPO, clinical-stage oncology biotech with meaningful cash runway and promising early clinical signals, but no publicly evidenced commercial customers or revenue base.
Komodo Health still has a differentiated healthcare data moat and credible 2026 commercial traction, but the combination of opaque financials, limited public pricing, and a stale $3.3B mark keeps the valuation case under pressure.
Thinking Machines is a strategically credible Southeast Asian applied-AI company with real partner and customer proof, but public evidence does not support a premium unicorn narrative or high-conviction valuation call; research-more until revenue quality, terms, and concentration become legible.
Volta's financing-led AI-factory model is differentiated, but public evidence supports research-more discipline rather than underwriting its reported $2.4 billion valuation.
EcoFlow has broad product reach and reported scale, but private-company economics, current valuation, and safety exposure remain too unverified for an underwritten entry.
Treeline combines experienced oncology founders and substantial disclosed funding with a still-unvalidated clinical platform, so the appropriate stance is research-more pending transaction, financial, and human efficacy evidence.
Starcloud merits continued diligence after credible orbital-compute proof, but its $2.3 billion financing mark is expensive relative to still-missing commercial, reliability, regulatory, and unit-economic evidence.
Research more: OYO's reported profitability turn and global scale are investable signals, but leverage, unresolved proceedings, execution risk, and a stretched $7-8 billion IPO target prevent price-specific underwriting.
Track PaleBlueDot AI: its broad compute platform, financing access, and reported contract demand are credible signals, but the $3.2 billion mark is stretched without audited conversion, margin, liquidity, and security-term evidence.
Focused Energy is unusually well capitalized for a pre-commercial fusion developer, but the public record still lacks disclosed valuation terms, customer contracts, and plant-level proof needed to move beyond a research-more stance.
Alpaca looks like a differentiated self-clearing brokerage infrastructure platform with strong partner reach and growth signals, but opaque private economics, conflicting scale disclosures, and a serious control-risk record keep the case in research-more territory.
LumApps has a credible AI employee-hub platform and real enterprise scale, but private-company opacity and integration risk keep the call at track.
Neuralink has real clinical momentum and a clean recent valuation anchor, but public economics, reimbursement, and governance remain too opaque to upgrade it beyond research-more.
ICON has real deployment proof and fresh capital, but missing audited unit economics and retention data still make the new $1.4 billion valuation hard to underwrite confidently.
Outschool looks like a scaled live-learning marketplace with clear adoption proof, but public evidence still does not justify underwriting the legacy $3B mark without private financials, retention, and capital-structure disclosure.
Xendit has real regional payments scale and product breadth, but opaque current economics, rail concentration, and regulatory exposure still justify a research-more stance.
Tomorrow.io combines a real orbital weather-sensing moat with enterprise traction and fresh unicorn financing, but valuation confidence stays constrained by ARR, margin, and cap-table opacity.
Dream Security has real sovereign-AI scale and a $3.0B financing signal, but the public evidence still leaves revenue quality, customer concentration, and founder/legal risk insufficiently resolved for anything stronger than a Track recommendation.
Doctolib still looks like the European healthcare workflow leader, but disclosure gaps, regulatory overhang, and valuation compression keep the stance at research-more.
Colossal has turned de-extinction into a real commercial platform with sovereign capital and spinouts, but the $10.3B mark still prices a long, uncertain path to the first species revival.
Angle Health looks like a real, fast-scaling employer-health platform, but the public evidence is still not strong enough to support an investable valuation call beyond research more.
Machina Labs combines real defense traction with differentiated manufacturing tech, but opaque economics and a narrow niche keep it in track-not-buy territory.
Vayyar combines credible 4D radar traction in automotive and care with sparse financial disclosure, making the current unicorn-level valuation plausible but not yet fully underwriteable.
ENN Fusion is a credible, parent-backed Chinese fusion moonshot with a real proton-boron technical program and a reported ~$1.6B July 2026 valuation, but the public evidence still looks like option value rather than investable fundamentals: no revenue, no named customers, no plant economics, and no clear licensing path. The right call is to track it closely or invest only with strong structure and milestone discipline.
TauRx has real late-stage Alzheimer’s option value, but the current tracker-style ~$2.5B valuation looks stretched relative to the public evidence and unresolved binary risks.
Research-more: Ticaros has credible platform science and a visible lead clinical path, but public pricing, economics, and financing terms remain too opaque to support confident entry valuation.
Beast Industries has real scale, category-creating creator leverage, and credible multi-line monetization, but at roughly $5B the valuation looks fair rather than attractive and the investability case is still limited by disclosure gaps and live operational/regulatory risk.
DEEPX has crossed into real physical-AI commercialization, but the current private-market valuation still runs ahead of public disclosure quality on margins, customer durability, and financing certainty.
Replit has real category-leading adoption and enterprise momentum, but the current $9B mark still outruns the quality of public financial disclosure.
Abogen has added a reported Phase III shingles program and a proposed Novartis license, but limited clinical outcomes, commercial evidence, and private financial disclosure still prevent a price-supported investment case.
Neo's reported asset scale and investor backing warrant further diligence, but inconsistent transaction disclosures, limited financial visibility, and an unverified regulatory perimeter prevent a defensible entry valuation.
Research-more: Resilience has meaningful Lilly-linked production and a focused CDMO platform, but undisclosed financials, leverage, utilization, and customer economics prevent a confident valuation.
Valo Health has credible strategic-partner validation, but clinical attrition and opaque current financing support a research-more decision.
Svante has credible technology, manufacturing scale-up, and strategic backing, but unresolved project-finance, commercial-revenue, liquidity, and valuation evidence warrants a research-more stance.
SiMa.ai is a credible, well-backed Physical AI silicon company, but its reported roughly USD1.45 billion valuation prices execution that is not yet independently visible, so the disciplined stance is research-more pending audited financials and stronger benchmark evidence.
Matchroom is a strategically durable sports-rights and events platform, but opaque entry valuation and incomplete cash-flow disclosure make the appropriate stance research more.
FDA approval and randomized clinical evidence validate a differentiated transplant therapy, but opaque launch economics and manufacturing execution keep Orca Bio on the watchlist.
Oratomic has credible scientific ambition and exceptional reported capital backing, but remains a high-risk, pre-revenue quantum hardware bet that is not yet underwritable.
Instabase has credible enterprise document-AI workflow depth and meaningful financing, but valuation reset, security follow-up, and limited operating disclosure support a cautious track stance.
Eka Robotics has a credible force-aware robotics thesis and substantial reported financing, but commercial scale and production economics remain unproven.
General Intuition has a differentiated gameplay-data and research thesis, but the reported $6.2 billion valuation is ahead of public proof on revenue, customer durability, and transfer to physical-world deployments.
Freenome has reached a public listing and FDA-approved CRC product milestone, but limited operating disclosure and execution risk warrant research-more rather than a price-insensitive buy.
Namirial has credible European trust-services scale and strategic momentum, but current valuation and operating quality cannot be underwritten from public evidence alone.
Leju shows credible product and shipment momentum, but weak primary disclosure, unproven repeat industrial demand, and unavailable IPO terms make further diligence necessary before investment.
Element Labs pairs exceptional semiconductor pedigree with strong capital access, but a reported valuation above $4 billion is not yet supported by public product, customer, or financial proof.
Linkerbot shows credible product breadth, financing access, and reported shipment momentum, but its USD 3 billion valuation cannot be underwritten without audited economics, customer verification, and independent scale evidence.
Fresh capital and reported deployment scale establish product relevance, but financial opacity, regulatory route-to-market exposure, and an undisclosed current valuation support only a Track recommendation.
Science has entered early European commercialization with PRIMA and a $230M Series C, but the lack of disclosed reimbursement economics, revenue, and governance detail still justifies a track call at a stretched valuation.
Mammoth remains a high-upside CRISPR platform with partner validation, but public disclosure is still too thin to underwrite revenue quality or valuation confidence.
Premium consumer-robotics challenger with real product momentum and scale signals, but still opaque on financials, governance, and margin durability.
Inari remains a technically credible but still commercially opaque seed gene-editing platform, so the refresh supports continued diligence rather than a buy-style call.
Stark shows real strategic momentum in European autonomous strike systems, but the public evidence is still too thin to underwrite the latest private mark as fundamentals rather than scarcity.
Reve's layout-first creative workflow remains differentiated, but the public evidence still does not support a priced investment case.
Newcleo's Nasdaq listing and $1 billion-plus capital base strengthen the balance sheet, but the thesis still depends on first-of-a-kind reactor execution, licensing, and customer conversion at a stretched valuation.
Fuse Energy is a rapidly scaling UK energy challenger with strong reported household growth and product breadth, but its $5 billion valuation remains difficult to underwrite because audited economics, cap-table terms, liquidity, and regulatory exposures remain opaque.
Veho is a differentiated last-mile delivery platform for premium e-commerce brands, but its stale $1.5B valuation mark, opaque financials, and contractor-classification exposure keep the investment case at track.
Quantinuum is the leading trapped-ion quantum platform, but the investment case is restrained by an extreme valuation, heavy Honeywell control, and early commercial scale.
Wellhub remains the global category leader in employer-sponsored wellness distribution, but undisclosed margins, retention, and cash-flow economics keep the refresh at a Track stance with a stretched secondary valuation.
Lyten combines differentiated lithium-sulfur and 3D-Graphene technology with acquired industrial capacity, but the absence of audited economics, binding customer proof, and clear factory ramp data keeps the name at Track with high execution risk.
Track Rappi until audited consolidated financials or an S-1 close the underwriting gap; the $5.25B private mark still looks stretched versus $1.7B-$2.0B secondary indications despite positive EBITDA and improving profitability.
xAI has exceptional financing, product, and infrastructure scale, but the public record still cannot underwrite the reported $230B-$250B marks from standalone economics.
Eon is a repeat-founder, tier-1-backed cloud backup posture management company with a differentiated agentless product, but its $4.0B valuation remains hard to underwrite because core financial metrics are undisclosed.
Covariant remains strategically relevant in warehouse robotics, but the Amazon reverse acqui-hire left too much financial, IP, and retention opacity to price the company confidently.
PsiQuantum still looks like the sector's most credible photonic FTQC platform, but the current evidence supports a research-more stance because valuation, liquidity, and operating economics remain underdisclosed.
Flock Freight still owns the shared-truckload niche, but the lack of audited FY2024-FY2025 financials and opaque 2025 Series E terms keep it at track with stretched valuation and high execution risk.
Formation Bio remains a high-risk, research-more biotech platform: marquee capital and pharma partnerships support the thesis, but opaque financials, unverified platform efficiency, and binary clinical outcomes still justify caution.
Lalamove remains a category-leading on-demand intra-city logistics network, but public evidence still leaves post-2022 audited financials, current cash runway, and realized unit economics unresolved.
Pass-with-watch in 2026: Forto retains real operating scale and a broad shipper footprint, but opaque retention, concentration, and current financial disclosure still outweigh the software-pivot upside.
MasterClass is a premium EdTech brand with strong content differentiation, but faces a severe valuation gap from its 2021 peak, ongoing financial pressure from layoffs and high content costs, and growing commoditization risk from AI.
Flexport: Credible digital freight platform at a stretched valuation — TRACK until profitability confirmed
Kunlunxin has real, independently corroborated commercial traction (China Mobile, Tencent) inside a booming domestic chip market, but its reported ~$50B IPO target rests on unreconciled revenue, an unconfirmed manufacturing foundry, and a chip-purchase-linked structure flagged by analysts for circular-financing risk.
Mission-driven EOR unicorn with B Corp certification and strong G2 recognition, facing intense competition from better-capitalized rivals in a commoditizing compliance-infrastructure market, with fully opaque unit economics at a $1.2 billion valuation.
A credible, marquee-backed limestone-DAC leader whose thesis rests on unproven unit economics, heavy subsidy dependence, and an unverified valuation — a track / research-more, not a buy.
A genuinely profitable, policy-protected national OS champion whose appraisal-based valuation and mandate-dependent demand can be tracked but not independently underwritten without standalone disclosure.
Historical XFC product and plant milestones are credible diligence leads, but current operating economics, customer performance, and financing terms are too weakly evidenced to support a priced investment.
Cathedral has exceptional reported financing and investor backing, but its $1.4 billion valuation is not underwritten by public operating proof.
SHAREBOT addresses a credible robotics-adoption wedge, but opaque economics and a conditional valuation reference limit conviction.
Rokid has credible product and channel momentum, but privacy-control questions and the absence of audited economics, current capitalization, and primary exit evidence make it a high-risk company to track rather than underwrite today.
Shihang Intelligent shows unusually strong financing, order, and field-validation signals for a 2023-founded marine-robotics company, but opaque valuation, revenue conversion, and regulatory execution keep it in research-more territory.
Seekr pairs genuine defense and regulated-industry traction with a credible trustworthy-AI platform, but the valuation still looks expensive relative to disclosed revenue and the private-market economics remain opaque.
Roark looks like a real counter-UAS business, but the financing, valuation, and customer-proof record is still too opaque to underwrite the reported private mark.
Botshare shows real operating momentum in robot leasing and RaaS, but the public record still falls short of what is needed to underwrite its unicorn valuation with conviction.
Elite Robots looks like a real cobot business with fresh 2026 financing and broad product reach, but opaque operating economics and lingering legal overhang keep the right call at research-more.
Agilink has strong early commercialization momentum and investor pull, but independent proof remains thin and the $1B+ valuation looks stretched.
Skyroot has orbital proof, fresh capital, and visible buyer interest, but the public record still does not disclose enough pricing, margin, or backlog detail to justify the valuation with confidence.
Hive Box combines rare national locker density and a recent profit inflection with unresolved IPO, regulatory, and disclosure risk.
Basis has real accounting-firm traction, but its $1.15 billion valuation is difficult to underwrite without public ARR or margin disclosure.
Robot Era has real logistics deployment traction and major 2026 financing, but undisclosed unit economics keep the valuation case stretched and the right stance at research-more.
HomeLight is a credible multi-product residential transaction platform with meaningful distribution and funding access, but opaque financials, balance-sheet-sensitive liquidity products, and regulatory exposure keep the case at research-more.
Pacific Fusion combines elite technical leadership and an unusually large milestone-tranched Series A with opaque valuation terms, undisclosed full-module economics, and no binding commercial offtake, so the report remains a research-more call.
Kikoff has meaningful consumer reach and a differentiated low-cost credit-building bundle, but the public record still leaves retention, unit economics, and servicing quality too opaque to justify the headline valuation with conviction.
Acronis combines unusually broad MSP distribution with a unified cyber-protection platform, but opaque private financials and federal procurement headwinds keep the investment case at research-more.
Keenon Robotics looks like a scaled commercial service robotics leader, but financial opacity, a long funding drought, and active U.S. IP litigation keep the investment call at track.
barq is a fast-scaling Saudi payments wallet with strong user and volume growth, but opaque economics and service friction make the $1.85 billion valuation look expensive.
Eudia shows credible enterprise legal-AI demand and a differentiated human-plus-software model, but opaque current economics, controls, and valuation support further diligence rather than an entry-price decision.
Overhaul is strategically relevant and commercially credible, but the public record still supports research-more rather than a confident buy.
Velaura AI pairs a genuinely production-proven, power-efficiency silicon platform and a credible board with a $1B+ valuation that currently rests on zero named AI-silicon customers and no disclosed revenue or royalty rate.
Collibra looks like a real late-stage category platform, but public evidence is too opaque to justify underwriting anywhere near its 2021 $5.25B mark without major private diligence.
Panthalassa pairs a marquee Thiel-led syndicate and a genuinely novel ocean-compute concept with pre-revenue, unproven-at-scale technology and no priceable disclosure, making it a high-risk venture-optionality bet.
Angitia is a credible, well-funded bone-biologics company with real Phase 2 option value, but the public record is too opaque on cash, CMC, pricing, and true current valuation to justify a conviction premium-price investment today.
ONE's LFP platform and customer activity support continued diligence, but delivery conversion, current unit economics, financing terms, and liquidity remain unverified.
Reported scale and a compact, value-oriented format merit continued diligence, but financial opacity, execution risks, and the absence of a verified current valuation preclude an investment call.
Fora has credible advisor and booking momentum, but its reported $1 billion valuation remains difficult to underwrite because revenue, margins, retention, and downside terms are not publicly disclosed.
Mirador combines substantial private financing and a credible precision-immunology platform with a broad clinical pipeline, but public information remains too opaque on valuation, cash runway, and clinical proof to support a buy recommendation.
Even Realities is credible enough to keep on an active diligence list, but public evidence does not justify paying through the reported $1 billion valuation without deeper private economics and term verification.
eMed still looks like a credible employer GLP-1 scale-up, but the refreshed public record leaves revenue quality, margin durability, customer concentration, and governance too opaque to justify a higher-conviction call.
FBN remains a credible, broad ag-commerce and farm-finance platform, but current economics and pricing opacity still justify a research-more stance.
Epic Games owns exceptional gaming and engine assets, but current public evidence still supports a cautious research-more stance because Fortnite concentration, private-company opacity, and legal/regulatory friction keep the stock-equivalent risk profile elevated despite strong strategic backing.
New Ruipeng is a strategically important scaled pet-healthcare asset, but the current Hurun-like valuation reference still looks expensive versus the last disclosed revenue base and the available public comp set.
HeyTea has a differentiated product and reported global scale, but current economics, customer durability, and valuation cannot be underwritten from available public evidence.
March 2026 growth capital and reported EBITDA profitability support an operating recovery, but unverified cash conversion, financing terms, and the scope of a September 2026 data incident keep the recommendation at research-more.
CoinDCX shows meaningful scale and financing access, but current economics and control evidence do not support underwriting beyond research-more.
Zankore has credible strategic sponsorship and an ambitious AI-compute plan, but its financing scale currently runs ahead of disclosed operating and commercial proof.
Track Sunwoda EVB: credible scaled OEM traction is offset by opaque standalone economics, a lower nominal 2026 financing mark, and unresolved quality and recall exposure.
Core Automation has credible frontier-AI talent and technical ambition, but absent commercial proof and unresolved financing terms make the reported valuation too uncertain for conviction.
Sudo AI merits continued tracking for its simulation-first manipulation platform and financing momentum, but the reported valuation above US$2 billion is not underwritten by public commercial, financial, or production evidence.
Track Beren through the November 2026 FDA decision: regulatory optionality and launch financing are real, but external-control risk and undisclosed transaction economics prevent an investable valuation.
AMI combines exceptional research capital and credible technical leadership with an expensive entry valuation that remains ahead of public product, customer, economics, and governance proof.
Factorial is a technically credible solid-state battery platform company, but its public disclosure still does not underwrite revenue quality or capital efficiency well enough to call it a clear buy.
Endless is a credible but still opaque Web3 infrastructure bet: the financing signal is real, but public evidence on revenue, users, governance, and treasury quality is still too thin to underwrite the $1B mark.
monobank remains Ukraine's dominant mobile-first neobank and a private fintech unicorn, but the $1.0 billion valuation mark still sits ahead of the public disclosure needed to underwrite it confidently.
Flash Express remains Thailand's scaled logistics winner, but stale 2022 pricing, opaque private terms, and post-2024 disclosure gaps keep the investment case in research-more territory.
Galaxea AI shows real embodied-AI technical momentum and early customer reach, but opaque economics and a stretched private valuation keep the right stance at track.
Tenex is a credible AI-native MDR operator with strong early traction and ample capital, but the public file still leaves unit economics and valuation too opaque for conviction.
PlusAI still shows real OEM and pilot traction, but the refreshed valuation case remains research-more until closing terms, dilution, and audited scale are verified.
Dreame is a scaled private consumer-appliance company with clear robot-vacuum leadership, but public evidence still does not support a clean valuation call.
Hailo still shows real product and deployment strength, but opaque financials, liquidity stress, and an unresolved strategic-sale transition keep the investment case in research-more territory.
Character.AI combines unusual consumer engagement with unusually heavy legal and safety risk, so the current value case is still better framed as a cautious avoid than a clean growth multiple.
Climeworks leads commercial DAC but its flagship plant is producing 0.3% of capacity—a binary operational risk that dominates the investment case until resolved.
CAUTION — World-Class Team, Extreme Valuation; Watch for Commercial Proof Before Entry
IM Motors is credible enough to keep diligencing because it has sponsor backing, product depth, and real deliveries, but the missing valuation and subsidiary-financial evidence keep it in research-more territory rather than investable conviction.
Fintech-IT Group controls the technology and economics behind Ukraine's dominant mobile-first neobank, but a $1B tech-entity valuation implies a stretched 11× FY2024 revenue multiple against a wartime backdrop of declining developer revenues and opaque consolidated financials — warranting deep further diligence before any commitment.
Fangqing has a credible technical and strategic story in a hot domestic AI-compute market, but the current unicorn valuation already runs ahead of public product, customer, and financial proof.
Neo Fusion is strategically important within China's fusion roadmap, but thin disclosure, unproven commercialization, and high milestone risk support a research-more recommendation.
Track Generalist AI: the team, capital base, and cross-hardware model thesis are compelling, but independent deployment proof and commercial economics remain insufficient for price underwriting.
Reflection AI has a real product launch and serious capital access, but public revenue, customer, and governance proof are still too thin to justify treating the company as conventionally underwritten software.
Substrate remains a high-upside but high-risk research-more story: it has raised over $100 million at a roughly $1 billion valuation and is building a differentiated X-ray lithography-plus-foundry stack, but the public record still lacks customer, throughput, yield, and financing-stack proof.
Track: Dogotix has unusual strategic quality for an early humanoid company, but the current valuation is still ahead of independently underwritten proof.
Mark43 has meaningful public-sector reach and a broad mission-critical platform, but undisclosed economics, ambiguous customer metrics, and unpriced acquisition terms leave valuation and returns ununderwritable.
LigaChem’s partnered ADC platform and selective in-house clinical progress offer meaningful optionality, but losses, uncertain cash runway, contingent deal economics, and the absence of a defensible current valuation support research-more rather than a high-conviction entry.
DayOne shows meaningful scale and capital access, but concentrated customers, opaque economics, and unsettled IPO terms make the reported target difficult to underwrite.
Prague Technology merits tracking rather than a buy because founder and sector context are credible but company identity, commercialization, financing terms, and valuation remain insufficiently verified.
StepStar is a technically credible and well-funded foundation-model company with a distinctive multimodal-to-device strategy, but opaque economics, contested valuation marks, and unresolved commercialization risks support research-more rather than a buy.
EXU has a high reported financing mark but insufficient public operating, customer, control, and transaction-term evidence to underwrite that valuation.
Magic AI has credible long-context coding-model upside, but insufficient public commercial proof and undisclosed financing terms support a research-more stance.
ADGT has credible sponsor backing and a differentiated regulated-market thesis, but insufficient public operating and valuation evidence for a buy recommendation.
Sudu Technology has credible technical and financing signals but remains a high-risk, pre-commercialization opportunity because production performance, customer traction, and valuation inputs are not publicly established.
Research more: Gilmour has scarce sovereign-space infrastructure and fresh institutional backing, but orbital reliability, revenue-bearing backlog, and runway remain unproven.
GetYourGuide has credible marketplace scale and company-reported adjusted-EBITDA profitability, but missing audited economics, capital terms, and normalized supplier and customer outcomes make the investment research-more rather than buy.
Fundamental has real technical and strategic signal, but the current valuation still outruns public operating disclosure.
Factory looks like a real enterprise software-delivery platform with strong product breadth, marquee customer proof, and a fresh $5 billion financing mark, but the public record still leaves revenue quality, margins, and contract durability too opaque for a firmer underwriting call.
PhysicsX combines credible platform depth and strong financing momentum with public-denominator opacity that keeps the $2.4 billion Series C hard to underwrite from public evidence alone.
Securonix remains a strong enterprise cloud-SIEM platform, but public evidence still does not support a purchase-grade valuation or a clean current underwriting model.
Tether is a scaled, profitable stablecoin platform, but disclosure and regulatory overhang keep valuation discipline tight.
Nothing has built a rare design-led consumer-hardware brand with real scale and an investable valuation mark, but private-company opacity, uneven product execution, and reliance on continued category expansion keep the name in track rather than buy territory.
A first-of-its-kind commercial plasma-pyrolysis producer with real technology and blue-chip backing, but thin public financials, single-plant scale, customer/loan concentration and a DOE loan under cancellation threat warrant deeper diligence before underwriting the $1B+ valuation.
Boom Supersonic has demonstrated real technical progress and airline demand, but it remains a pre-revenue, high-capital-risk business with an expensive path to certification and scale.
Devo's differentiated cloud-native security platform supports a track stance, but the historic $2B valuation remains unsupported by current financial disclosure.
Deepwatch combines credible AI-native MDR delivery and customer proof with persistent financial opacity and leadership uncertainty, keeping it in track mode rather than buy territory.
Etched now has working silicon, a first named customer, and a reported $21B private-market valuation, but the thesis still rests on unverified benchmarks, undisclosed revenue, and a brittle transformer-only architecture.
Orca Security remains an attractive product and go-to-market story but an avoid on valuation because revenue quality, margins, and cash durability remain opaque while Wiz and native cloud alternatives keep pricing pressure high.
Axelera AI has credible technical differentiation and real commercial momentum, but public disclosures are too thin to underwrite price or unit economics.
Collaborative Robotics looks credible as an early practical-robotics platform, but it is still too opaque on economics and customer scale to underwrite aggressively.
Exceptional founder pedigree + massive market; valuation is a pre-product conviction bet with high execution risk and severe evidence gaps at every chapter of diligence.
Retro has credible science, elite backers, and a real first-in-human milestone, but public evidence still supports a research-more stance because efficacy, economics, and commercialization are not yet proven.
Sidecar Health has differentiated transparent-pricing insurance and real strategic validation, but underwriting opacity, balance-billing friction, and undisclosed cap-table economics keep the company in research-more territory at a stretched valuation.
Xpanceo has built rare capital, prototype breadth, and a plausible staged path to a post-screen interface, but the company is still pre-commercial, pre-clinical, and priced at a level that assumes milestones not yet publicly verified.
Statsig remains a credible experimentation platform, but the OpenAI-Amplitude split and opaque private economics still make it unattractive for new capital.
Aiven remains a credible managed open-source platform, but the stale $3B 2022 valuation, opaque financials, and absent cash-flow disclosure keep the investment case in avoid territory.
Rebellions combines credible sovereign-backed momentum with real production deployments, but its $2.34B pre-IPO valuation still outruns disclosed commercial scale.
Historically well-funded NDA-stage biotech with real asset credibility, but stale valuation anchors and missing private metrics keep the call at research-more.
Source Foundry attacks a real and strategically important semiconductor bottleneck, but the public record still falls far short of what is needed to cleanly underwrite the reported ~$5B valuation.
Humanity Protocol has product activity and identity-market optionality, but the 2026 key compromise, unproven commercial conversion, and absent current financial disclosure keep the recommendation at research-more.
The public record supports a research-more decision, not price underwriting: early product and partnership signals remain unaccompanied by verified financing terms, paid-customer durability, current financials, or deployment performance.
Moqi is credible enough to track because its founders, financing signals, and humanoid-robotics position are real strengths, but the roughly $1 billion reference remains unproven without commercial and financial disclosure.
Aaru has credible enterprise and validation signals, but its reported valuation materially outruns the public economics and proof package.
Apeel has credible post-harvest products and international optionality, but commercial contraction and absent current financial, capitalization, and retention evidence make a priced investment premature.
Rentberry looks like a real rental-workflow product with continued capital access, but public evidence still leaves valuation, governance, and monetization questions too open for a more aggressive stance.
Flourish combines rare founder pedigree with a differentiated energy-efficiency thesis, but public evidence is still far too thin to underwrite a $2.5B pre-product valuation with conviction.
Exa looks like a real and differentiated agent-search infrastructure company, but the public economics and current $2.2 billion price are still too opaque to justify an invest-now call.
humans& has top-tier founder-market fit and capital for a frontier-AI platform, but the public record still supports only a research-more stance because product, customer, and financial proof lag the valuation narrative.
Genki Robotics combines founder pedigree and strong Japan robotics tailwinds, but the current $1 billion Series A price materially outruns public proof on product, customers, and economics.
GoodLeap is a scaled sustainable-home financing platform, but a stale $12B valuation, opaque post-2021 economics, and active consumer-finance litigation keep the right stance at track rather than buy.
TAE has one of the stronger publicly visible private-fusion programs, but today's entry price remains unsupported by disclosed plant economics, customer proof, or the pending merger's full disclosure pack.
EvolutionaryScale produced frontier-quality protein language models, but the November 2025 CZ Biohub absorption eliminated the standalone commercial thesis and leaves investor outcomes publicly unaccounted for.
Ninja Van remains a real regional logistics platform with credible B2B adjacency, but public evidence still does not support a current valuation or a self-sustaining cash-flow thesis.
Ripple is a scaled private fintech with real enterprise adoption and regulatory breadth, but opaque economics and XRP decoupling keep the equity case in research-more territory.
Altos Labs is a highly capitalized private research platform with strong scientific ambition but limited public proof of commercialization.
Morphi is strategically interesting, but the public record does not yet justify paying up at its reported unicorn valuation.
LONGi Hydrogen is commercially real and parent-backed, but the public record is still too thin to underwrite a premium entry price.
Noom is a real scaled consumer-health platform, but the public evidence still leaves enough opacity around revenue, cash, and current valuation that research-more remains the right stance.
Unconventional AI remains a highly capitalized research-stage compute bet: the financing and founder pedigree are exceptional, but the public evidence still stops short of physical silicon, commercial traction, or underwriting-grade operating metrics.
A credentialed, well-funded pre-clinical ADC platform with genuine differentiation potential but no data, no disclosed target, and no confirmed valuation — research-more until key facts are shown.
OrCam has a credible assistive-technology proposition, but reported revenue contraction and unresolved financing terms leave current commercialization and equity value unproven.
Xingyun Group has meaningful cross-border infrastructure and historical financing scale, but opaque parent financials, unresolved governance linkage, and high compliance exposure keep the investment view at research-more rather than buy.
Psibot combines a credible embodied-AI platform and strategic industrial backing with a high reported valuation, but insufficient public operating disclosure to support an investment decision.
Envision AESC has enough customer and plant proof to matter, but the public file still does not justify premium underwriting without audited revenue, margin, leverage, and cap-table evidence.
Town shows unusually fast company-reported traction and ample financing, but missing retention, unit-economics, security-control, and financing-term evidence prevents underwriting the $1 billion mark.
Mirendil combines an experienced frontier-AI team, top-tier backing, and meaningful compute infrastructure with a reported billion-dollar valuation that remains unsupported by public product, customer, or economic proof.
Terminus looks like a real scaled AIoT operator with fast revenue growth and broad deployments, but stale valuation marks, opaque unit economics, and execution risk still justify research-more rather than a buy.
TAR has a clear time-to-power thesis and strong funding momentum, but public evidence is still too thin to underwrite revenue, customer traction, or valuation with confidence.
SSI is a high-conviction, pre-revenue AI safety bet priced on founder optionality and compute access, not observable commercial traction.
Sanctuary AI has differentiated manipulation IP and a credible 2026 software pivot, but undisclosed revenue, customer retention, and financing structure keep underwriting in research-more territory.
Brex's $5.15B Capital One exit ends the standalone venture thesis and shifts diligence to bank-integration execution.
TypeSafe AI has a differentiated structured-decision product and real launch momentum, but the $7.5B price leaves little room for error without audited revenue and retention proof.
Chipper Cash has a broad payments platform and meaningful historical reach, but limited current disclosure supports a research-more stance rather than an investment endorsement.
Xoople has credible EarthAI positioning and serious backing, but the public record still does not justify underwriting a fresh entry without disclosed valuation terms and stronger commercial proof.
Hark combines elite fundraising and talent with a still-unproven consumer AI/hardware platform, so the public record continues to support an avoid stance at a $6 billion valuation.
Simplexity Robotics merits research-more status: financing and technical signals are strong, but public evidence still does not establish paid deployments, recurring revenue, safety performance, or a defensible company valuation.
A founder-led RL-first frontier lab with exceptional capital backing, but public proof of product, revenue, and operating maturity remains thin.
EnergyX has genuine strategic backing and DLE technical progress, but the company still lacks commercial-scale operating proof and binding project finance, so the public record supports TRACK with high risk.
UniUni looks like a genuine scale business, but the public record is still too thin on margin, liquidity, and transaction certainty to underwrite the US$1.0B valuation with conviction.
Zhipingfang Technology is a credible Chinese embodied-AI contender with strong strategic backing and a real industrial anchor order, but the June 2026 repricing above $2.8B materially outruns still-undisclosed fundamentals and keeps the company in research-more territory.
GVE has a credible strategic cyber-infrastructure thesis, but current public evidence does not justify paying the highest visible valuation marks; track it, do not underwrite it aggressively, until customer and financial proof catch up.
Recursive has exceptional technical and financing signals, but the $4.65 billion valuation remains unsupported by public revenue, customer, unit-economics, and governance evidence.
Tongdun has strategic relevance in risk-control infrastructure, but limited current disclosure and unresolved legal, customer, and valuation questions warrant further research before investment.
Nio GeniTech has strategic technology and policy tailwinds, but the current public record still provides less commercial and financial proof than a price-sensitive investment decision requires.
Flapping Airplanes is a differentiated, well-funded AI research bet, but investment underwriting should remain at research-more until its data-efficiency thesis, commercial path, governance, and entry price are supported by primary evidence.
Trellix remains a scaled, PE-backed XDR platform with real enterprise reach, but current public evidence still does not support a clean valuation or full operating underwrite.
Prometheus combines extraordinary capital formation with thin public operating proof, so the evidence supports continued diligence rather than paying into the current mark.
Odyssey's world-model story looks stronger on product cadence and capital backing, but public evidence still does not disclose revenue, customer conversion, or financing terms well enough to underwrite the valuation cleanly.
ClickUp has scaled into a broad AI workspace with real ARR momentum and visible product breadth, but stale price discovery and missing board-grade economics still keep the call at research-more.
Reka has a credible multimodal platform and strong strategic validation, but public evidence is still too thin to underwrite the business beyond a research-more posture.
Cornerstone Robotics looks like a credible late-stage surgical-robotics contender with real regulatory momentum and a powerful Medtronic channel catalyst, but its public economics remain too thin for a conviction valuation call.
XpressBees is a scaled logistics network with credible revenue traction, but stale valuation data and unresolved liquidity disclosure make it hard to underwrite with conviction.
Lightwheel remains a compelling physical-AI infrastructure platform with real ecosystem leverage and customer proof, but the public record still falls short of audited revenue, reconciled valuation, and durable customer economics.
Advance Intelligence Group has a credible asset-level value anchor and visible operating momentum, but limited parent-level disclosure keeps the posture at track.
The Boring Company has real operating proof and fresh capital, but the public record is still too opaque on economics, control, and commercialization risk to underwrite the reported valuation.
Megvii has real technical depth and commercial breadth, but sanctions, biometric-regulation risk, and opaque current financials keep the investment case below threshold for a confident long position.
Turntide has credible industrial electrification traction, but absent public financials and a severely reset cap table still make it an avoid.
Shrapnel still looks like a differentiated UE5 extraction shooter with creator-economy and China-access optionality, but the public record leaves revenue, valuation, and operating economics unpriced.
Cowboy Space is a well-funded but still pre-commercial orbital-compute thesis: the $2B Series B is real, yet revenue, customers, and core execution proof remain unresolved.
24M Technologies built a credible battery-licensing platform, but partner concentration, FREYR's termination, and 2026 liquidation evidence leave no current investment case.
Avoid at an unverified entry price until current operations, solvency, customer commitments, and capitalization are independently established.
Infinite Reality has assembled real immersive-commerce and media assets, but the gap between its confirmed fundamentals and its self-reported valuation remains so extreme that the equity case is currently dominated by governance, legal, and financing downside rather than platform upside.
Story Protocol has credible technical differentiation and real IP-infrastructure pedigree, but the public evidence still supports an avoid recommendation because revenue, enterprise adoption, and legal enforceability remain unproven while the token and commercialization thesis have deteriorated sharply.
ArtIn Energy remains a high-risk, valuation-heavy story whose financing is public but whose operating proof is thin.
Ascend Elements has real battery-material technology and customer interest, but its April 2026 Chapter 11 filing turns the case into a distressed-asset situation rather than a normal late-stage growth investment.
Northvolt proved that Europe could assemble a strategically important battery platform with real customer demand and massive financing access, but the legacy equity story appears broken by insolvency; only successor asset exposure may merit fresh underwriting.
Natron Energy is a post-shutdown liquidation legacy case: its sodium-ion technology was real, but the company now has no going-concern valuation after entering ABC wind-down.
80 Acres Farms moved from a scaled indoor-produce operator to Chapter 7 liquidation after capital intensity, merger complexity, and financing failure overwhelmed the business.